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 ABSTRACT i 
 
Abstract 
Cryptococcus neoformans is an opportunistic pathogen and a leading cause of 
life‑threatening fungal infections in the immunocompromised. Individuals that are 
at greater risk are those with defective T-cell mediated immunity such as those 
with HIV/AIDS. Despite treatment with anti-fungal drugs, mortality remains 
excessively high and patients experience serious side effects hence the need to 
explore new therapeutic strategies. Activation of macrophages is essential for the 
control of cryptococcal infection. However, in the absence of T-cell mediated 
immunity, activation of macrophages is disrupted and clearance of cryptococcal 
infection is abrogated.  
Herein I first report a zebrafish-C. neoformans model of infection and show that 
zebrafish can clear, control or fail to control cryptococcal infection. I then go on 
to test whether cytokines or PRR ligands are capable of stimulating innate 
immune resistance to C. neoformans in zebrafish. I demonstrate that concomitant 
injection of IFNγ with C. neoformans results in reduced fungal burden and 
increased fungal clearance. IFNγ increases the recruitment of phagocytes to the 
site of infection and enhances phagocytosis by macrophages. Macrophage 
deficient larvae fail to clear or suppress cryptococcal infection despite treatment 
with IFNγ. In addition, infected macrophages display low lysosomal pH and 
elevated expression of IL-1β in IFNγ-treated larvae. Although neutrophils take up 
the fungus, their depletion does not alter cryptococcal burden.  
Secondly, I demonstrate that S. aureus CWP is a potent inducer of innate 
defences against C. neoformans. Using chemically digested S. aureus CWP to 
remove wall teichoic acid or mutants that do not produce wall teichoic acid (tarO) 
or lipoproteins (lgt), I establish that protective effects of S. aureus CWP require 
wall teichoic acid but not lipoproteins. Protection by S. aureus CWP are 
associated with increased recruitment of macrophages but not enhanced 
phagocytosis or TNFα expression.  
 ABSTRACT ii 
 
This work provides new insights into cellular responses and effector molecules in 
the context of cryptococcal disease progression while identifying potential 
immunomodulatory targets.  
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1.1 Cryptococcus and cryptococcosis 
Fungal pathogens have become of increasing medical importance in the last 
couple of decades due to the emergence of organ transplants, 
immunosuppressant treatments, and the HIV/AIDS pandemic. Cryptococcus is 
not only the most common human fungal pathogen causing life-threatening 
disease in the immunocompromised population, but it is also an important 
pathogen in the immunocompetent.  
In this chapter, I will discuss the genus Cryptococcus with emphasis on the 
species C. neoformans and C. gattii. I will then describe the life cycle and genome 
followed by a detailed description of the Cryptococcus disease including clinical 
presentation, diagnosis, and current treatment options. Thereafter, I will describe 
the pathogenesis and the immune response to C. neoformans infection including 
its interactions with host immune cells. I will then introduce animal models that 
are used to study C. neoformans infection with emphasis on zebrafish larvae and 
its immune system. I will finish this chapter with the aims and strategies that were 
used.  
1.2 Pathogenic Cryptococcus species  
Cryptococcus is a basidiomycetous yeast, round or oval, and replicates by 
budding. There are over 80 species that belong to the genus Cryptococcus and 
most of which are nonpathogenic to humans (Arturo Casadevall  1988; Fell et al, 
2000). Among these, C. neoformans and C. gattii are the most common species 
that cause human disease. However, there have been rare reports of C. laurentii 
(Johnson et al, 1998; Kordossis et al, 1998) Kunova & Krcmery, 1999), 
C. curvatusi (Dromer et al, 1995) and C. albidus (Burnik et al, 2007; de Castro et 
al, 2005; Kordossis et al, 1998; Loison et al, 1996) causing infections in humans. 
Interestingly C. laurentii is a well-known postharvest biocontrol yeast against blue 
mold rot caused by Penicillium expansum in apple fruit (Roberts, 1990; Yu et al, 
2007).  
Previously, C. neoformans and C. gattii species complex were classified into four 
serotypes (A - D) based on capsular agglutination reactions. According to the 
current classification, serotype A, D and AD (hybrid following mating of serotype 
 CHAPTER 1| INTRODUCTION 3 
 
A and D) are now known as C. neoformans while serotype B and C bear the 
name C. gattii (Kwon-Chung et al, 2002; Kwon-Chung & Varma, 2006). 
1.2.1 Cryptococcus neoformans 
Discovery- Cryptococcus neoformans was first described in 1894 by Otto Busse, 
a professor of pathology at Greifswald in Germany, following isolation from a 
sarcoma-like lesion of a female patient’s tibia (al-Doory, 1971; Mitchell & Perfect, 
1995). Later in the same year, Francesco Sanfelice named the yeast 
Saccharomyces neoformans when he isolated it from fermenting peach juice 
(Reviewed in Srikanta et al, 2014). Jean-Paul Vuillemin first suggested the 
species’ name, Cryptococcus neoformans, in 1901. However, it was not until the 
1950’s that the name was widely accepted and later published by Lodder and 
Kreger-van Rij in the first major nomenclature of known yeasts (Lodder & Kreger-
Van Rij, 1952).  
Ecology - Cryptococcus is a ubiquitous saprobic fungus and a free-living 
organism that is well adapted to a variety of environmental niches. 
Cryptococcus neoformans is specifically associated with avian guano (Agha 
Kuchak Afshari et al, 2012; Casali et al, 2003; Li et al, 1993; Nielsen et al, 2007; 
Sriburee et al, 2004) but has been isolated also from other sources including trees 
(Litvintseva et al, 2011), decaying wood (Lazera, 1993; Lazéra et al, 1996; 
Randhawa et al, 2006), and soil (Randhawa et al, 2008) usually contaminated 
with avian excreta or decayed wood (Ajello, 1958; Emmons, 1955). In relation to 
human disease or colonization, C. neoformans represents the most frequent 
fungal isolate from AIDS patients (Mitchell & Perfect, 1995). In very rare events, 
C. neoformans has been isolated from skin, saliva, oropharynges washings, toes 
and faecal specimens in healthy individuals posing as a transient commensal 
(Howard, 1973; Randhawa & Pal, 1977). Even though most patients with 
disseminated cryptococcosis are immunocompromised, C. neoformans can also 
cause disease in apparently immunocompetent individuals (Chen et al, 2008; 
Chen et al, 2000).  
Classification - Classification of the genus Cryptococcus is based on molecular 
characterisation by PCR finger printing, Random amplified polymorphic DNA 
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(RAPD), Amplified Fragment Length Polymorphism (AFLP) and multi-locus 
sequence typing (MLST) analyses (Hagen et al, 2015). 
Cryptococcus neoformans is classified into two varieties: var. grubii (serotype A) 
and var. neoformans (serotype D). C. neoformans var. grubii, is the most virulent 
and most common cause of cryptococcosis worldwide, whereas C. neoformans 
var. neoformans is less virulent but more prevalent in Europe (Litvintseva et al, 
2006; Dromer et al, 2007; Xu et al, 2000). C. neoformans comprises five distinct 
molecular types.  C. neoformans var. grubii, serotype A molecular types include 
VNI, VNII and VNB. Whereas C. neoformans var. neoformans, serotype D 
comprises of VNIV while VNIII (serotype AD hybrid) is C. neoformans intervariety 
hybrid (Reviewed in Hagen et al, 2015; Figure 1). VNI isolates are prevalent in 
the environment globally and are responsible for most cryptococcal infections 
outside Africa. VNII are found worldwide but exceptionally rare in the environment 
and in causing human disease (Litvintseva et al, 2006; Meyer et al, 2003) 
whereas VNB isolates are primarily confined to sub-Saharan Africa. Conversely 
VNB isolates are unique to Bostwana (Cogliati, 2013; Litvintseva et al, 2006). The 
prevalence of VNIV isolates from the environment and patients are moderately 
comparable to VNI (Dromer et al, 2007). There are no recorded differences in the 
immunological status of the host infected by C. neoformans var. grubii and 
C. neoformans var. neoformans (Irokanulo et al, 1997; Jain & Fries, 2008).  
1.2.2 Cryptococcus gattii  
Cryptococcus gattii, formerly known as Cryptococcus neoformans var. gattii 
(serotype B and C), is currently classified as an independent species (Kwon-
Chung et al, 2002). Unlike C. neoformans, C. gatti mostly causes disease in 
immunocompetent patients (Chen et al, 2008; Chen et al, 2000). Previously, 
C. gattii infection was thought to be prevalent only in tropical and subtropical 
climates and its presence in temperate regions was rare (Kwon-Chung & Bennett, 
1984a; b).  However, C. gattii has also been isolated in temperate regions of 
Europe (Baró et al, 1998; Colom et al, 2005). It is also known for the ongoing 
outbreaks in temperate regions including British Colombia and Vancouver islands 
in Canada (Hoang et al, 2004; MacDougall et al, 2007). C. gattii is associated 
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with the eucalyptus tree (Eucalyptus camaldulensis and Eucalyptus tereticornis) 
(Callejas et al, 1998; Ellis & Pfeiffer, 1990b; Fortes et al, 2001).  
Cryptococcus gattii comprises four major distinct molecular types, which include 
VGI, VGII, VGIII, and VGIV (Meyer et al, 2009, Figure 1). Among environmental 
isolates, VGII is the most frequent molecular type followed by VGI, VGIII and 
VG4. However, VGI and VGII are more common in clinical isolates followed by 
VGIII and VGIV. VGIV is rarely seen in the environment (Chen et al, 2014). The 
molecular type VGII is highly virulent and is responsible for most infections in 
healthy hosts in an on-going outbreak in parts of Pacific Northwest USA and 
Canada (Byrnes et al, 2010; Byrnes et al, 2009a; Byrnes et al, 2011; Walraven 
et al, 2011). In human cryptococcal disease caused by C. gattii, molecular 
type‑associated clinical and host features have been observed. For instance, VGI 
infections often present with meningitis, including granulomas and lung lesions 
(Chen et al, 2012) while VGII infections typically display pulmonary disease 
(Galanis et al, 2009; Harris et al, 2011). Both VGI and VGII have a predilection 
for immunocompetent individuals. In contrast, molecular type VGIII has a 
predilection for infecting immunocompromised HIV/AIDS patients in Southern 
California and Southwestern USA and isolated cases outside the USA have been 
reported (Choi et al, 2010; Firacative et al, 2011; Hagen et al, 2012; Trilles et al, 
2008). VGIV has been seen to be associated with HIV/AIDS in Africa (Chen et al, 
2000; Sorrell et al, 1996). Apart from these four distinct haploid molecular types, 
the PCR fingerprinting and AFLP typing have demonstrated diploid or aneuploid 
hybrids. These hybrids are thought to have originated from mating events 
between major molecular types C. gattii and C. neoformans. These include 
VGI/VNIV (Serotype B and D, AFLP8) hybrids (Bovers et al, 2006), the VNI/VGI 
hybrids (AFLP9) (Aminnejad et al, 2012; Bovers et al, 2008b), and the VNI/VGII 
hybrids (AFLP11) (Aminnejad et al, 2012; Figure 1).  
Interestingly, there is an ongoing debate regarding the lineages and 
nomenclature of C. neoformans/C. gattii species complex mainly between the 
two-species concept proposed by Kwon-Chung and Varma (2006) and the 
sevens species concept by Bovers et al. (2008a) and Ngamskulrungroj et al. 
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(2009) and recently supported by Hagen et al. (2015). How this debate can have 
an impact on the care of patients with cryptococcal diseases fuels another 
debate. 
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Figure 1: Species of C. gattii/C. neoformans complex 
Classification of C. gattii/C. neoformans species complex and include species name, molecular 
types as described using MLST, AFLP, PCR fingerprinting and RFLP genotyping and proposed 
species names (Bovers et al, 2008a; Hagen et al, 2015; Ngamskulrungroj et al, 2009). 
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Clade I, AFLP2
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VNII
VNII
VNIV
VNIII
Clade D, AFLP4
Clade C, AFLP5
Clade A, AFLP6
Clade E, AFLP7
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VGI
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VGIV
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-
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1.3 Life cycle of Cryptococcus 
Cryptococcus is a basidiomycetous yeast that replicates by budding.  The 
budding yeast is the most frequently isolated form of C. neoformans from both 
patients and environmental niches. However, C. neoformans can undergo a 
transition from the yeast form to filamentous growth form via two distinct 
pathways: mating (sexual cycle) and monokaryotic fruiting. Filamentation enables 
the fungus to acquire nutrients outside the confines of the colony and in the 
production of basidiospores. Basidiospores are believed to be the infectious 
propagules of Cryptococcus  
Mating – C. neoformans is a heterothallic basidiomycete that means it can exist 
in two mating types, MATa and MATα. The sexual cycle involves fusion of 
opposite mating types, MATa and MATα haploid cells to produce dikaryotic 
filaments. Dikaryotic filaments eventually form a basidium. The two nuclei (from 
opposite mating types) of the basidium fuse and undergo meiosis to produce 
basidiospores comprised of MATα and MATa type spores in equal numbers 
(Kwon-Chung, 1975; 1976; 1980).  
There are significant differences in mating within the three Cryptococcus 
varieties. Mating in C. neoformans var. grubii is strain specific while 
C. neoformans var. neoformans is more robust and not confined to specific 
strains (Litvintseva et al, 2003; Nielsen et al, 2003). Mating has not been 
observed under laboratory conditions in C. gattii strains obtained from diverse 
sources and even in the environment where both MATa and MATα strains 
coexist, no evidence of recombination has been seen (Fraser et al, 2003; Halliday 
& Carter, 2003). A significant exception are the strains from Vancouver outbreak, 
which appear clonal and entirely of the MATα and mate robustly (Fraser et al, 
2003).  
Mating type determines virulence in C. neoformans. MATα type is the most 
virulent mating type and consists most (96 % average) clinical and environment 
isolates (Kwon-Chung & Bennett, 1978; 1984a; Litvintseva et al, 2005) with one 
published exception of a Cryptococcus species from sub-Saharan Africa, which 
has almost equal ratios of MATa and MATα cells (Litvintseva et al, 2003). It is 
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worthwhile to point out that mating of C. neoformans has never been reported 
occurring in nature, but C. neoformans readily mate under laboratory 
environment such as on media supplemented with pigeon excreta and live plants 
(Kwon-Chung, 1976; Nielsen et al, 2007; Xue et al, 2007). In less pathogenic 
C. neoformans var. neoformans, MATα type are most virulent whereas, 
co-infection of C. neoformans var. grubii with both mating types, results in MATa 
and MATα strains reaching the lungs and spleen at equivalent levels (Nielsen et 
al, 2003). However, MATα readily disseminate to the CNS than congenic MATa 
type (Nielsen et al, 2005). 
Monokaryotic fruiting is thought to be a modified form of mating but involves the 
fusion of the same mating type (Lin et al, 2005). For example, MATα cell develops 
into diploid (α/α) cells, via either endoduplication or fusion of the nuclei after 
recombination of the two cells. The diploid monokaryotic hyphae form unfused 
clamp connections. This results in the formation basidium, followed by meiosis 
and production of haploid basidispores (Wickes et al, 1996). Mating and 
monokaryotic fruiting have similar features. However, the filaments that are 
produced during fruiting have unfused clamp connections and with a single 
nucleus while those produced following mating have fused clamp connections 
and contain two nuclei (Wickes et al, 1996). Monokaryotic fruiting is frequently 
observed in MATα type and formation of basidiospores and filaments has been 
observed under laboratory conditions in C. neoformans var. neoformans strains 
in response to environmental stimuli including nitrogen deficiency, desiccation, 
and darkness (Wickes et al, 1996). Monokaryotic fruiting was first thought to be 
strictly an asexual reproduction. However, Lin et al (2005) demonstrated that 
fruiting is a form of sexual reproduction between strains of the same mating type 
(Lin et al, 2005). Recently, Fu et al (2013) showed that monokaryotic hyphal 
production could be activated by arresting yeast cell cycle in the G2 stage with 
high temperature (Fu et al, 2013). It is still unknown whether monokaryotic fruiting 
occurs in C. gattii.  
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1.3.1 Infective forms of C. neoformans  
Cryptococcus neoformans infection is acquired via inhalation of desiccated 
airborne yeast cells or sexually generated basidiospores into the lungs 
(Casadevall, 1998). However, size of the infectious propagule can pose as a 
restriction to pulmonary entry. For example, particles that are larger than 5µm 
such as encapsulate yeast are removed by the ciliary action of the lung epithelium 
(Hatch, 1961). Basidiospores have the potential to be deposited and penetrate 
the lung alveoli due to their small size (less than 2µm). Whereas yeast cells may 
lose their capsule upon exposure to conditions of low supply of moisture or 
deprivation of nutrients resulting in the reduction in size to less than 3µm (Ruiz et 
al, 1982; Wickes, 2002). Thus, desiccated yeast cells could also be small enough 
to get deposited and enter the lung alveoli following inhalation (Ellis & Pfeiffer, 
1990b; Sukroongreung et al, 1998; Velagapudi et al, 2009). Basidiospores are 
thought to be the main infectious propagule-causing cryptococcosis. For 
example, one study has shown that basidiospores are more virulent and require 
very few numbers to cause cryptococcosis in mice than desiccated yeast cells 
(Sukroongreung et al, 1998). Moreover, basidiospores are less likely to undergo 
desiccation and can easily become aerosolised.  However, encapsulated yeast 
cells struggle to survive in low supplies of moisture and deficiency of nutrients 
(Wickes et al, 1996). Using soluble components in receptor-ligand blocking 
experiments, Giles et al. (2009) identified Dectin-1 as a the most potential 
phagocytic receptor for C. neoformans spores (Giles et al, 2009). However, 
recent findings by the same group using a different approach, gain-of-function 
and loss-of-function assays with intact cells, demonstrated that Dectin-1 and 
other individual C-type lectins do not play critical roles in uptake and host innate 
defence by phagocytes against C. neoformans spores (Walsh et al, 2017) 
highlighting the need for further study into the pathogenesis of C. neoformans 
spores.  
1.3.2 C. neoformans genome 
The first genome of C. neoformans to be sequenced was that of laboratory strains 
JEC21 and B-3501A, which are closely related to VNIV 
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(C. neoformans var. neoformans). The 20 Mb genome is composed of 14 
chromosomes and over 6500 genes. The chromosomes are extremely rich in 
genes. However, there is a sole large cluster on each made up of degenerating 
transposons that are thought to represent centromeres (Loftus et al, 2005). Very 
recently, the genome sequence of C. neoformans var. grubii has been published 
(Janbon et al, 2014). It is approximately 18.9 Mb in length, which is similar to 
C. neoformans var. neoformans and C. gattii (D'Souza et al, 2011; Loftus et al, 
2005). It consists of 14 chromosomes and 6,962 protein-encoding genes that 
occupy 85% of the entire genome. Centromeres and intergenic regions make up 
the remaining 15%. Like other basidiomycetes, C. neoformans is richer in introns 
than many fungal species (Csuros et al, 2011). More than 40,000 introns have 
been identified in the genome, and most of these introns are located within the 
coding DNA sequence. Over 99 % of expressed genes have at least one intron 
(Janbon et al, 2014). 
1.4 Cryptococcosis 
1.4.1 Cause, transmission and affected organs, life cycle  
Cryptococcosis is a disease caused by the fungi of the genus Cryptococcus, 
mostly by the species C. neoformans and C. gattii. C. neoformans is thought to 
be acquired through inhalation of small basidiospores (about 1-2µm) or 
desiccated yeast cells (found in the environment) into the lung alveoli (Ellis & 
Pfeiffer, 1990a; Sukroongreung et al, 1998; Velagapudi et al, 2009). Incidental 
findings of C. neoformans yeast cells in pulmonary foci and hilar lymph nodes at 
autopsy are consistent with this hypothesis (Baker, 1976; Baker & Haugen, 1955; 
Salyer et al, 1974). Inhalation of C. neoformans can result in pulmonary 
colonisation or disease and can also disseminate to other organs but tends to 
localise in the central nervous system causing meningitis (Mitchell & Perfect, 
1995). Throughout life, humans are thought to be continuously exposed to 
C. neoformans. Individuals who have never been aware of having crytococcal 
infection have antibodies to C. neoformans (Chen et al, 1999). In fact, most 
children show antibody reactivity to C. neoformans before the age of five 
(Goldman et al, 2001). The outcome of C. neoformans infection depends on the 
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individuals’ immune status. In the immunocompetent, an efficient immune 
response will eliminate most of the inhaled cryptococci. However, in the 
immunocompromised, such as those with HIV/AIDS, cryptococcal cells will 
proliferate and disseminate to the brain by crossing the blood brain barrier and 
cause meningoencephalitis. Although C. neoformans can invade any organ in the 
human body, infection of the CNS is the most commonly identified and serious 
clinical manifestation of cryptococcosis. Without treatment, CNS infection is fatal. 
HIV-associated cryptococcosis often presents with meningitis rather than 
respiratory disease. Cryptococcal meningitis is an AIDS-defining disease in HIV 
infected patients (Mitchell & Perfect, 1995). In some immunocompetent 
individuals, cryptococcal infection can remain dormant but viable in small lymph 
complex in the lung without causing any overt symptoms (Baker, 1976; Garcia-
Hermoso et al, 1999; Salyer et al, 1974). If such individuals become 
immunocompromised later in life either due to HIV infection or corticosteroid 
treatment, the latent infection may become activated and begin to proliferate and 
disseminate into extrapulmonary sites (Dromer et al, 2011; Garcia-Hermoso et 
al, 1999). Other than pulmonary and brain involvement, C. neoformans has been 
reported to cause a distinct clinical entity involving the skin known as primary 
cutaneous cryptococcosis (Neuville et al, 2003).  
Unlike C. neoformans which predominantly affects the immunocompromised and 
presents with meningoencephalitis, pulmonary cryptococcosis is considerably 
more common with C. gattii infections, and mostly the immunocompetent are 
affected (Chen et al, 2000; Galanis et al, 2010). Similary, mice infected with 
C. neoformans die due to CNS involvement, while mice infected with C. gattii 
succumb to pulmonary infection (Ngamskulrungroj et al, 2012). Interestingly, 
C. gattii VGIII has a predilection for infecting immunocompromised HIV/AIDS 
patients in Southern California and Southwestern USA (28 of 276 cryptococcal 
strains) (Byrnes et al, 2011; Chaturvedi et al, 2005). Isolated cases outside the 
USA have also been reported (Choi et al, 2010; Firacative et al, 2011; Hagen et 
al, 2012; Trilles et al, 2008). However, the prevalence of C. gattii in HIV/AIDS 
patients is not well documented as recovered isolates are rarely assigned species 
status.  
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1.4.2 Epidemiology  
Although most people are exposed to Cryptococcus infectious propagules, they 
never become ill from it. C. neoformans infections are very rare in healthy 
individuals, and most cases occur in individuals with a pre-existing condition or 
disease. Predominantly, cryptococcosis due to C. neoformans affects individuals 
with advanced HIV/AIDS. However a growing number of cases are observed 
among solid organ transplant recipients, patients on prolonged 
immunosuppression therapy (glucocorticosteroids, cytotoxic chemotherapy, 
TNF-α inhibitors) and patients with hematological disorders such as chronic 
leukaemia and lymphoma (Pappas, 2001; 2013; Zhu et al, 2010). A very small 
proportion of cryptococcosis cases have been seen in clinically 
non-immunocompromised patients (Pappas, 2001; 2013; Zhu et al, 2010). On the 
other hand, C. gattii was mainly recognized as an emerging infection in healthy 
individuals in the northwest of North America (MacDougall et al, 2007). However, 
a subsequent report showed some of that patient population had underlying 
immunosuppression including HIV AIDS, solid organs transplant or corticosteroid 
treatment (Galanis et al, 2010; Harris et al, 2011). Below, I will describe the 
epidemiology of cryptococcosis categorised for HIV and non-HIV patients. µ 
1.4.2.1 In HIV/AIDS patients 
Cryptococcosis is the leading fungal cause of morbidity and mortality among HIV 
patients, and cryptococcal meningitis is an indication of the advanced stage of 
HIV infection (Mitchell & Perfect, 1995; Tenforde et al, 2017). The most recent 
estimates are that approximately 280 thousand cases and >180 thousand deaths 
occur each year due to cryptococcal meningitis among HIV/AIDS patients 
worldwide (Rajasingham et al, 2017). Cryptococcosis is the leading cause of 
meningitis among HIV/AIDS individuals in sub-Saharan Africa accounting for 
26 ‑ 60 % of all cases (Békondi et al, 2006; Gordon et al, 2000; Hakim et al, 2000; 
Rajasingham et al, 2015). About three-quarters of cryptococcal meningitis cases 
occur in sub-Saharan Africa followed by East, South and Southeast Asia 
(Rajasingham et al, 2017). Despite treatment with currently available anti-fungals, 
the mortality rate remains as high as 70 %  in resource-limited settings 
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(Baldassarre et al, 2014; Gaskell et al, 2014; Jarvis et al, 2014; Kendi et al, 2013; 
Lessells et al, 2011; Letsou & Gusberg, 1990; Rothe et al, 2013), 40 % in 
middle-income countries (Jongwutiwes et al, 2007; Rajasingham et al, 2012; 
Vidal et al, 2013) and approximately 20 - 30 % in high-income countries 
(Lortholary et al, 2006; Pyrgos et al, 2013; Rajasingham et al, 2017). In North 
America, there has been a substantial decline in HIV-associated cryptococcal 
meningitis due to early diagnosis combined with antiretroviral therapy (ART) 
(Mirza et al, 2003; Pyrgos et al, 2013). In contrast, this has not been the case in 
sub-Saharan Africa despite the expansion of ART access programs. For 
example, studies in South Africa and Botswana showed no significant reduction 
in the cases of HIV-associated cryptococcosis (Jarvis et al, 2009; Tenforde et al, 
2017). Recently, a clinical trial on HIV-associated cryptococcal meningitis 
reported that 49 % of the enrolled participants were already taking ART (Rhein et 
al, 2016), suggesting that the HIV-associated cryptococcosis remains a huge 
burden in developing countries despite mass ART programs in place. 
Interestingly, there is a huge discrepancy in the incidences of cryptococcosis 
between males and females including HIV- or organs transplant-associated 
cryptococcosis with males having higher incidences of C. neoformans infection 
than females (Hajjeh et al, 1995; Mitchell & Perfect, 1995; Tenforde et al, 2017). 
This difference was observed even in the pre-HIV era in which the incidence of 
cryptococcosis was 2-3:1 males:females (Edwards et al, 1970; Mitchell & Perfect, 
1995). A recent study by Carvour et al. (2015) showed that females present with 
more severe disease and are less likely to survive than males when data was 
adjusted for potential confounders such as age, race, birth sex, healthcare facility 
type and opportunistic infections (Carvour et al, 2015). This was a small study, 
and large studies are required to establish a hypothesis. As for C. gattii, the 
prevalence in HIV/AIDS patients is not known mainly due to lack of routine 
species allocation of most Cryptococcus isolates. However, C. gattii VGIII strain 
is responsible for HIV/AIDS associated infections in Southern California and 
abroad (Choi et al, 2010; Firacative et al, 2011; Hagen et al, 2012; Trilles et al, 
2008).  
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1.4.2.2 In HIV naïve patients  
Solid organs transplant patients - It is difficult to establish the worldwide incidence 
of cryptococcosis in HIV naïve patients because the numbers are masked by 
HIV-associated cryptococcosis particularly in low- and middle- income countries. 
In the United States, cryptococcosis is the third most common fungal infection 
(after invasive candidiasis and aspergillosis) among recipients of solid organs 
transplant (SOT) (Pappas, 2001; Pappas et al, 2010). Cryptococcosis usually 
occurs late, between 16 to 21 months post-transplantation (Pappas et al, 2010). 
The recipients of liver transplants develop cryptococcosis as early as under 12 
months-post-transplantation compared to kidney transplant recipients probably 
because of exacerbated immunosuppression in the former subgroup (Husain et 
al, 2001; Singh et al, 2007). The actual incidence of cryptococcosis in SOT 
recipients ranges from 0.2 – 5 % with an average of ~2.8 % (George et al, 2017; 
Person et al, 2010; Sun et al, 2009). The disease is confined to the lungs but may 
also spread to the CNS and other body organs. 39-55% of cryptococcosis cases 
in SOT recipients have CNS involvement (Husain et al, 2001; Pappas, 2001; 
Pappas et al, 2010; Singh et al, 2007). Data from one multinational study showed 
that 61% of the patients had disseminated cryptococcosis, about 32% of the 
patients had disease confined to the lungs, and 8.1% had skin, soft-tissue, or 
osteoarticular infections (Singh et al, 2007). Liver recipient patients are six-times 
more at risk of developing disseminated cryptococcosis than other types of SOT 
recipients. Fungemia is seen in up to 33% of SOT recipients with cryptococcal 
disease (Husain et al, 2001; Singh et al, 2007; Wu et al, 2002).  The mortality 
rates in SOT recipients with cryptococcal disease have ranged from 14-27% and 
as high as 49% in those with CNS involvement (Neofytos et al, 2010; Sun et al, 
2009; Wu et al, 2002). 
Non-HIV patients, non-transplant patients - Other than affecting patients with HIV 
or SOT recipients, cryptococcosis also occurs in individuals with other 
predisposing factors or underlying disease including cancer, steroids, diabetes 
mellitus, kidney disease, cirrhosis and in individuals with no identifiable 
immunodeficiency (Fang et al, 2015; Jongwutiwes et al, 2008; Lin et al, 2015; 
Pappas et al, 2001; Shih et al, 2000; Singh et al, 2015; Thomas et al, 1998; 
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Yuchong et al, 2012). A US study by Brizendine et al. (2013) showed that out of 
302 patients diagnosed with cryptococcal disease between 1996 and 2010, 36 % 
and 28 % were HIV positive and organs transplant recipients respectively while 
another 36 % were non-HIV, Non-transplant (NHNT) infected persons. Of the 
NHNT group, 36 % were phenotypically healthy patients, 25 % received steroid 
therapy, 28 % had cancer, and 11 % had chronic liver or renal disease while 12 % 
had diabetes mellitus (Brizendine et al, 2013). Of note, cases of C. neoformans 
among apparently immunocompetent patients occur across the globe with most 
cases reported in Asia (Zhu et al, 2010). Cryptococcal disease has also been 
associated with genetic polymorphism of phagocytic FCGR2A and 3A genes in 
HIV naïve Caucasians (Meletiadis et al, 2007), polymorphism of non-phagocytic 
FCGR2B but not FCGR3A in the Chinese population (Hu et al, 2012) and 
polymorphism of FCGR3A in HIV infected patients (Rohatgi et al, 2013). 
Recently, Panackal et al. (2015) reported a group of non-HIV with crytococcal 
meningitis that displayed activation and expansion of intrathecal cells including 
HLA-DR+, CD4+ and CD8+ cells. The T cells expressed increased levels of IFNγ 
and reduced levels of IL-2 and IL-13. However, despite maintained recruitment 
of macrophages to the site of infection, they were characteristically M2 
macrophages and demonstrated poor uptake of fungal cells suggesting that 
failure of macrophage activation risks susceptibility of cryptococcal disease 
(Panackal et al, 2015). 
Meningoencephalitis caused by C. gattii in the immunocompetent has been 
reported throughout the tropics including Australasia (Speed & Dunt, 1995), 
South America and particularly in the ongoing outbreak in the Pacific Northwest 
of North America since 1999 (Phillips et al., 2015). C. gattii was thought to occur 
only in apparently immunocompetent individuals, however, of the 76 patients in 
US C. gattii outbreak between 2004 and 2010, 76 % of them had pre-existing 
predisposing conditions including steroid therapy, chronic lung, kidney or heart 
diseases and other conditions (Harris et al, 2011). Anti-GM-CSF has also been 
associated with cryptococcal meningitis caused by C. gattii in otherwise 
immunocompetent individuals (Rosen et al, 2013; Saijo et al, 2014). 
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Thus, the foregoing demonstrates the diversity of susceptible populations ranging 
from apparently healthy hosts to individuals with significant immunological 
impairments caused by chemotherapy or immunosuppressive therapy, organ 
dysfunction and those with immunodeficiencies, either innate or acquired. Given 
the heterogeneity of the host groups, it is difficult to draw conclusions regarding 
epidemiology, clinical presentation or outcomes of each group.   
1.4.3 Clinical manifestations 
1.4.3.1 CNS cryptococcosis 
Clinical manifestations of cryptococcosis most commonly involve the lungs, 
central nervous system and rarely other body organs. Cryptococcal meningitis 
(CM) is a subacute meningoencephalitis and is the most common clinical 
presentation of cryptococcosis in HIV-infected patients (Mitchell & Perfect, 1995). 
Patients with CM usually present with neurological symptoms, including a 
headache and altered mental status which may be accompanied by fever, nausea 
and vomiting. The median incubation period from onset of symptoms to 
presentation is two weeks in HIV-associated CM and 6-12 weeks in HIV naïve 
patients. A significant number of patients develop visual problems, such as 
diplopia and the subsequent reduction in acuity as a result of high intracranial 
(CSF) pressure and/or optic nerve involvement (Moodley et al, 2012). In the 
absence of treatment, the patient may become confused, develop seizures and 
reduced level of consciousness resulting in coma (Bicanic & Harrison, 2004; 
Mitchell & Perfect, 1995). In non-HIV infected patients, there is a significant 
heterogeneity, and clinical manifestation can be influenced by the patient’s 
immune competency (Pappas, 2001).  
1.4.3.2 Pulmonary cryotococcosis 
Pulmonary cryotococcosis is the most common manifestation of disease in 
HIV-negative (non-immunocompromised) patients (Kiertiburanakul et al, 2006). 
Pulmonary cryptococcosis is not commonly reported and is certainly 
misdiagnosed as other pulmonary infections such as tuberculosis in the 
immunocompromised (Batungwanayo et al, 1992; Bernicker et al, 1996; Jarvis et 
al, 2010; Murray et al, 1999; Wong et al, 2007). Approximately 10-55% of 
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HIV-associated cryptococcosis present as pulmonary disease (Reviewed in 
Jarvis & Harrison, 2008). The clinical pattern of cryptococcal pulmonary disease 
is significantly heterogeneous, ranging from asymptomatic colonisation to severe 
symptoms such as pneumonia and acute respiratory distress syndrome 
(Campbell, 1966; Nadrous et al, 2003; Perfect et al, 1983). In most cases, 
patients present with coughing with scanty sputum, chest pain, fever, malaise, 
dyspnoea, pleuritic chest pain and very rarely, haemoptysis and weight loss 
(Chechani & Kamholz, 1990; Meyohas et al, 1995; Rozenbaum & Gonçalves, 
1994; Wasser & Talavera, 1987). Often, clinical presentations are 
indistinguishable from other causes of pneumonia in these patients (Loerinc et 
al, 1988; Visnegarwala et al, 1998). Pleural effusion, cavitation, and hilar 
lymphadenopathy have been described in patients with immune reconstitution 
inflammatory syndrome (IRIS) (Jenny-Avital & Abadi, 2002; Trevenzoli et al, 
2002). The disease progresses rapidly in immunocompromised hosts and may 
require anti-fungal therapy. Pulmonary cryptococcosis may ensue in the absence 
of disseminated disease, and similarly, disseminated disease (i.e. meningitis) 
may develop in the absence of noticeable pulmonary pathology. In normal hosts, 
infection is confined to the lung and may not require active treatment (Aberg et 
al, 1999; Chang et al, 2006; Kerkering et al, 1981; Nadrous et al, 2003). However, 
symptoms when present are the same as in the immunocompromised and may 
be mild to severe (Emmons et al, 1995; Mitsuoka & Kanazawa, 2005; Nadrous et 
al, 2003).  
1.4.3.3 Cryptococcosis in other sites 
Other than the lung and CNS involvement, the next most common organs of 
disseminated cryptococcosis include the skin and medullary cavity of bones 
(Mitchell & Perfect, 1995). Cutaneous cryptococcosis usually presents in the form 
of papules, pustules, nodules, ulcers or draining sinuses (Neuville et al, 2003). 
Umbilicated papules that can be mistaken for molluscum contagiosum have been 
reported in HIV-positive patients (Gasiorowski et al, 2001; Picon et al, 1989). 
Cellulitis with necrotising vasculitis has been seen in SOT recipients (Baer et al, 
2009; Horrevorts et al, 1994; Sun et al, 2010), patients with long-term 
corticosteroid treatment (Hafner et al, 2005) and a patient with rheumatoid 
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arthritis (Probst et al, 2010). Cryptococcal disease with bone involvement 
manifests osteolytic lesions that resemble cold abscesses and may be 
misdiagnosed as tuberculosis or neoplasm (Burch et al, 1975; Wood & 
Miedzinski, 1996). Very rare forms of cryptococcosis include myocarditis, 
hepatitis, renal disease, prostatitis, peritonitis and adrenal involvement (Joshi et 
al, 1989; Lewis et al, 1985; Siddiqui et al, 2005b). 
1.4.4 Diagnosis  
The physical findings to make a diagnosis in patients with cryptococcosis highly 
dependent on the immunocompetence of the patient prior to infection and the site 
or sites involved. For example, due to the poor inflammatory response to 
cryptococci, particularly in those patients with advanced HIV infection, the organs 
or tissue may be largely affected before patient present for medical evaluation 
thus obscuring diagnosis. Below I will describe steps taken for diagnosis of CNS 
and pulmonary cryptococcal disease.  
1.4.4.1 Cryptococcal meningitis  
There are several tests that are used for the diagnosis of cryptococcal disease 
involving the CNS (Boulware et al, 2014). The standard diagnostic methods focus 
on detection by microscopy, culture or antigen. The methods include India ink 
staining, CSF culture and cryptococcal antigen test (CrAG). India ink test remains 
the common diagnostic method for identifying Cryptococcus in CSF and yet has 
a sensitivity of less than 86% and is even less sensitive in patients with low fungal 
burden (Coovadia et al, 2015; Dominic et al, 2009). CSF culture is considered 
the gold standard; however, it requires laboratory infrastructure, trained 
personnel, can take longer (up to 10 days) and can also give false negative 
results when fungal burden is low (Barenfanger et al, 2004). However, despite 
the downsides of quantitative CSF culture, the method is used to measure 
response to treatment and is important in the diagnosis and differentiation of 
cryptococcal meningitis relapse and paradoxical cryptococcal immune 
reconstitution inflammatory syndrome (IRIS) (Boulware et al, 2010; Haddow et al, 
2010). The other method that has become an important diagnostic method is the 
detection of cryptococcal antigen (CrAg) in CSF, serum or plasma. The WHO 
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guidelines recommend that lumbar puncture should be performed promptly and 
rapid CSF CrAg assay carried out on all patients with HIV with suspected 
cryptococcal meningitis (WHO, 2011). Several platforms for the detection of CrAg 
including latex agglutination or enzyme immunoassays that have been available 
for several years (Temstet et al, 1992). The recently developed CrAg lateral flow 
test detects the cryptococcal polysaccharide capsule by use of gold-conjugated 
anti-cryptococcal monoclonal antibodies impregnated onto an 
immunochromatographic test strip (Vidal & Boulware, 2015). This test is stable at 
room temperature, inexpensive and takes minutes to acquire results. A recent 
multi-national diagnostic study found that CrAg lateral flow assays (LFA) have 
99.3 sensitivity and 99.1% specificity in CSF (Boulware et al, 2014). There is a 
semi-quantitative CrAg LTA that has been shown to correlate with quantitative 
cultures before treatment, but its usefulness drastically falls-short when 
monitoring treatment response (Kabanda et al, 2014).  
1.4.4.2 Pulmonary cryptococcosis  
Diagnosis of pulmonary cryptococcosis involves isolation of Cryptococcus from 
the pulmonary sample in addition to related clinical and radiological findings. In 
the immunocompetent, single or multiple pulmonary nodules are frequently found 
ranging from 5 to 30 mm in diameter. The immunocompromised display a wide 
spectrum of radiological abnormalities, with a reduced proportion of nodules but 
are associated with diffuse, spreading disease (Jarvis & Harrison, 2008). Other 
common abnormalities include lymphadenopathy, lesions and pleural effusions, 
which are indistinguishable from pulmonary tuberculosis (Chen et al, 2015; 
Dogbey et al, 2013; Young et al, 1980). Microscopic examination of respiratory 
specimens such as sputum, Cryptococcus appear as an encapsulated budding 
yeast. Culture on selective media takes 2 to 5 days for colonies to develop. 
However, whilst sputum culture has been widely described for diagnosis, it is not 
routinely used for diagnosis. Yeast cells observed in HIV positive patients may 
be assumed as Candida (Driver et al, 1995). Another diagnostic method that has 
been reported for cryptococcal pneumonia is through bronchoscopy and testing 
bronchoalveolar lavage samples with CrAg (Baughman et al, 1992; Chechani & 
Kamholz, 1990; Malabonga et al).  
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1.4.5 Management of cryptococcal disease  
The management of cryptococcosis depends on the severity of the infection and 
the affected body organs.  
1.4.5.1 Management of meningeal cryptococcosis  
The management of meningitis is categorised into three phases: which includes 
induction, consolidation and maintenance treatment. The ultimate objective of the 
induction treatment is the rapid sterilisation of the cerebrospinal fluid which is 
measured by the rate of fungal clearance per millilitre of CSF per day. Early 
fungicidal activity (EFA) is a term used to describe the quantitative clearance. 
Slower rates of EFA are associated with high mortality at two and ten-week post 
initiation of therapy (Bicanic et al, 2009). The current guidelines by the Infectious 
Disease Society of America (IDSA) recommend two weeks of intravenous 
amphotericin B at 0.7-1.0mg/kg per day plus oral flucytosine (100mg/kg per day) 
for treatment of cryptococcal meningitis as an induction therapy. Amphotericin B 
is known to cause serious side effects including anaemia, kidney problems, 
hypokalaemia, and phlebitis. Amphotericin B is administered intravenously and 
thus requires inpatient hospitalisation and significant nursing care. Therefore, 
amphotericin B therapy should include pre-hydration, electrolyte replacement, 
monitoring and management of toxicity. In resource-limited settings where 
flucytosine is unavailable or where resources are not reliable or sustainable to 
monitor and prevent amphotericin B toxicity, the IDSA and the WHO recommends 
initial induction therapy for 1 week of intravenous amphotericin B (1mg/kg per 
day) in combination with 2 weeks of fluconazole (800mg/kg per day) (Perfect et 
al, 2010; WHO, 2011). High dose fluconazole (1200mg/kg per day) monotherapy 
for 10-12 weeks is recommended if amphotericin B and flucytosine are 
unavailable (Perfect et al, 2010; WHO, 2011). 
The second phase, following two weeks of induction is consolidation therapy that 
consists of fluconazole 400-800mg/day for at least eight weeks (Perfect et al, 
2010). However, in case induction monotherapy of fluconazole (1200mg/kg per 
day) is used or CSF sterility has not been achieved at end of 2 week-induction 
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therapy, the high-dose fluconazole should continue throughout the consolidation 
phase (Perfect et al, 2010).   
Following satisfactory induction and consolidation treatment, CSF 
culture-negative patients should be given a maintenance therapy of fluconazole 
200mg per day (Perfect et al, 2010; WHO, 2011). This maintenance therapy is 
recommended to avoid relapse as shown before in patients who discontinued 
treatment (Bozzette et al, 1991). IDSA recommends that maintenance therapy 
can be discontinued if the patient is on ART and has had over three months of 
undetectable HIV RNA levels with a CD4+ cell count of ≥100 cells/µL (Perfect et 
al, 2010). In settings where viral load testing is not available, maintenance 
therapy must be continued for 12 months and discontinued only if CD4+ cell 
counts are more than 200 cells/µL (WHO, 2011). If the patient shows 
immunological failure, poor adherence to ART, or reduction of the CD4+ cell count 
to less than 100 cell/µL, then fluconazole maintenance therapy should be 
reinstituted (Perfect et al, 2010).  
1.4.5.2 Management of cryptococcosis complications  
Intracranial pressure - Approximately 50 % of HIV-infected patients with 
cryptococcal meningitis have higher baseline intracranial pressure of >25cm of 
CSF and is associated with high fungal burden in the CSF (Rhodes et al, 1980). 
IDSA and WHO guidelines recommend that a baseline CSF pressure is obtained 
and baseline lumbar puncture (LP) carried out promptly. If the intracranial 
pressure is ≥25 cm of CSF and there are symptoms associated with increased 
intracranial pressure, then an LP should be done to drain the CSF to reduce the 
pressure to normal (≤20 cm of CSF) or by half if it is extremely high. Additional 
LPs including daily LPs should be carried out if necessary until the normal 
pressure has been reached. IDSA further recommends that LP should wait if the 
patient has focal neurological signs or a compromised mentation pendant CT or 
MRI scan (Perfect et al, 2010). If the scan identifies an obstruction that needs 
decompression, then drainage can be performed safely using ventriculostomy of 
VP shunt (Woodworth et al, 2005).  
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Cryptococcal immune reconstitution inflammatory syndrome - Following 
treatment of cryptococcal meningitis and ART initiation, some patients may 
present with clinical manifestations of recurrent symptomatic cryptococcal 
meningitis. These patients are suspected to have developed a paradoxical 
cryptococcal immune reconstitution inflammatory syndrome (C-IRIS), treatment 
failure or relapse.  IRIS is a condition observed in some AIDS or 
immunosuppressed patients on ART in which the immune system begins to 
recover but then overreacts to previously treated opportunistic infections or 
subclinical infections that paradoxically cause the symptoms of the severe 
infection (Cheng et al, 2000; Shelburne et al, 2002). Although treatment failure 
and C-IRIS are highly indistinguishable, patients with paradoxical C-IRIS usually 
present with symptoms of meningitis with negative CSF culture and higher CSF 
white blood cell (WBC) count whereas the former have a positive CSF culture 
and non-pronounced CSF inflammatory profile (Boulware et al, 2010; Haddow et 
al, 2010).   
Management of C-IRIS - Management of C-IRIS includes management of 
increased intracranial pressures that involves drainage of large volumes of CSF 
using lumbar puncture. IDSA guidelines recommend administration of 
0.5-1mg/kg of prednisone or dexamethasone to be spread over a period of 2-6 
weeks. These recommendations are mainly based on opinions of experts and 
clinical experience and not on research findings (Abassi et al, 2015; Perfect et al, 
2010).  
1.4.5.3 Management of non-meningeal cryptococcosis  
Pulmonary cryptococcosis - Cryptococcosis involving the lungs encompasses 
clinical manifestations ranging from asymptomatic pneumonia to severe acute 
respiratory distress syndrome (ARDS) (Pappas et al, 2001; Vilchez et al, 2001; 
Visnegarwala et al, 1998). The goal of the treatment regimen is to gain control of 
the signs and symptoms of cryptococcal pneumonia and prevent dissemination 
to the CNS. IDSA recommends firstly ruling out meningitis in immunosuppressed 
patients with pulmonary cryptococcosis because cryptococcal meningitis will 
require differing dosage and length of induction therapy. Cryptococcal pneumonia 
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associated with CNS disease or severe pneumonia should be treated like 
cryptococcal meningitis (Perfect et al, 2010). For moderate symptoms without the 
presence of pulmonary infiltrates and immunosuppression, patients should be 
treated with oral fluconazole 400mg per day for 6-12 months, however, if a patient 
is HIV-positive, on ART and has a CD4+ count of >100 cells/µL, the fluconazole 
treatment should be longer than 12 months. For patients with ARDS and IRIS 
corticosteroids treatment should be considered to dampen the immune response. 
In addition, surgery should be considered in patients with persistent symptoms of 
pneumonia and radiographic abnormalities that are unresponsive to anti-fungal 
therapy (Perfect et al, 2010). In case fluconazole is unavailable or 
contraindicated, IDSA recommends the use of itraconazole, voriconazle or 
posaconazole as alternatives (Perfect et al, 2010).  
Non-meningeal, non-pulmonary cryptococcosis - In the majority of patients, 
non-meningeal and non-pulmonary cryptococcosis represent a disseminated 
form whose clinical pattern is restricted to a single organ or tissue. Thus, IDSA 
recommends that a similar treatment regimen to that of CNS or disseminated 
cryptococcosis should be considered. The selection of anti-fungal drugs and 
duration should depend on the patient’s immune status, responsiveness to 
treatment and disease severity. In patients with no obvious immunosuppressive 
risk factors, without CNS disease or fungemia but with localised infection, 
treatment similar to moderate pneumonia should be prescribed (Perfect et al, 
2010).  
1.4.6 C. neoformans virulence factors 
1.4.6.1 The Capsule 
C. neoformans is the only fungal pathogen with a capsule, a distinctive 
polysaccharide structure surrounding the cell body. The capsule is invisible by 
regular microscopy but can be made visible by suspending the yeast in an India 
ink preparation and is seen as a characteristic clear zone outside the cell wall 
(Figure 2). The capsule is composed of the two major types of polysaccharides, 
glucuronoxylomannan (GXM; 90-95%) and glucuronoxylomannogalactan 
(GXMGal; 5-10%) (Bose et al, 2003; Cherniak et al, 1982; Cherniak & Sundstrom, 
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1994). In addition, the capsule also contains 1 % of mannoproteins (MP) but its 
role in the capsule architecture remains unknown (Cherniak & Sundstrom, 1994; 
Jesus et al, 2010; Rodrigues & Nimrichter, 2012). Its diameter is roughly 4-6 μm 
but can reach up to 30 μm (Aksenov et al, 1973; Granger et al, 1985; Vartivarian 
et al, 1993). The function of the capsule in the environment is not known, however 
it is speculated that the capsule acts as a food source and protects the fungus 
from environmental desiccation and predators such as nematodes and amoebae 
(Chrisman et al, 2011; García-Rodas et al, 2011; Mylonakis et al, 2002; 
Steenbergen et al, 2003).  
Virulence - The polysaccharide capsule is the main virulence factor of 
C. neoformans and in the host, it operates by disrupting normal immune cell 
responses at different levels during infection to evade killing by host cells. For 
example, the capsule demonstrates robust anti-phagocytic properties by 
providing a physical and chemical shield to fungal motifs that bind to macrophage 
receptors (Bolaños & Mitchell, 1989; Bulmer & Sans, 1967; Granger et al, 1985; 
Levitz & DiBenedetto, 1989; McGaw & Kozel, 1979), thus preventing recognition 
and inhibiting phagocytosis of the fungus. Acapsular mutants are readily 
phagocytosed, however, the addition of purified polysaccharide prevents uptake 
by phagocytes (Kozel, 1995). In addition, acapsular mutants fail to replicate inside 
phagocytes (Feldmesser et al, 2000) suggesting that the capsule is required for 
intracellular survival. The soluble polysaccharides are also thought to interfere 
with macrophage metabolism by binding to glycolytic enzymes such as 
phosphofructokinase following leakage into the cytoplasm due to permeable 
phagolysosomes (Grechi et al, 2011). One of the interesting characteristics of the 
capsule is its ability to change size in response to changes in the 
microenvironmental. For example, during infection and interaction with 
macrophages the capsule significantly increases in size (Feldmesser et al, 2001), 
presumably a virulent phenotype to deter phagocytosis. In the mammalian host, 
the capsule is involved in inhibition of phagocytosis and modulating immune 
response to its favour (Zaragoza et al, 2008). The capsule also protects the 
fungus against reactive oxygen species, which are vital antimicrobial molecules 
produced by macrophages (Zaragoza et al, 2008). In contrast to acapsular 
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mutants, ingested encapsulated C. neoformans cells do not induce nitric oxide 
synthase production in macrophages (Naslund et al, 1995). 
Synthesis and regulation of capsular polysaccharide - Genes required for 
biosynthesis of the polysaccharide capsule include cap59 (Chang & Kwon-
Chung, 1994), cap64 (Chang et al, 1996), cap60 (Chang & Kwon-Chung, 1998) 
and cap10 (Chang & Kwon-Chung, 1999). Disruption or deletion of any of these 
genes results in loss of virulence in mice models of cryptococcal infection (Chang 
& Kwon-Chung, 1994; 1998; 1999; Chang et al, 1996). In addition, the capsule of 
C. neoformans is highly regulated with regards to its size and complexity to 
enable survival of the fungus within the host. Depending on environmental 
conditions, the size of the capsule varies, becoming specifically large during 
mammalian infection (Rivera et al., 1998). In vitro, capsule expansion is possible 
under conditions similar to host environments such as low iron, serum, 
physiological concentrations of CO2 and pH (pH7) (Bahn et al, 2005; Vartivarian 
et al, 1993; Zaragoza et al, 2003). The iron sensing mechanisms that regulate 
capsule formation include transcription factors Hap3 and Hap5 (Jung et al, 2010), 
the HOG pathways (Bahn et al, 2005) and chromatin remodelling involving 
histone acetyltransferase Gcn5 (O'Meara et al, 2010). In addition, there is a 
correlation between strain virulence and the size of the capsule in vivo (Clancy et 
al, 2006) indicating that regulation of capsular size is important in the 
pathogenesis of cryptococcal infection. 
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Figure 2: Cryptococcal capsule in India ink staining and electron microscopy 
micrograph 
Micrographs were taken (A) under light and (B) scanning electron microscopy with Cryptococcus 
suspended in India ink (images obtained and modified from Zaragoza et al. (2009).
10µmm
BA
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1.4.6.2 Melanin 
Melanin is a brown-black pigment that is synthesised by a process catalysed by 
laccase in the presence of o-diphenolic compounds such as 
3,4‑dihydroxyphe‑nylalanine (L-Dopa) and accumulates in the cell wall 
(Eisenman et al, 2007; Wang et al, 1996; Williamson, 1997; Williamson et al, 
1998). It is believed that melanin protects C. neoformans from UV light and 
extremely high or low temperatures in the environment (Rosas & Casadevall, 
1997; Wang et al, 1995; Wang & Casadevall, 1994). During infection, melanin 
protects C. neoformans from toxic oxygen- and nitrogen-derived oxidants 
released by host immune cells (Casadevall et al, 2000; Nosanchuk et al, 2000).  
Apart from its ability to absorb these free radicals, melanin protects 
C. neoformans from killing by anti-fungal drugs. For example, melanised 
C. neoformans are more resistant to amphotericin B and caspofungin, compared 
to non-melanised cryptococci (Ikeda et al, 2003; van Duin et al, 2002). Melanised 
cells are also resistant to phagocytosis, cell death and are more virulent than non-
melanised cells (Casadevall et al, 2000; Huffnagle et al, 1995) suggesting that 
melanin is a key virulence factor of C. neoformans. Melanin may also inhibit T 
cell-mediated pulmonary inflammation and immunity (Huffnagle et al, 1995). It is 
thought that the predilection of C. neoformans for the CNS is associated with its 
ability to convert catecholamines such as dopamine, norepinephrine and 
epinephrine into melanin (Polacheck et al, 1990). Catecholamines function as 
neurotransmitters in the CNS. This hypothesis is consistent with the observation 
that catecholamine rich areas of the brain are often infiltrated with C. neoformans 
during cryptococcal meningitis, and fungal cells isolated from the brain appear 
pigmented upon microscopic examination (Lee et al, 1996). Progressive 
thickening and pigmentation of the fungal cell wall have also been observed 
during infection in a murine model of cryptococcal meningitis (Nosanchuk et al, 
1999; Rosas et al, 2000). 
1.4.6.3 Anti-phagocytic protein 1 
Cryptococcus neoformans secretes anti-phagocytic protein (App1). App1 is 
downstream of the sphingolipid pathway and is present in the supernatant of 
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C. neoformans culture (Luberto et al, 2003). The Δapp1 C. neoformans mutant is 
readily phagocytosed by macrophages (Luberto et al, 2003). Addition of rApp1 
protein blocks the complement-mediated phagocytosis of C. neoformans in a 
dose-dependent manner (Luberto et al, 2003). App1 binds to complement 
receptor, CR3 and anti-phagocytic activity of rApp1 is completely abrogated in 
alveolar macrophages in the absence of CR3 (Stano et al, 2009).  
1.4.6.4  Urease  
Fungi produce enzymes that are required for the breakdown of molecules to 
obtain nutrients from the surrounding environment. C. neoformans also secretes 
several enzymes one of which is urease. Since C. neoformans is often present in 
avian droppings (Patridge & Winner, 1965), the fungus must breakdown 
creatinine, xanthines and uric acid to survive and proliferate in this environment. 
Urease catalyses the hydrolysis of urea to ammonia and carbamate (Kwon-
Chung et al, 1987; Vogel, 1969; Zimmer & Roberts, 1979). C. neoformans urease 
mutant strain has significantly reduced virulence than the wild-type in murine 
models of infection since mice infected with the mutant survive longer than mice 
infected with the wild-type strain (Cox et al, 2000; Olszewski et al, 2004). In 
addition, urease knockout C. neoformans strains cause meningitis but not 
pneumonia (Cox et al, 2000). Urease plays an important role in fungal 
transmigration through epithelial barriers and dissemination to the brain but is not 
essential for growth in the brain (Olszewski et al, 2004; Shi et al, 2010; Singh et 
al, 2013). Although urease activity has been demonstrated in most clinical 
isolates (Bava et al, 1993; Cox et al, 2000; Ruane et al, 1988), occasional 
urease-negative strains have also been recovered in clinical isolates (Bava et al, 
1993). This indicates that urease may be dispensable for infection, provided other 
virulence factors compensate for its roles in virulence. 
1.4.6.5 Thermotolerance  
The ability of C. neoformans to grow at mammalian temperatures is essential for 
virulence (Martinez et al, 2001; Perfect, 2006; Robert & Casadevall, 2009). Since 
the ability to grow at physiological temperatures is a prerequisite for any 
pathogen, the thermotolerance of C. neoformans is essential over any other 
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virulence factor (Robert & Casadevall, 2009). Most Cryptococcus species 
possess other virulence factors including capsule and laccase but do not cause 
disease in mammals because they are unable to grow at physiological 
temperatures (Petter et al, 2001). Similar findings have been demonstrated in 
vertebrate and invertebrate models of infection (Garcia-Solache et al, 2013; 
McClelland et al, 2006). 
1.4.6.6 Phospholipase 
Phospholipase is an enzyme that breaks down phospholipids. An isoform of 
phospholipase B, Plb1, is produced during infection and promotes fungal viability 
within phagocytes (Cox et al, 2001).  Deletion of Plb1 results in reduced virulence 
and decreased capacity to disseminate to the brain (Cox et al, 2001). 
C. neoformans culture supplemented with phospholipids induces the expression 
of Plb1 and increases capsule size. Break down of host phospholipids by Plb1 
may facilitate damage to the phagosome enabling fungal cells to acquire nutrients 
from the cytoplasmic components (Chrisman et al, 2011). Interestingly, Plb1 
mutant strains demonstrates decreased vomocytosis and intracellular 
proliferation compared to controls (Chayakulkeeree et al, 2011; Evans et al, 
2015) suggesting that this enzyme is important for survival in the phagosome.  
1.4.6.7 Other virulence factors 
Apart from virulence factors described above, C. neoformans has others that 
have been discussed in this recent review (Coelho et al, 2014).  
1.4.7 Pathogenesis of C. neoformans  
This section will give a general overview of immune responses to cryptococcal 
infection and the subsequent sections will describe in detail the role of various 
immune components in cryptococcal infection.  
Following inhalation of spores or desiccated yeast cells into the lungs, 
C. neoformans encounters alveolar macrophages or dendritic cells which will 
phagocytose the fungus and then initiate an appropriate immune response. The 
responses include secretion of cytokines, activation and recruitment of immune 
cells and presentation of antigen to the T cells (reviewed (Levitz, 1994). In most 
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immunocompetent individuals, C. neoformans is cleared, while in others, the 
fungus will be confined within a self-limiting granuloma in the hilar lymph nodes 
at the site of infection (Dromer et al, 1992; Goldman et al, 2001). This granuloma 
is characteristically composed of a compact aggregate of macrophages with 
multinucleated giant cells and histiocytes containing numerous yeasts within their 
cytoplasm (Levitz, 1994; Shibuya et al, 2005). CD4+ lymphocytes are also seen 
at the site (Shibuya et al, 2002). The coincidental findings of cryptococcal 
granulomas in lungs at autopsy lead to the hypothesis that some 
immunocompetent individuals harbour the granuloma until death without 
developing overt disease (Baker, 1976; Haugen & Baker, 1954; Salyer et al, 
1974). However, in the immunocompromised, such as those with AIDS, a totally 
different histology is seen in the lungs. There is a significantly reduced numbers 
of lymphocytes and histiocytes accompanied by extracellular and proliferating 
yeast cells (Shibuya et al, 2002; Shibuya et al, 2005). It is thought that the 
immunocompromised fail to control the pulmonary cryptococcal colonisation 
resulting in dissemination to other organs with a predilection for the CNS (Mitchell 
& Perfect, 1995; Figure 3).  
It appears that C. neoformans infection occurs throughout the course of one’s 
entire life. For example, serological studies have shown that over three-quarters 
of children aged between 0-10, living in urban areas have been infected with 
C. neoformans, although they did not present any obvious clinical manifestations. 
Moreover, their antibody titres increased with age (Chen et al, 1999; Goldman et 
al, 2001) suggesting an occurrence of repeated infections. It is thought that 
almost all cases of clinical cryptococcosis are a result of reactivation from latency 
in instances where severe defects in cell-mediated immunity (CMI) have occurred 
(Garcia-Hermoso et al, 1999; Mitchell & Perfect, 1995).
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Figure 3: Pathogenesis of cryptococcosis 
(a) Infection occurs when host inhales infectious propagule, usually desiccated yeast or 
basidiospores from the environment. (b) This is followed by recruitment of phagocytes and 
ingestion of the fungi. Three outcomes are expected and depend on the immunocompetence of 
the infected host. (c-e) Infection in the immunocompetent host may be (c) cleared  or remain (d) 
dormant in a self-limiting granuloma which may lead to (e) clearance. (f-g) In the 
immunocompromised host (f) granuloma consist of large numbers of extracellular cryptococci (g) 
leading to dissemination to the CNS. 
Images were taken and modified from 
http://www.csus.edu/indiv/m/mckeoughd/aanatomyrev/cns/cns%20frontal/cnsfrontal.htm 
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1.4.7.1 Dissemination to the CNS 
Dissemination of the fungus from the lungs via the circulatory system into the 
CNS compartment is the distinct feature of cryptococcal pathogenesis. Three 
hypothetical mechanisms of how C. neoformans makes its way through the blood 
brain (BBB) barrier have been proposed (Figure 4). First, through a process 
called paracytosis, in which the cryptococci penetrate between tight junctions of 
endothelial cells. A protease such Mpr1 is thought to enhance trans-endothelial 
migration (Vu et al, 2014). Interestingly, addition of C. neoformans MPR1 into 
Saccharomyces cerevisiae genome enabled the fungus to penetrate through 
endothelial cells in an in vitro transwell assay (Vu et al, 2014). S. cerevisiae does 
not normally cross the BBB. Furthermore, using intravital imaging, Shi et al. 
(2010) showed that C. neoformans cells get trapped in the mouse brain capillary 
and then cross the microvasculature and urease is required for transmigration 
into the brain (Shi et al, 2010). Second, transcytosis has been proposed to be 
another means C. neoformans access the brain (Chang et al, 2004). 
C. neoformans hyaluronic acid located on the cell surface attaches to CD44 on 
the brain microvascular endothelial cells (Jong et al, 2008). This attachment 
activates protein kinase C-dependent actin remodelling in the endothelial cells, 
resulting in uptake of the attached Cryptococcus cell (Jong et al, 2008). The third 
proposed hypothesis for C. neoformans crossing the BBB is by hiding inside 
macrophages, referred to as ‘Trojan horse’ (Charlier et al, 2009; Santiago-Tirado 
et al, 2017; Sorrell et al, 2016). This idea is held by the observation that deletion 
of alveolar macrophages in a murine model significantly attenuates cryptococcal 
dissemination to the brain (Kechichian et al, 2007). In addition, infecting bone 
marrow-derived monocytes with C. neoformans in vitro and transferring the cells 
to mice results in increased brain cryptococcal CFU compared to administration 
of free fungal cells alone (Charlier et al, 2009) suggesting that phagocytes act as 
fungal carriers into the brain.  
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Figure 4: Crossing the blood-brain barrier  
Illustration of three possible ways C. neoformans can penetrate the BBB into the CNS (a) 
Transcytosis (b) paracytosis (c) ‘Trojan horse’ (Liu et al, 2012; May et al, 2016). 
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1.5 Host immunity to Cryptococcus neoformans  
1.5.1 Innate immune and cellular responses against C. neoformans  
In this section, I will discuss the components of innate immune responses 
including complement and cellular responses to C. neoformans.   
Physical barriers - Defence against inhaled C. neoformans basidiospores begins 
in the physical barriers of the respiratory tract. These include nasal mucosal and 
the mucociliary escalator of the respiratory epithelium.  The epithelium provides 
protection by creating a semipermeable barrier that is permeable to exchange of 
nutrients, water, and gases while being impermeable to most inhaled pathogens. 
The pathogens are deposited against the airway surface fluid, allowing clearance 
through the mucociliary escalator (Knowles & Boucher, 2002).  However, the 
small size of the Cryptococcus basidiospores (less than 2µm) allows some of the 
inhaled spores to evade these defence mechanisms and deposit in the lung 
alveoli (Ellis & Pfeiffer, 1990b; Sukroongreung et al, 1998; Velagapudi et al, 
2009).   
Complement- Complement is a vital constituent of the innate immune response 
that facilitates opsonisation of pathogens leading to enhanced uptake by 
phagocytic cells. Other roles include activation of inflammation, chemoattraction 
and pathogen lysis by formation of a membrane attack complex (Voelz & May, 
2010). Very early in complement-cryptococci interaction research it was 
established that encapsulated cryptococci are potent activators of the 
complement system. Incubation of C. neoformans with normal serum results in 
activation and binding of complement fragments to the typical cryptococcal 
capsule (Goren & Warren, 1968). The capsule strongly activates the complement 
system via the alternative pathway leading to deposition of C3b on the 
cryptococcal capsule (Kozel & Pfrommer, 1986; Kozel et al, 1989). This causes 
phagocytosis via the complement receptor CR3 (Taborda & Casadevall, 2002; 
Zaragoza et al, 2003). Studies of human cryptococcal disease and animal models 
of cryptococcosis have demonstrated that complement activation also occurs in 
vivo. Macher et al. (1978) found that serum from patients presenting with 
crytococcemia had marked depletion of complement activity including loss of 
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haemolytic complement activity, inability to opsonise encapsulated cryptococci 
for phagocytosis by phagocytes. Very low levels of circulating C3,alternative 
complement factor B and loss of ability to deposit C3 fragment on yeast cells 
were also observed (Macher et al, 1978). The depletion of complement has also 
been observed in experimental guinea pigs and mice models of cryptococcosis. 
Intracardial injection of heat-killed C. neoformans in guinea pigs resulted in the 
loss of the haemolytic complement activity of serum (Gadebusch, 1961; Macher 
et al, 1978). Recently Sun et al. (2015) showed a significantly lower number of 
neutrophils attached to C. neoformans cells in the presence of C5-/- mice plasma 
than when incubated with plasma from the wild-type mice (Sun et al, 2015). 
The role of complement system in host resistance to cryptococcal disease has 
been demonstrated using either genetic deletions or induced deficiencies of 
complement components in animal models. These animal models include a 
C4-deficient guinea pig which lacks a classical pathway but with a fully functional 
alternative pathway (Ellman et al, 1970), a C5-deficient mouse (Nilsson & Müller-
Eberhard, 1967), a C3-defiecient mouse (Shapiro et al, 2002) and treatment of a 
mouse or guinea pig with cobra venom factor which depletes C3 and C5 (Vogel 
et al, 1996). Cryptococcal infection in C3-deficient mice or depletion of C3 using 
cobra venom in mice or guinea pigs results in shortened survival time and 
reduced ability to clear infection than C3-sufficient mice (Diamond et al, 1973; 
Graybill & Ahrens, 1981; Shapiro et al, 2002). Similarly, C5 deficient mice have a 
high fungal burden, develop acute, fatal cryptococcal pneumonia, have 
remarkably reduced ability to clear infection and die much sooner following 
intravenous inoculation with C. neoformans than C5-sufficient mice (Lovchik & 
Lipscomb, 1993; Rhodes, 1985; Rhodes et al, 1980). Tissue images of 
C5-deficient mice by electron microscopy showed less neutrophil infiltration in the 
pulmonary vessels and reduced internalised cryptococcal yeast cells than 
wild-type mice (Lovchik & Lipscomb, 1993). Vacchiaerelli et al. (1998) showed 
that C3a and C5a enhances IL-8 secretion by human neutrophils in response to 
GXM of C. neoformans (Vecchiarelli et al, 1998). Recently, Sun et al. (2015) has 
shown that swarming of neutrophils towards C. neoformans is absent in the 
presence of C3-/- and CD11b-/- mouse plasma (Sun et al, 2015) suggesting that 
 CHAPTER 1| INTRODUCTION 37 
 
complement components C3 and CD11b are essential for the swarming of 
neutrophils towards C. neoformans in vitro. C5a-C5aR signalling directs 
migration of neutrophils towards C. neoformans resulting in phagocytosis and 
killing of the pathogen (Sun et al, 2015). In addition, mice treated with anti-C5aR 
mAb had abrogated recruitment of neutrophils to the lungs resulting in impaired 
intravascular clearance of the fungus (Sun et al, 2015). Interestingly, 
encapsulated C. neoformans or addition of GXM suppresses the expression of 
C5aR in neutrophils (Monari et al, 2002) suggesting that C. neoformans may 
modulate the function of neutrophils at the site of infection. In contrast, C4 protein, 
a vital component of the classical complement pathway is not needed for host 
immune resistance to cryptococcosis. Guinea pigs deficient in C4 have the same 
susceptibility to lethal cryptococcal infection as that of the wild-type, suggesting 
that the alternative complement system is the main protective complement 
pathway in cryptococcal disease (Diamond et al, 1974). 
Deposition of C3 components on the surface of encapsulated cryptococci has 
been seen in histopathological tissue sections from patients and experimental 
animal models of cryptococcosis. Cryptococci isolated from lesions of patients 
with cutaneous cryptococcosis were found to have C3 fragments but not C1q on 
the surface of the yeast cells (Chiang et al, 1985). Truelsen at al., (1992) showed 
that a majority of cryptococci found in liver, lung and kidney tissues sections in 
mice were bound to C3 fragments in each tissue. There was absence of C3 
binding to cryptococci in brain tissue sections (Truelsen et al, 1992). These 
findings are consistent with studies by Diamond et al. (1974) who found small to 
none detectable levels of C3 on the surface of cryptococci cells harvested from 
the fresh human cerebrospinal fluid of four patients with cryptococcal 
meningoencephalitis (Diamond et al, 1974). The absence of C3 deposition on the 
surface of yeast cells in brain tissue may provide an additional explanation for the 
predilection of C. neoformans for the central nervous system (Kozel, 1996).  
The important functions of the complement system during cryptococcal infection 
are to attract phagocytic effector cells and enhance uptake of yeast cells by these 
phagocytic cells. The implication of complement in opsonisation of 
C. neoformans was demonstrated over three decades ago in phagocytosis 
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assays in which phagocytic indices by neutrophils and monocytes were reduced 
in heat-inactivated serum (Diamond & Erickson, 1982) whereas C. neoformans 
opsonised with normal human serum was readily phagocytosed by neutrophils 
(Kozel et al, 1987).  Several other studies also revealed the involvement of the 
complement pathway in the uptake of cryptococci in which depletion of specific 
complement proteins resulted in abrogated phagocytosis by phagocytic cells 
(Davies et al, 1982; Diamond et al, 1974). Incubation of C. neoformans yeast 
cells in C3-/- or C5-/- mouse plasma completely abolishes phagocytosis by 
neutrophils (Sun & Shi, 2016). Kozel et al. (1988) examined binding of C3 
fragments and subsequent phagocytosis in several capsulated C. neoformans 
strains. Capsule from strains tested did bind to C3 but some were phagocytosed, 
while others were not, suggesting that the complement cascade mediated 
opsonisation is necessary but not sufficient for phagocytosis to occur (Kozel et 
al, 1988).  
Other components important for cryptococcal infection are surfactants which are 
complex fluids consisting of phospholipids and four proteins namely SP-A, SP-B, 
SP-C, and SP-D (Johansson et al, 1994). SP-A binds to both encapsulated and 
acapsular cryptococci in a calcium-dependent manner which can be affected by 
mannose and glucose (Walenkamp et al, 1999). However, SP-A does not 
influence cryptococcal disease progression. No significant difference in fungal 
burden or TNFα production was observed between SP‑A deficient mice and 
wild-type (Giles et al, 2007). In contrast, SP-D binds more strongly to acapsular 
yeasts than SP-A (Schelenz et al, 1995; van de Wetering et al, 2004) and 
promotes uptake of thin capsular C. neoformans cells by mouse macrophages 
both in vitro and in vivo (Geunes-Boyer et al, 2012; Geunes-Boyer et al, 2009). 
In addition, SP-D enhances fungal survival (Geunes-Boyer et al, 2009) and 
shields C. neoformans against reactive oxygen species in the mouse model 
leading to disease progression (Geunes-Boyer et al, 2012).  
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1.5.2 Phagocytes  
1.5.2.1 Neutrophils 
Neutrophils are the first type of phagocytic effector cells that migrate to the site 
of infection to kill and eliminate pathogens but do not play a significant role in 
cryptococcal disease. In vitro, neutrophils have been shown to kill Cryptococcus 
by an oxidative-dependent mechanisms mediated by hydrogen peroxide, 
hypochlorous acid, hydroxide (Chaturvedi et al, 1996) and oxidative-independent 
activity arbitrated by calprotectin and defensins (Mambula et al, 2000; Qu & 
Wang, 1991). Treatment with inhibitors and scavengers of respiratory burst 
oxidants slightly reduce the anti-cryptococcal activity of human PMN (Mambula 
et al, 2000). Mice lacking myeloperoxidase, a neutrophil-specific enzyme of the 
reactive oxygen species cascade, have reduced ability to clear infection in the 
lungs and the spleen and succumb much earlier than wild-type upon intranasal 
or intravenous infection with C. neoformans (Aratani et al, 2006). Neutrophils are 
also capable of killing C. neoformans extracellularly. Qureshi et al. (2010) 
showed that inhibition of sphingomyelin synthase activity markedly abrogates 
extracellular killing of C. neoformans by preventing the secretion of extracellular 
anti-cryptococcal factors of neutrophils (Qureshi et al, 2010). Further studies 
have shown that the addition of G-CSF to human neutrophils significantly 
enhances the killing of C. neoformans in vitro (Chiller et al, 2002). In a mouse 
model of cryptococcal disease, treatment with fluconazole combined with G-CSF 
results in increased survival (Graybill et al, 1997). Treatment of 
HIV/AIDS-associated neutropaenia with G-CSF is associated with increased 
secretion of leukotrienes from neutrophils and restoration of fungistatic and 
fungicidal activity of neutrophils (Coffey et al, 1998; Vecchiarelli et al, 1995).  
However, despite neutrophil ability to kill C. neoformans, the pathogen evades 
neutrophils by inhibiting neutrophil migration (Coenjaerts et al, 2001; Ellerbroek 
et al, 2004b; Monari et al, 2002), extracellular trap (NET) formation (Rocha et al, 
2015), killing and respiratory burst (Chaturvedi et al, 1996; Qureshi et al, 2010) 
2010). C. neoformans GXM prevents neutrophil migration by slightly inhibiting 
L-selectin, a molecule required for the initial step of neutrophil migration into 
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tissues (Dong & Murphy, 1996). GXM also inhibits adhesion of neutrophils to 
endothelium by interferering with E-selectin binding (Ellerbroek et al, 2002), IL-8 
receptor (Lipovsky et al, 1998), CD14 or TLR4 (Ellerbroek et al, 2004) and CD18 
(Dong & Murphy, 1997) on human neutrophils. Furthermore, Ellerbroek et al. 
(2004) found that O-acetylation of GXM blocks migration of neutrophils 
(Ellerbroek et al, 2004). Paradoxically, cryptococcal GXM elicits production of 
cytokines and chemokines (Lipovsky et al, 1998; Retini et al, 1996), thereby 
demonstrating indirect chemotactic activity on the PMNs (Dong & Murphy, 1993; 
1995). Melanised C. neoformans inhibits sphingomyelin synthase that 
remarkably impairs the neutrophil killing activity against the fungi (Qureshi et al, 
2010). The cryptococcal capsule also inhibits uptake by neutrophils (Richardson 
et al, 1993).  
During early intranasal infection of C. neoformans, neutrophils migrate (are 
recruited) to the pulmonary vessels (Abe et al, 2000; Feldmesser et al, 2000) 
2000; Herring et al, 2005). Neutrophil recruitment to the lungs is driven by 
chemokines including IL-8 (Guillot et al, 2008a), C-X-C chemokines, MIP-2 and 
KC (Kawakami et al, 1999a) which become elevated following C. neoformans 
infection. C5a-C5aR signalling also mediates migration of neutrophils towards 
C. neoformans (Lovchik & Lipscomb, 1993; Sun et al, 2015) leading to 
C3-mediated fungal internalisation (Kozel et al, 1984), increased expression of 
Erk, p38 MAPK and eventually killing of the cryptococci (Sun et al, 2015). 
Interestingly, p38 MAPK pathway inhibition results in a profound reduction of 
neutrophil migration and anti-cryptococcal activity (Sun et al, 2015). Further 
studies using real-time in vivo imaging have revealed that neutrophils can 
infiltrate the brain microvasculature, take up the cryptococcal cells and return to 
the circulation, thereby effectively eliminating the fungus from the brain (Zhang et 
al, 2016).  
The importance of neutrophils in the protective role against cryptococcal disease 
remains uncertain. Depletion of neutrophils from previously infected (immunised) 
mice with an IFNγ-producing strain of C. neoformans, H99γ, did not affect the 
fungal burden (Wozniak et al, 2012). This data are consistent with previously 
published studies which showed that depletion of neutrophils in mice a day before 
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intratracheal infection with C. neoformans, results in prolonged survival with 
increased production of IL-10, TNF-α, IL-4 and IL-12 in the lungs (Mednick et al, 
2003) suggesting that neutrophils are not essential for host resistance to 
cryptococcal disease. In addition, cryptococcosis is not associated with neutrophil 
deficient diseases or conditions characterised by defects in neutrophils 
(Casadevall, 1998). In fact, increased numbers of neutrophils in the lungs during 
cryptococcosis cause more damage to the lungs in response to the infection 
(Osterholzer et al, 2009). In contrast to the resistant role of neutrophil depletion, 
mice deficient in the neutrophil enzyme MPO are highly susceptible to 
C. neoformans, display increased IL-4 and decreased IL-12 and IFNγ levels in 
the lungs (Aratani et al, 2006) showing the complex nature of the role of 
neutrophils in cryptococcal disease.  
1.5.2.2 Dendritic cells 
Dendritic cells (DCs) are phagocytes and professional antigen presenting cells to 
naïve T cells that induce an adaptive immune response. DCs and alveolar 
macrophages are essential in the early host response. Depletion of CD11c+ cells 
in CD11c-DTR mice one day before infection with a C. neoformans strain that is 
not lethal in many mouse strains resulted in rapid clinical deterioration and death 
within six days after infection (Osterholzer et al, 2009). Early studies on 
evaluating the role of DCs in cryptococcosis showed that classified DC subsets 
are required for the host resistance to cryptococcal infection. Mice were 
immunised with cryptococcal culture filtrate antigen (protective immunogen) or 
heat-killed cryptococcal filtrate antigen (non-protective immunogen) and the 
lymph node drainage of each mouse was examined for DC subsets. Myeloid DCs 
appeared to be essential for eliciting protective immunity against C. neoformans 
by activating CD4+ T cell responses (Bauman et al, 2000) augmented by TNFα 
(Bauman et al, 2003). However, plasmacytoid DCs elicited non-protective 
immune responses (Bauman et al, 2000; Siegemund & Alber, 2008). 
Recruitment - CCR2 mediates recruitment of DCs to the lungs. CCR2 deficient 
mice have markedly impaired DC recruitment and they develop a phenotype 
similar to a Th2-type immune response such as IL-4 production (Osterholzer et 
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al, 2008). The CCR2-dependent infiltration of CD11c+ DCs in the lungs in mice 
with cryptococcal infection is associated with continuous migration and 
differentiation of Ly-6Chigh mononuclear cells into CD11b+ DCs (Osterholzer et al, 
2009a). Inhibition of TNFα reduces movement of mature DCs and results in 
chronic cryptococcal infection (Herring et al, 2005). 
Antigen presentation - DCs are a link between innate and adaptive immunity, and 
their role is vital for host defence and survival. Syme et al. (2002) found that DCs 
are the most efficient antigen presenting cell types of C. neoformans antigens to 
T cells. Although many DCs bind and internalise C. neoformans, only a small 
proportion of these cells are required for antigen presentation to T cells (Syme et 
al, 2002). Studies in vivo showed that fluorescently labelled C. neoformans cells 
were taken up by DCs in the lungs within two-hours post infection (Wozniak et al, 
2006). Seven days post-inoculation there was upregulation of CD80, CD86 and 
MHC class II on DC. In vitro culture of lung DCs from infected mice with 
Cryptococcus-specific T cells resulted in proliferation of T cells, shown by 
increased IL-12 secretion. These findings indicate that the DCs in the lungs can 
take up and present C. neoformans antigens to the T cells (Wozniak et al, 2006). 
Inhibition of DCs by C. neoformans - Cryptococcal GXM profoundly inhibits 
immune response to cryptococcal infections (reviewed in Zaragoza et al, 2009). 
The capsule of C. neoformans greatly interferes with activation and maturation of 
DCs and prevents phagocytosis by DCs (Grijpstra et al, 2009; Lupo et al, 2008; 
Vecchiarelli et al, 2003). Acapsular C. neoformans strains are easily taken up by 
DCs without opsonisation and this leads to increased expression of MHC class II 
and other co-stimulatory molecules such as CD40 and CD83. However, 
encapsulated C. neoformans strains are not taken up by DCs (Kelly et al, 2005) 
and do not induce expression of these molecules except when opsonised by an 
anti-GXM antibody which is recognised by receptors CD32 and CD16 
(Vecchiarelli et al, 2003). Grijpstra at al., (2009) also showed that non-capsulated 
C. neoformans strain cap56∆, but not cap10∆, elicit maturation and activation of 
DCs as evidenced by increased expression of CD86 and CD80 (Grijpstra et al, 
2009). Furthermore, cap56∆ induced upregulation of other genes involved in 
maturation of DCs such as cytokines IL-12, IL-1α, IL-1β, IL-6 and TNFα; 
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chemokines CCR7, CCL17, CCL22, and CXXL10; in addition to membrane 
proteins and genes involved in antigen processing and presentation. On the 
contrary, encapsulated C. neoformans strain reduced the expression of these 
genes and down-regulated several genes, particularly those coding for 
chemokines (Lupo et al, 2008).  
Recognition and uptake of C. neoformans - DCs recognise and phagocytose 
C. neoformans through a mannose receptor and FCγR-II in vitro (Syme et al, 
2002) but not via TLR2 or TLR4 (Nakamura et al, 2006). Several studies have 
shown that a mannose receptor is a cryptococcal mannoprotein (MP) receptor 
(Mansour et al, 2006; Mansour et al, 2002). MPs are present in the capsular 
polysaccharides and fungal cell wall. MPs are recognized by several mannose 
receptors including CD206 and DC-SIGN (CD209) in DCs (Mansour et al, 2006; 
Mansour et al, 2002). MPs elicit the activation and maturation of DCs shown by 
enhanced secretion of IL-12, TNFα and IκBα phosphorylation (Dan et al, 2008a; 
Pietrella et al, 2005). Co-incubation of DCs with purified MPs results in increased 
expression of co-stimulatory molecules including MHC class I, Class II, CD40, 80 
and 86 (Pietrella et al, 2005). DCs carrying C. neoformans MPs are efficient 
inducers of T cell (CD4+ and CD8+) proliferation (Pietrella et al, 2005). Secretion 
of pro-inflammatory cytokines and chemokines by DCs and MP-specific MHC 
class II‑restricted CD4+ T cells responses is enhanced upon co‑stimulation with 
C. neoformans MPs combined with TLR agonists such as PAM3CSK4, Poly(I:C) 
and imiquimod (Dan et al, 2008a).  
Killing - Upon uptake by DCs, the fungi are taken to the endosomal compartment 
that fuses to the lysosome of the DC. The fungi are then killed by oxidative 
dependent and/or independent mechanisms (Wozniak & Levitz, 2008). 
Lysosomal extracts from BMDCs kill C. neoformans in vitro and are toxic to all 
cryptococcal serotypes (Hole et al, 2012; Wozniak & Levitz, 2008). Some DC 
lysosomal enzymes, particularly cathepsin B, inhibit growth of C. neoformans 
(Hole et al, 2012).  
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1.5.2.3 Macrophages 
Importance of macrophages on C. neoformans infection - Alveolar macrophages 
are the first line of defence against pulmonary pathogens (Fels & Cohn, 1986).  
Histological samples from patients with pulmonary cryptococcosis display a 
predominant presence of alveolar macrophages (Shibuya et al, 2002; Shibuya et 
al, 2005). Murine studies to determine the role of macrophages in cryptococcal 
disease have yielded conflicting findings. Depletion of macrophages and dendritic 
cells with a diphtheria toxin one day before C. neoformans challenge in mice 
results in significantly decreased survival (Monga, 1981; Osterholzer et al, 2009). 
However, an intratracheal or intranasal treatment with chlodronate liposomes to 
deplete alveolar macrophages results in unaltered cryptococcal burden (Shao et 
al, 2005). The latter approach leaves macrophages and dendritic cells in other 
tissues undeleted and may have compensated the local loss (Osterholzer et al, 
2009). Interestingly, studies in zebrafish have shown that depletion of 
macrophages results in high fungal burden and reduced survival (Bojarczuk et al, 
2016; Tenor et al, 2015) underlining the critical role of macrophages during 
cryptococcosis.  
Macrophage activation - Macrophages can undergo polarisation to a different 
activation phenotype following exposure to a specific stimulus (Davis et al, 2013; 
Leopold Wager & Wormley, 2014). Exposure of macrophages to Th1-type stimuli 
such as IFNγ or microbial ligands like LPS differentiate them into classically 
activated macrophages, also referred to as M1 macrophages (Hussell & Bell, 
2014; Mantovani et al, 2004; Mosser & Edwards, 2008). M1 macrophages 
mediate antimicrobial activities through the generation of reactive oxygen species 
and nitrogen species (Ding & Vaziri, 1998). The M1 macrophages also shift their 
metabolism from mitochondrial oxidative phosphorylation to glycolysis in the 
presence of Th1-type stimuli (Rodríguez-Prados et al, 2010). Phenotypic 
signatures for identification of M1 macrophages include IL-12, iNOS, chemokine 
(CXC motif) ligand 9 (CXCLC9), CXCLC10, CXCLC11, and suppressor of 
cytokine signalling 3 (SOCCS3) (reviewed in Mosser & Edwards, 2008; Murray & 
Wynn, 2011). 
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On the other hand, exposure of macrophages to Th2-type cytokines such as IL-4 
and IL-13 or parasite-derived products, fungal chitin or allergens differentiate 
them into alternatively activated macrophages, also known as M2 macrophages 
(Reviewed in Mantovani et al, 2013; Mosser & Edwards, 2008; Van Dyken & 
Locksley, 2013; Wiesner et al, 2015). M2 macrophages are efficient destroyers 
of parasites and play a critical role in repairing damaged tissue (Allen & 
Sutherland, 2014; Rückerl & Allen, 2014). The characteristic features associated 
with M2 macrophages include chitinase-like molecules such as Yml and YM2, 
found in an inflammatory zone (FIZZI, also called resistin-like-α or Relm-α), 
mannose receptor (CD206) and arginase-1 (Arg1) (Mosser & Edwards, 2008; 
Murray & Wynn, 2011; Stein et al, 1992).  
A major difference between the two classes is that M2 macrophages produce 
Arg1 which catalyses the conversion of L-arginine to produce urea, polyamines, 
and ornithine (Bogdan et al, 2000) whereas M1 macrophages generate iNOS, 
which catalyses the formation of nitric oxide and citrulline from L-arginine. iNOS 
and Arg1 compete for the same substrate, L-arginine (McNeill et al, 2015) 
resulting in either hindering or promoting the production of NO in the 
macrophages.   
Macrophage polarisation during C. neoformans infection - Experimental 
pulmonary cryptococcosis is associated with the induction of a strong Th2-type 
response and activation of alternative macrophages (Chen et al, 2008; Huffnagle 
et al, 1998; Milam et al, 2007; Müller et al, 2007; Osterholzer et al, 2009). 
Similarly, mice lacking Th1-type cytokine, IFNγ, have high levels of Th2-type 
cytokine production and alternatively activated macrophages in the lungs during 
cryptococcal infection (Arora et al, 2011). Muller at al., (2007) showed that 
Th2-type cytokine, IL-13, promotes M2 skewed macrophage differentiation, 
Th2-type cytokine phenotypes and allergic-type responses during experimental 
pulmonary C. neoformans infection in mice (Müller et al, 2007). In an 
experimental model to understand the relationship of Th1 and Th2 cytokines on 
macrophage activation, mice were infected with C. neoformans 52D strain. The 
immune response phenotypes showed plasticity, Th2-type cytokines appeared 
early in the infection followed by Th1-types cytokines later in the infection. 
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However, infection was not cleared despite the Th1-type responses, suggesting 
that early Th1‑type immune responses are required for protection against 
cryptococcosis (Arora et al, 2011). Macrophages also demonstrated plasticity in 
activation depending on whether they were exposed to IFNγ and/or IL-4 during 
cryptococcosis. For example, the higher IL-4/IFNγ ratio skewed macrophages 
toward M2 while higher IFNγ/IL-4 skewed macrophages toward M1 phenotype 
(Arora et al, 2011). Some macrophages treated with IL-4 and IFNγ expressed 
both M1 and M2 hallmark markers showing that these cytokines have an additive 
effect (Arora et al, 2011). Indeed, macrophages that polarise to M1 phenotype 
when exposed to IFNγ can repolarise back to M2 when stimulated with IL-4 and 
vice versa (Davis et al, 2013; Gratchev et al, 2006; Stout et al, 2005) signifying 
the critical role of the local cytokine microenvironment in driving macrophage 
polarisation.  
Fungicidal and fungistatic activity of macrophages – Human macrophages can 
arrest the growth of C. neoformans in vitro (Levitz & Farrell, 1990). In the 
phagolysosome, C. neoformans is exposed to low pH, reactive oxygen species, 
reactive nitrogen species and deficiency of nutrients (Shoham & Levitz, 2005). 
Mice deficient in phagocyte NADPH component Phox-/- have enhanced Th1-type 
responses accompanied by improved Cryptococcus containment in pulmonary 
granulomatous lesions and reduced fungal dissemination to the brain (Snelgrove 
et al, 2006). Therefore, counterintuitively, abrogation of this important 
antimicrobial activity, ROS, rendered mice more resistant to cryptococcal 
infection. On the other hand, exposure of C. neoformans to chemically generated 
antimicrobial nitric oxide inhibits fungal growth under acidic conditions (Alspaugh 
& Granger, 1991). The enzyme that catalyses the formation of NO, iNOS, is 
present in lung granulomas of mice infected with C. neoformans (Goldman et al, 
1996; Goldman et al, 2000; Hardison & Brown, 2012a). In addition, iNOS-/- mice 
have reduced survival and fail to clear Cryptococcus infection (Aguirre & Gibson, 
2000). These findings were confirmed recently by Wager et al. (2015) who 
showed that macrophages from iNOS‑/‑ mice or WT mice treated with iNOS 
inhibitors fail to control intracellular replication of C. neoformans even in the 
presence of uninterrupted ROS secretion (Leopold Wager et al, 2015). This 
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suggests that NO, and not ROS, is required for control of C. neoformans. The 
question is whether these findings can be extrapolated to human disease 
because there is little evidence describing the production of NO in healthy human 
macrophages. Even in studies that have reported production of NO by human 
macrophages, the levels are extremely low (Albina, 1995; Amin et al, 1995; 
Schneemann et al, 1993). Recently, Gross et al. (2014) showed that the gene 
that mediates iNOS in humans is silenced by CpG methylation, histone 
modification and chromatin suppression, which is contrary to mouse 
macrophages (Gross et al., 2014). There is some evidence showing production 
of NO in chronic human lungs disease. For example, granulomas from lung tissue 
in humans and other primates contain iNOS positive macrophages (Facchetti et 
al., 1999, Mattila et al., 2013), indicating that human macrophages in appropriate 
chronic inflammatory contexts are capable of secreting NO, an aspect lacking in 
normal human macrophage physiology. This raises a need for further studies that 
would characterise human macrophage responses to C. neoformans.  
Evading killing by macrophages - C. neoformans is known to inhibit the killing 
machinery of macrophages. C. neoformans suppress NO production in 
macrophages through a mechanism independent of capsular polysaccharide 
(Kawakami et al, 1997a; Xiao et al, 2008). Suppression of iNOS leads to M2 
macrophage activation, abrogation of anti-fungal activity and progressive disease 
(Arora et al, 2005; Arora et al, 2011; Hardison et al, 2010; Naslund et al, 1995; 
Xiao et al, 2008). In addition, chitin indirectly induces the production of IL-5, IL-13 
and IL-4, leading to M2 skewed macrophages (Van Dyken et al, 2014). In the 
macrophage phagosome, C. neoformans face low pH, ROS and NO. Early 
studies demonstrated that C. neoformans does not actively evade low pH of the 
macrophage phagolysosome, but in fact, replicates better in acidic pH rather than 
alkaline environments (Diamond & Bennett, 1973; Levitz et al, 1999). In contrast, 
Smith et al. (2015) have recently shown that C. neoformans can inhibit 
phagosome acidification, calcium flux, and protease activity, modulating the 
phagosome to allow cryptococcal replication. Interestingly, they also 
demonstrated that live, but not heat-killed, C. neoformans induces premature 
removal of early phagosome markers, Rab5 and Rab11 (Smith et al, 2015). Live 
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C. neoformans can damage the lysosome in BMDMs in a time-dependent 
manner. Activation of BMDM with IFNγ prevented the lysosomal damage and 
enhanced anti-cryptococcal activity of the macrophages (Davis et al, 2015).  
Outcomes of Cryptococcus-macrophage interactions - C. neoformans is capable 
of replicating inside the macrophage phagosome (Tucker & Casadevall, 2002; 
Voelz et al, 2009) and can escape through non-lytic exocytosis or transfer 
laterally to another macrophage (Alvarez & Casadevall, 2006; Ma et al, 2006; 
Nicola et al, 2011). Non-lytic exocytosis, also known as vomocytosis is thought 
to be an immune evasion strategy that may facilitate C. neoformans 
dissemination from the lungs to other body organs including the brain (Johnston 
& May, 2013). A study recently examined the behaviour of clinical C. neoformans 
isolates in vitro in relation to disease severity. C. neoformans strains that were 
taken up quickly by macrophages had low intracellular proliferation rates in vitro 
and were associated with higher CSF cryptococcal burden and, unexpectedly, 
prolonged survival of HIV patients. In contrast, C. neoformans strains with a high 
phagocytic rate had a smaller capsule size, increased laccase activity and were 
less susceptible to anti-fungal therapy (Sabiiti et al, 2014). This study highlights 
that cryptococcal-macrophage interactions play a critical role in driving the 
outcomes of cryptococcosis in humans.  
1.6 Experimental models for cryptococcosis 
1.6.1 In vitro cell models  
The interactions of C. neoformans with host cells including primary cells and cell 
lines such as macrophages, neutrophils, endothelial and epithelial cells and 
neutrophils have been widely studied. Most studied interactions have been those 
with macrophages. The uptake of unopsonised C. neoformans by macrophages 
is very poor, but readily are taken up following opsonisation with complement or 
antibody (Bolaños & Mitchell, 1989). Internalised C. neoformans cells can remain 
viable and proliferate within macrophages, and on some occasions, they can 
undergo non-lytic exocytosis, lateral transfer or death. It is worthwhile to mention 
that outcomes of these interactions differ depending on the type of macrophages 
used. For instance, vomocytosis rates are markedly higher in human primary 
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macrophages compared to mouse J774 cell lines (Ma et al, 2006; Voelz et al, 
2009). Cells that are commonly used include J774, RAW and primary cells such 
as bone marrow-derived mouse cells and monocyte-derived human macrophage 
cells (Ma et al, 2006; Ralph et al, 1975; Srikanta et al, 2011; Tsuchiya et al, 1980).  
1.7 Invertebrate models  
1.7.1 Galleria mellonella 
Galleria mellonella are the larvae of the greater wax moth and have been used 
to study virulence of a variety of pathogenic fungal species. The larvae can live 
at temperatures ranging from 25° C to 37° C, thus enabling investigation of 
temperature-depended pathogenesis (Mylonakis et al, 2005). Another advantage 
of Galleria mellonella is that inoculation is not complicated and can be done by 
either injection (Mylonakis et al, 2005) or topical application (Bouklas et al, 2015). 
Inoculation by injection provides the means to inoculate specific fungal doses. 
This is due to its larger size (about 1.5 -2.5 cm in length) compared to small sized 
insects such as Drosophila, in which maintaining a specific dose of inoculation 
can be difficult (Kavanagh & Fallon, 2010). Inoculation of fungi into the haemocoel 
is less damaging because injection does not require piercing of the haemocoel. 
Instead, exerting a gentle pressure on the side can open the pro-leg, and then a 
needle can be inserted. The crack will re-seal immediately following removal of 
the needle without forming a scar (Cotter et al, 2000). Piercing through the insect 
may activate immune responses aimed at repairing the wound and this may 
interfere with the experimental results (Kavanagh & Fallon, 2010). Haemocytes, 
which are equivalent to white blood cells in mammals, have been shown to 
contain proteins homologous to human neutrophil proteins p47phox and p67phox 
indicating that the haemocytes might be involved in NADPH oxidase activity 
(Bergin et al, 2005). Galleria mellonella is promoted as a model specifically for 
studying diseases that disseminate throughout the body via the circulatory 
system as in C. neoformans infections (Kavanagh & Fallon, 2010). The 
G. mellonella‑C. neoformans model was first reported by Mylonakis et al, (2005). 
In this model, despite effective uptake of fungal cells by insect haemocytes, 
Galleria larvae were killed by all C. neoformans strains tested (Mylonakis et al, 
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2005). This suggests that C. neoformans can evade or manipulate G. mellonella 
immunity, as it does with phagocytes in vitro. Recently Bouklas et al. (2015) 
showed no correlation between survival of G. mellonella and that of mice 
following cryptococcal infection. C. neoformans strains that were highly virulent 
in mice were not in G. mellonella suggesting that the moth may not completely 
model host-pathogen interactions seen in mammalian models (Bouklas et al, 
2015). 
1.7.2 Drosophila melanogaster and Drosophila S2 cells 
The fruit-fly Drosophila melanogaster offers a possibility to investigate local or 
systemic C. neoformans infection. Infection into the haemocoel involves an 
insertion of a needle into the thorax or abdomen as demonstrated by Luo et al. 
(2009). This method of infection generates a systemic infection since the fungus 
is inoculated directly into the haemolymph. The disadvantage of this method is 
that it is inconsistent with a natural route of infection as pathogens such as 
Cryptococcus would not be able to penetrate the insect cuticle unless a hole was 
already made. Alternatively, the pathogen can be incorporated into fly food. Use 
of Drosophila melanogaster to study pathogenic fungi is growing because 
immune signalling pathways in this organism are similar to that of mammals (De 
Gregorio et al, 2002; Hoffmann & Reichhart, 2002). For example, proteins 
involved in autophagy pathway mediate intracellular replication of C. neoformans 
in both Drosophila S2 cell and mammalian cell systems (Qin et al, 2011).  
1.7.3 Caenorhabditis elegans 
Caenorhabditis elegans is a non-parasitic transparent nematode used to study 
C. neoformans infection. Infections of C. elegans are administered via ingestion. 
C. neoformans are cultured on YPD agar overnight, and the nematodes are 
transferred to the plates and infects the nematode by being ingested, causing 
fatal disease (London et al, 2006). However, this mode of infection does not 
resonate with inoculation in mammals. Following ingestion by the nematode, 
C. neoformans are confined to the intestines, which is in contrasts to lung 
inhalation and subsequent dissemination in mammalian models. Also, it is difficult 
to enable C. elegans to ingest an exact dose of the pathogen, which can strictly 
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limit the scope of experiments. Furthermore, C. elegans lack phagocytes, 
therefore studying of definitive immune response like phagocytosis is not possible 
(Sabiiti et al, 2011). Despite these limitations, susceptibility to C. neoformans 
infection is similar to mammalian models. For instance, C. neoformans strains 
with defective virulence in mammalian hosts usually demonstrate the same 
attenuation in C. elegans (Mylonakis et al, 2002). C. elegans can also be used to 
identify C. neoformans genes required for virulence by screening large numbers 
of mutants. For example, Lee et al. (2010) identified certain mutations in 
C. neoformans that caused defective growth in vitro cerebrospinal fluid and had 
the corresponding attenuation in C. elegans (Lee et al, 2010). Interestingly, 
although an intact C. neoformans polysaccharide capsule is critical for 
pathogenesis in Galleria and Acanthamoeba, it does not cause killing of 
C. elegans (Mylonakis et al, 2002; Steenbergen et al, 2001). 
1.7.4 Dictyostelium discoideum (Social amoebae) 
Dictyostelium discoideum is a soil-living social amoeba and a useful model for 
studying the interactions between pathogen and host cells such as proliferation 
of pathogens within phagocytes. The D. discoideum genome has been 
sequenced (Eichinger et al, 2005) and is malleable to genetic manipulation 
(Hägele et al, 2000; Pradel & Ewbank, 2004). Some parallels have been drawn 
regarding virulence of Cryptococcus between Dictyostelium and human hosts. 
For instance, the C. neoformans polysaccharide capsule is vital for infection in 
Dictyostelium since non-encapsulated mutants fail to replicate in the amoeba 
(Steenbergen et al, 2003). Pre-incubation of D. discoideum with C. neoformans 
promotes virulence of the fungus in a murine model of infection (Steenbergen et 
al, 2003) possibly because the capsule of the fungus enlarges during 
co‑incubation (Chrisman et al, 2011).  
1.7.5 Acanthamoeba castellanii 
Acanthamoeba castellanii is considered one of the protozoan predators of 
C. neoformans in the environment. A. castellanii can ingest yeast cells followed 
by intracellular replication and formation of vesicles carrying polysaccharides in 
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the cytoplasm of the amoeba. The vesicles in the amoeba are similar to those 
seen in C. neoformans infected macrophages (Steenbergen et al, 2003).  
1.8 Vertebrate models  
1.8.1 Mouse (Mus musculus) 
Mice are the most common mammalian model systems used for 
Cryptococcus-related studies. This is not surprising since murine models are well 
established and characterised systems in many medical research laboratories 
and a variety of genetic backgrounds are widely available. A variety of inoculation 
routes to establish C. neoformans infection in mice include intranasal, 
intraperitoneal, intracerebral, intravenous, intratracheal, and via inhalation 
(Zaragoza et al, 2007). Due to the availability of vast data on the mouse immune 
system it means that parallels and gaps can be identified readily, enabling the 
design of robust experimental approaches. Susceptibility to C. neoformans 
between different inbred mouse strains varies significantly. For example, CBA/J 
mice are more susceptible to intratracheal C. neoformans infection than BALB/c 
mice (Zaragoza et al, 2007). Like cryptococcosis in humans, intrapharyngeal 
aspiration C. neoformans infection with H99 strains results in meningitis which is 
the major cause of fatality in animals (Ngamskulrungroj et al, 2012).  
1.8.2 Rat (Rattus rattus) 
Rats are comparable to mice but slightly bigger allowing the performance of 
complex experimental manipulations such as endotracheal intubation, 
bronchoalveolar lavage, consecutive venepunctures, CSF collection, 
radiography, computed tomography, and magnetic resonance imaging 
(Krockenberger et al, 2010). Rats in the wild have been documented to develop 
chronic pulmonary cryptococcal disease (Scrimgeour & Purohit, 1984) indicating 
that the rat is a potentially powerful disease model. A pulmonary cryptococcal 
disease rat model has been generated and infection is established following 
intratracheal inoculation (Krockenberger et al, 2010). A rat model that can survive 
long-term cryptococcal infection has been reported and is a useful tool for 
studying latency-of-infection (Goldman et al, 1996). In a rat model, arrested local 
cryptococcal growth is associated with granulomatous inflammation while 
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persistent pulmonary infection is sustained by downregulation of both cellular and 
humoral responses (Goldman et al, 2000).  
1.8.3 Rabbit (Oryctolagus cuniculus) 
The rabbit is relatively larger than mice or Guinea pigs. As such, the rabbit has 
been promoted as a model for cryptococcal meningitis. Stein et al. (2003) 
proposed that the rabbit is an exceptional model for cryptococcosis because 
infection can be studied at a localised site in a sequential manner such as the 
ability to repeatedly collect body fluid samples (Steen et al, 2003). Historically the 
rabbit has not been a model of choice for C. neoformans disease because it is 
naturally resistant to the pathogen (Perfect et al, 1980). However, it has been 
argued that the rabbit’s body temperature of 39.5° C and use of steroids in this 
model closely resemble clinical situations in which patients with 
steroid-associated cryptococcal disease often present with fever (Perfect & 
Casadevall, 2002). Pre-treatment of the rabbit with steroid therapy followed by 
Cryptococcus infection successfully results in the development of 
meningoencephalitis (Perfect et al, 1980). C. neoformans mutants that 
demonstrated a significant reduction in viability when exposed to human CSF 
showed attenuation in virulence in a rabbit model too (Lee et al, 2010), displaying 
a powerful example of how a whole-organism model can confirm hypotheses of 
disease attenuation derived from findings in vitro.  
1.8.4 Guinea pigs (Cavia porcellus) 
Unlike other mammalian models, the Guinea pig is relatively one of the most 
recent mammals to be used to study cryptococcal disease (Kirkpatrick et al, 
2007). Due to being larger than mice, Guinea pigs are ideal for more complex 
experimental manipulations. For instance, infection models requiring intravenous 
inoculation are relatively easier in Guinea pigs. In addition, the oral doses of 
anti-fungal drugs that are used in Guinea pig experiments to clear a fungal 
infection are similar to the doses administered in humans (Odds et al, 2000). For 
example, intravenous administration of itraconazole is effective against 
disseminated fungal infections including cryptococcosis as shown in a Guinea pig 
model (Odds et al, 2000).  
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However, the use animals larger than mice comes with higher costs and 
demanding husbandry requirements that need more intense observations during 
experimental infections. Moreover, availability of molecular tools such as 
antibodies and genetically defined strains are limited.  
1.8.5 The zebrafish  
The zebrafish (Danio rerio) belongs to the minnow family (Cyprinidae) of the order 
Cypriniformes. Zebrafish originates from the streams of Southeast Asia and are 
broadly spread across India, Bangladesh, Nepal, Myanmar and Pakistan, but 
now commonly found worldwide as an aquarium fish (Lawrence, 2007). The adult 
fish are approximately 4 cm long and have a lifespan of up to 5 years (Lawrence, 
2007; Siccardi et al, 2009).  
1.8.5.1 The zebrafish as a model organism. 
George Streisinger first introduced the zebrafish model for the study of human 
disease in the late 1960s. He published his protocols on how to create 
homozygous diploid clones of zebrafish in a 1981 issue of Nature (Meeker & 
Trede, 2008). Much of the early research in zebrafish focused on studying 
vertebrate genetics and developmental biology (Fishman, 2001). Later, the study 
of human diseases and screening of therapeutic drugs were introduced (Barut & 
Zon, 2000; Penberthy et al, 2002). Attributes that favour the zebrafish rising 
popularity for biomedical research include small size (3-4cm long as an adult), 
rapid development and generation time (4 months), high fecundity (200 eggs per 
clutch), optical transparency allowing real-time tracking of the maturation 
processes at an early age of development, feasibility to perform large-scale 
genetic screens (Haffter et al, 1996; Lawrence, 2007), and genetic similarities to 
humans (for example see Lamason et al, [2005]). Zebrafish pairs produce 
approximately 300 eggs per week and eggs are externally fertilised. Development 
of the embryos therefore takes place outside the body of the female. To date, 
zebrafish study areas include cancer, cardiovascular diseases, ageing, infection 
and immunity (Davis et al, 2002; Menudier et al, 1996; Neely et al, 2002). 
The zebrafish model for studying infection - The availability of a wide range of 
molecular tools, mutant resources and ease in generating transgenic reporter 
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lines have contributed to the versatility of the zebrafish model in the study 
infection. A growing list of bacterial, viral and fungal pathogens have been 
experimented on in zebrafish. Infections are usually initiated by inoculating the 
pathogen into zebrafish via different sites in accordance with the type of 
experiment to be carried out. The routes of infection include microinjection via the 
blood island, which is the most commonly used method. With systemic infection 
via blood islands, zebrafish are susceptible to bacterial infections including 
Mycobacterium marinum, Salmonella typhimurium, and Escherichia coli (Davis 
and Ramakrishnan, 2009, Volkman et al., 2010, Benard et al., 2012). Other 
routes of infection include injection into the hindbrain and yolk sac. The yolk sac 
is used for slow-growing pathogens such as Mycobacterium marinum (Pressley 
et al, 2005), and is suitable for large-scale screening because it is technically 
easier than other routes (Carvalho et al., 2011). Quantitation of the pathogen 
burden can be done by determination of CFU, pixel count using fluorescent 
images or high-throughput quantitation using COPAS systems (Carvalho et al., 
2011, Veneman et al., 2014). There is a large volume of data describing zebrafish 
infection models of bacteria including Staphylococcus aureus, Burkholderia 
cenocepacia, Salmonella typhimurium, Shigella flexneri, 
Mycobacterium marinum, of fungi including Candida albicans, Aspergillus 
fumigatus, Mucor circinelloides and Cryptococcus neoformans and of viruses 
including infectious hematopoietic necrosis virus, infectious pancreatic necrosis 
virus, nervous necrosis virus and snakehead rhabdovirus (reviewed in Sullivan & 
Kim, 2008).   
Zebrafish model of C. neoformans infection – There are currently three 
peer-reviewed papers that have reported zebrafish-Cryptococcus infection 
models. Most data resonate with previous findings, but there are also new 
discoveries. For example, macrophages are required for protection of zebrafish 
against cryptococcal disease. Ablation of macrophages by using either 
chrondonate liposomes or morpholino knockdown resulted in high fungal burden 
and increased mortality (Bojarczuk et al, 2016; Tenor et al, 2015) consistent with 
previously reported findings in mice (Monga, 1981; Osterholzer et al, 2009a). 
C. neoformans replicate intracellularly and undergo non-lytic exocytosis 
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(vomocytosis) in zebrafish macrophages in vivo (Bojarczuk et al, 2016; Tenor et 
al, 2015) which resonate with previous findings in vitro (Ma et al, 2006; Voelz et 
al, 2009). These findings suggest that zebrafish can be a powerful model to 
recapitulate observations that were somewhat only possible ex vivo. Also, 
Bojarczuk et al. (2016) and Tenor et al. (2015) have shown that the 
C. neoformans polysaccharide capsule enlarges during infection and inhibits 
phagocytosis by macrophages in vivo (Bojarczuk et al, 2016; Tenor et al, 2015). 
Recently another published paper has shown that C. neoformans can establish 
an infection in zebrafish that eventually disseminates to the brain (Davis et al, 
2016; Tenor et al, 2015) suggesting that zebrafish can also be used to study brain 
invasion.  
1.8.5.2 Zebrafish immune system 
1.8.5.2.1 Haematopoiesis in zebrafish 
As in all vertebrate embryos, haematopoiesis occurs in two temporally 
overlapping phases known as primitive and definitive haematopoiesis.  
Primitive haematopoiesis - The primitive haematopoiesis in zebrafish, takes place 
in the embryo at two distinct locations: the anterior lateral mesoderm (ALM) and 
the posterior lateral mesoderm (PLM) (AL-Adhami, 1977; Detrich et al, 1995; 
Thompson et al, 1998). Collectively, the anterior and posterior mesoderm are 
similar to the primitive blood islands in the mammalian yolk sac. Erythroid 
progenitors which appear as bilateral stripes, originate from PLM which later 
merges along the midline to form a chord-shaped structure known as 
intermediate cell mass (ICM) (Table 1) (Davidson & Zon, 2004). By about 24hpf, 
the ICM is localised in the trunk dorsal to the yolk sac extension and the 
erythrocytes enter the circulation (Davidson & Zon, 2004). Myeloid progenitors 
originate from cells in the most anterior lateral plate mesoderm which later forms 
the rostral blood islands (RBI). The anterior and posterior mesoderm are similar 
to the primitive blood islands in the mammalian yolk sac. The myeloid progenitors 
differentiate into primitive macrophages in the rostral blood islands (anterior yolk 
sac blood sinus) of the cardiac region, in the area underneath the hatching grand 
(Herbomel et al, 1999; Lieschke et al, 2002). Primitive macrophages are first seen 
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in zebrafish embryos at approximately the same time as erythropoiesis take 
place, between the 13 to 30 somite stages (12-16 hours post fertilisation). From 
the anterior yolk sac, primitive macrophages migrate randomly to lateral sites 
then finally migrate to the mesenchyme of the head or invade various tissues 
through the blood circulation (Bennett et al, 2001; Herbomel et al, 1999; Lieschke 
et al, 2002). The development of myeloid precursors in the ALM is mediated by 
spil expression whereas the erythroid differentiation of the erythroid progenitors 
is mediated by gata 1 expression in the PLM (Yamaguchi et al., 1998, Kulessa et 
al., 1995, Nerlov and Graf, 1998).  
During primitive haematopoiesis, neutrophils and thrombocytes have also been 
observed. However, studies to determine the origin of neutrophils have shown 
contrasting findings. Using fate-mapping studies, Le Guyader et al. (2008) 
showed that neutrophils originate from a primitive macrophage lineage whereas 
Warga et al, (2009) showed that neutrophils come from a primitive erythrocyte 
lineage (Le Guyader et al, 2008; Warga et al, 2009). Thus, primitive 
haematopoiesis mainly involves generation of primitive erythrocytes, primitive 
macrophages and myeloid cells. 
Since the primitive phase of haematopoiesis is transient and lasts for up to 
24 hours and blood circulation initiates at approximately 24 hpf, macrophage 
precursors of definitive haematopoiesis are seen at this stage (Burns et al, 2002; 
Gering & Patient, 2005; Kalev-Zylinska et al, 2002). 
Definitive haematopoiesis - Definitive haematopoiesis occurs at a later stage of 
development and predominantly involves maturation of erythroid, thrombocytic, 
myeloid and the lymphocytic lineages. Definitive haematopoiesis begins in the 
posterior blood island (PBI) at about 24hpi with the generation of 
erythroid-myeloid progenitor cells (EMPs) which are multipotent haematopoietic 
progenitor cells. The PBI later develops into the caudal hematopoietic tissue 
(Table 1) (Murayama et al, 2006). During this time, between 26-48 hpf, 
haemogenic endothelial cells in the ventral wall of the dorsal aorta differentiate 
into haematopoietic stem cells (HSC) as shown by HSC-associated genes 
including c-myb and runx1 (Burns et al, 2002; Kalev-Zylinska et al, 2002; 
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Thompson et al, 1998). This dorsal aorta is analogous to the mammalian aorta 
gonad mesonephros (AGM). The HSC then migrate from the dorsal aorta to the 
caudal haematopoietic tissue (CHT) (Kissa et al, 2008). The HSCs in the CHT 
then replace the EMPs as they become the progenitors of haematopoietic 
lineages for the rest of the embryonic development (Bertrand et al, 2010; Kissa 
& Herbomel, 2010; Murayama et al, 2006). In the CHT, the HSC differentiate into 
erythroid, myeloid, and thrombotic cells at approximately 72hpf. The CHT 
represents an intermediate location of haematopoietic development like the foetal 
liver in mammals (Murayama et al, 2006). The HSC then migrate to the 
pronephros and thymus via the blood circulation at about 48-56hpf (Bertrand et 
al, 2010; Kissa & Herbomel, 2010). From about 4dpf to adulthood, the kidney 
becomes the primary location of haematopoiesis including erythropoiesis, 
myelopoiesis, and thrombopoiesis (Lin et al, 2005) (Table 1).  
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Table 1: Haematopoiesis sites in zebrafish and their human counterpart 
Haematopoiesis stage 
 
Site in 
zebrafish  
Site in 
humans 
Reference 
Early (primary) 
haematopoiesis 
Intermediate 
cell mass 
(ICM) 
Yolk sac (Detrich et al., 
1995, 
Murayama et 
al., 2006, 
Thompson et 
al., 1998) 
 Dorsal aorta AGM 
 CHT Foetal liver 
Adult haematopoiesis Kidney marrow  Bone marrow  (AL-Adhami, 
1977, Traver, 
2004)  
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1.8.5.2.2 Innate immune system  
The cell phenotypes present in both zebrafish and mammals include motility, 
phagocytic activity in neutrophils (Le Guyader et al, 2008) and macrophages 
(Herbomel et al, 1999), myeloperoxidase in neutrophils, macrophage respiratory 
burst (Hermann et al, 2004) and the ability to activate T/B cells (Traver et al, 
2003). Unlike adult mammals, macrophages of early zebrafish embryos reside in 
tissues (Herbomel et al, 1999) rather than circulating in blood as monocytes. 
However, this is similar to the mammalian macrophages present in the 
developing embryo prior to definitive haematopoiesis (Naito, 2008).  
Macrophage progenitors in the developing embryo have been observed before 
the development of circulation (Herbomel et al, 1999). Immature granulocytes 
begin to be seen in the circulation by 48hpf while eosinophils are first detected at 
5dpf (Lieschke et al, 2001; Willett et al, 1999). 
1.8.5.2.3 Adaptive immune system  
The thymus in zebrafish is extremely important for adaptive immunity (Hansen & 
Zapata, 1998). The development of the thymus begins in zebrafish ontogeny at 
around 48hpf and the rudiment of the thymus is formed by 60hpf. T cell 
progenitors begin to invade the rudiment at 68hpf (Willett et al, 1999) and to 
populate the thymus by 3dpf. Thymocytes in the developing thymus express 
lymphoid genes such as rag1, 2 and ikaros (Willett et al, 1997). Moreover, mature 
lymphocytes have been observed in the thymic epithelium by 7dpf (Trede et al, 
2001). However, functional T cells have not been observed during the first three 
weeks of development anywhere outside the thymus (Trede et al, 2004). The 
thymus remains morphologically immature until three weeks post feltilisation 
(Lam et al, 2002). The B lymphocytes are seen in the kidney and pancreas at 
about 19dpf (Danilova & Steiner, 2002; Langenau et al, 2004; Willett et al, 1999). 
Antibody production were detected by western blotting at four weeks 
post-fertilisation. Humoral responses to T cell-dependent and –independent 
antigens are not detected until 4-6 weeks post fertilisation (Lam et al, 2004). 
Zebrafish rely on the innate immunity for protection from environmental 
pathogens in the first four weeks until it acquires morphologically and functionally 
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mature cells of the adaptive immune system. Conversely, newborn mammals rely 
on innate immunity plus adaptive immunity (antibodies) from their mother (Tizard 
2013) while they wait for their adaptive immune system to become fully functional. 
Thus, zebrafish larvae offer an opportunity to study the innate immune defence 
strategies without the interference of the adaptive immune response. 
1.8.5.2.4 Pattern recognition receptors  
TLR mediated signalling – Toll-like receptors (TLRs) are a family of type I 
transmembrane receptors that are highly similar from Drosophila to humans and 
share structural and functional characteristics (Lemaitre et al, 1995; Lemaitre et 
al, 1996; Medzhitov et al, 1997). There are at least 10 known TLRs in humans 
and 13 in mice. They differ mostly by ligand specificity, expression and activation 
of target genes (reviewed in Kumar et al, 2009). TLRs are integral glycoproteins 
which consist of an extracellular ligand-binding domain with Leucine-rich repeat 
(LRR) motifs and a Toll/Interleukin-1 (IL-1) receptors (TIL) homology domain 
located in the cytoplasm (Akira et al, 2006; O'Neill & Bowie, 2007). Some TLRs 
are localised on the cell surface (TLR1, 2, 4, 5, 6 and 10) while others are located 
in intracellular compartments such as endosomes and lysosomes (TLR3, -7, -8, 
-9, -11 and -13). In mammals, TLRs are predominantly expressed in antigen 
presenting cells (APCs) including macrophages, dendritic cells and B 
lymphocytes (Mogensen, 2009). However, many other cell types express TLRs 
too in response to localised infection (Miettinen et al, 2001). TLRs mainly 
recognise and bind to pathogen ligands such as lipoproteins (TLR2 ligand) of 
Gram-positive bacteria, lipid A motif of lipopolysaccharides (TLR4 ligand) of 
Gram-negative bacteria and flagellin(TLR5 ligand) which may be present on 
either gram type bacteria  (Hayashi et al, 2001; Poltorak et al, 1998; Schwandner 
et al, 1999). The other TLRs detect nucleic acids present in endosomal and 
phagosomal compartments. For example, TLR3 recognises a double-stranded 
RNA (dsRNA) during viral replication, while TLR7 and TLR8 bind to 
single-stranded RNA (ssRNA) of RNA viruses and TLR9 recognises viral and 
bacterial unmethylated CpG DNA (Alexopoulou et al, 2001; Diebold et al, 2004; 
Heil et al, 2004; Hemmi et al, 2000; Ohto et al, 2015). The TLR signalling pathway 
in mammals involves TIR-domain-containing adaptor molecules including 
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MyD88, MAL/TIRAP, TRIF/TICAM1, TRAM/TICAM2, and SARM (Akira et al, 
2006; Miettinen et al, 2001). All but TLR3 uses MyD88 adaptor molecule (Takeda 
& Akira, 2004). Downstream signalling leads to the activation of transcription 
factors such as ATF, NF-κB, AP-1, IRF and STAT families predominantly via 
central intermediate molecule TRAF6 (Takeda & Akira, 2004) (Figure 5).  
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Figure 5: Mammalian TLR signalling pathways 
Toll-like receptors are located on the cell surface and in the endosomes. They detect microbial 
signature components, foreign nucleic acids and danger associated self-molecules. TLR5, TLR4 
and heterodimers of TLR2/1 or TLR2/6 are present on the cell surface while TLR3, TLR7/8 and 
TLR9 are located in the endosomes. TLR4 is present both on the cell surface and on the 
endosomes. Following stimulation, TLR signalling is initiated via either adaptor molecules myD88 
or TRIF and TRAM. TLR4 migrate from the cell surface to the endosomes where it switches 
signalling from myD88 to TRIF. Upon engagement of signalling adaptor molecules, there is 
stimulation of downstream signalling pathways involving interactions between IRAKs and TRAFs 
resulting in activation of MAPKs, JNK and p38 and subsequent transcriptions factors NF-κB, IRFs 
and CREB and AP1. The important consequence of TLR signalling is the elicitation of 
pro-inflammatory cytokines and induction of type 1 IFNs when endosomal TLRs are involved.
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TLR in zebrafish - Zebrafish have a set of 20 putative orthologs of mammalian 
TLRs (Jault et al, 2004; Meijer et al, 2004). Out of these, 10 are orthologs of 
human TLR family members (Table 2). The TLR22 is fish specific and closely 
related to a toll9 gene of Drosophila melanogaster whereas the TLR21 is present 
in birds, amphibians and fish (Jault et al, 2004; Meijer et al, 2004). In zebrafish, 
TLR9 and TLR21 have been shown to recognise CpG-ODNs (Yeh et al, 2013). 
Zebrafish have gene duplicates for some of the corresponding mammalian TLRs. 
For example, TLR4 has tlr4ba/tlr4bb, TLR5 has tlr5a/tlr5b and TLR8 has 
tlr8a/tlr8b. However, it is not known whether having multiple receptors is 
associated with diversification in PAMP recognition (Meijer & Spaink, 2011). 
TLR18 in zebrafish is a homolog of human TLR1 (Meijer et al, 2004) while TLR20 
zebrafish protein is similar to mouse TLR11 and TLR12 (Pietretti et al, 2014). 
Some zebrafish TLR ligands have been identified. For example, zebrafish TLR2 
recognises bacterial lipoproteins or Pam3CSK4 (Meijer & Spaink, 2011; Yang et 
al, 2015) while TLR3, 5 and 9 bind to dsRNA, flagellin and unmethylated CpG 
DNA respectively (Alexopoulou et al, 2001; Hayashi et al, 2001; Matsuo et al, 
2008; Ohto et al, 2015; Uematsu & Akira, 2008). However, zebrafish TLR4 does 
not recognise LPS stimulation (Sepulcre et al, 2009; Sullivan et al, 2009) although 
molecules (MD1 and Rp105) which mediate recognition have been identified in 
zebrafish. Candel et al. (2015) showed that MD1 bind to Rp105 and TLR4 in 
zebrafish, however accessory molecules including LBP, CD14 and MD2 have not 
been identified in zebrafish (Candel et al, 2015; Kaiser & Normile, 2015; Sullivan 
et al, 2007) suggesting that the TLR4 binding conformation is not conserved in 
zebrafish (Sullivan et al, 2009). In fact, deletion of tlr4a, tlr4b and myD88 did not 
affect zebrafish immune response to LPS stimulation (Sepulcre et al, 2009) 
suggesting that TLR4 play a different role in recognition of pathogens and 
recognition of LPS in zebrafish may be different from that of mammals. TLR22 is 
fish specific and recognises dsRNA or PolyI:C followed by engagement of the 
common adaptor molecule TRIF to elicit IFN expression. TLR22 is thought to be 
a homolog of mammalian TLR3 (Matsuo et al, 2008).  
Homologs of signalling molecules downstream of mammalian TLR have been 
identified in zebrafish including MyD88, Mal/TIRAP, TRIF, IKAP, NEMO, SARM1 
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(Ordas et al, 2011) and TRAF family (Stein et al, 2007). Using knockdown 
studies, MyD88 and Traf6 have been shown to be required for pro-inflammatory 
innate immune response to microbial challenge in zebrafish (Bates et al, 2007; 
Stockhammer et al, 2010; Stockhammer et al, 2009; van der Sar et al, 2006). All 
of mammalian adaptor proteins except TICAM2 (TRAM) have been identified in 
zebrafish. However, zebrafish have TICAM1 and is located in the Golgi apparatus 
and can activate NF-κB enhancers and IRF3- and IRF7-mediated pathways but 
the N- and C-terminus domains which are present in mammals are absent in 
zebrafish (Fan et al, 2008; Poynter et al, 2015; Zhang & Gui, 2012).  
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Table 2: TLR that have been identified in zebrafish 
 
Adapted from Li et al. (2017) 
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NLR mediated signalling - Several families of receptors to detect pathogens that 
evade recognition by endosomal or cell surface receptors perform cytoplasmic 
surveillance. Cytoplasmic receptors include NOD-like receptors (NLRs), RIG-like 
receptors (RLR) and AIM2-like receptors (ALRs). The NLRs recognise different 
PAMPS and DAMPs (Schroder et al, 2010) while RLRs recognise viral RNA 
(Wilkins & Gale, 2010) and ALRs detect cytosolic DNA (Fernandes-Alnemri et al, 
2009; Hornung et al, 2009; Jin et al, 2012). The innate immune signalling 
pathways involving the NLRs and RLRs are similar across mammals and teleost 
fish. However, the signalling pathways associated with ALRs are not present in 
fish, suggesting that fish may have other mechanisms to deal with DNA viruses 
and intracellular bacteria (Cridland et al, 2012). There are almost 421 NLR family 
members in zebrafish (Howe et al, 2016). Molecular phylogeny data and 
expression studies of NLR subfamilies in zebrafish reveal three distinct NLR 
subfamilies which include NLR-A, NLR-B and NLR-C. NLR-A comprise eight 
genes that resemble mammalian NODs, whereas NLR-B, comprise nine genes 
that resemble mammalian NACHT-, LRR- and PYD-containing proteins (NLRP), 
and NLR-C comprise of 405 NLR genes that are unique to teleost fish (Cridland 
et al, 2012; Laing et al, 2008). Sha et al. 2009 has shown that mammalian NOD1, 
NOD2 and NLRC3 are conserved in zebrafish (Sha et al, 2009). NOD2 is 
associated with a dual oxidase enzyme that is essential for the production of 
antibacterial ROS in epithelial cells in mammals (Lipinski et al, 2009). Likewise, 
NRLs appear to be essential for innate antibacterial immunity in zebrafish. NOD1 
or NOD2 zebrafish morpholino show significantly reduced DUOX expression 
resulting in impaired immune response to systemic Salmonella infection (Oehlers 
et al, 2011). On the other hand, NLRP3 inflammasome is not present in zebrafish 
(Boyle et al, 2013; Laing et al, 2008; Stein et al, 2007). Some components of the 
adaptor molecules in the inflammasome pathways are present in zebrafish 
including apoptosis-associated speck-like protein containing CARD (ASC) that 
connects the upstream receptors (such as NLRs/PYHINs) to the downstream 
signalling caspases (Broz et al, 2010; Fernandes-Alnemri et al, 2007).  
C-type lectin signalling – The C-type lectin receptors (CLR) are part of a diverse 
superfamily of soluble and transmembrane proteins that bind carbohydrates. The 
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CLR are defined by a characteristic C-type lectin domain (Zelensky & Gready, 
2005). CLR are comprised of 17 groups characterised based on structure. The 
most studied groups include calcium dependent lectins with single CRDs, 
calcium-independent receptors with single CTLDs and calcium dependent lectins 
with multiple CRDs (Zelensky & Gready, 2005; Hoving et al, 2014). Stimulation 
of the CLR can activate intracellular signalling in two ways: firstly, via direct 
signalling by Dectin-1 and DNGR-1 through ITA-like motifs found in the 
cytoplasmic leg of these receptors (Zelensky & Gready, 2005; Geijtenbeek & 
Gringhuis, 2009). The second mechanism is through indirect signalling involving 
receptors including macrophage-inducible C-type lectin (Mincle), Dectin-2 and C-
type lectin domain family 5A (CLEC5A). The receptors bind to ITAM containing 
adaptor molecules such as FcRγ or DAP12 (Hoving et al, 2014). The downward 
signalling through both mechanisms involves the recruitment of syk leading to 
formation of CARD9, Bcl10 and Malt1 complex. This signalling pathway and 
others lead to induction of downstream molecules such NFκB and MAPK, that 
consequently activate cellular responses including phagocytosis, DC maturation, 
chemotaxis, the respiratory burst, inflammasome activation, and production of 
cytokines (Drummond et al, 2011; Strasser et al, 2012). The CLR are widely 
recognised to play a critical role in antifungal immunity, although they have been 
shown to orchestrate anti-viral, bacterial, helminth and protozoan immunity 
(Hoving et al, 2014). In antifungal immunity, Dectin-1 recognises β-glucans while 
the other receptors (the mannose receptor (MR), DC-SIGN, and Mincle) bind to 
undefined, mannose-based structures found in the mannan layer of the fungal 
cell wall (Hardison & Brown, 2012).  
Research into in CLR in zebrafish is significantly sparse. CLR genes have been 
identified in zebrafish. Recently, Zheng et al, (2015) identified a zebrafish MR 
gene that is structurally similar to other MRs from other species. In addition, 
zebrafish lectin-like receptor, CD209 (DC-SIGN) homologue, has been shown to 
participate in the initiation and development of adaptive immunity (Zheng et al, 
2015).  
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1.9 Hypothesis and aims 
Cryptococcus neoformans remains the most common fungal agent causing 
morbidity and mortality in the immunocompromised. Macrophages are highly 
specialised for host defence against C. neoformans. The effector functions of 
macrophages are defective in the presence of very low CD4+ T cells. However, 
the current antifungal drugs mainly target the pathogen and are unable to resolve 
macrophage inactivity. Activation immunotherapies that target the host, such as 
cytokines or agonists of PRRs, aimed at enhancement of innate immune 
resistance to pathogens are emerging. Currently several immunomodulatory 
therapies are licensed for medical use in the treatment and prevention of 
infectious diseases. The research presented in this thesis explores 
immunomodulation by activation of innate immune resistance as therapy for C. 
neoformans infections. 
Hypothesis 
I hypothesised that treatment that activates macrophages in the absence of T cell 
mediated immunity leads to clearance of C. neoformans infection 
Aims 
I aimed to establish a localised infection model in zebrafish to study infection 
outcomes following treatment with cytokines or TLR agonists 
Objectives 
To answer this hypothesis, the following objectives were employed. 
1. Development a zebrafish-C. neoformans intramuscular infection model  
2. Investigation of the effect of IFNγ on cellular and cytokine immune responses 
and clearance of infection.  
 Administration of IFNγ with anti-fungal drugs in HIV-associated 
cryptococcal meningitis results in increased clearance of infection from 
cerebrospinal fluid (CSF). This study is based on the hypothesis that IFNγ 
induces clearance of Cryptococcus by direct activation of effector cells 
including macrophages. Cellular and cytokine immune responses are 
analysed.  
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3. Investigation of the effect of TLR agonist on activation of innate immune 
resistance to C. neoformans and their underlying mechanisms.  
 TLRs are required for C. neoformans host immunity. However, 
manipulation of the receptors for the treatment of C. neoformans has not 
been investigated. The ability of several TLR agonist to improve 
containment of C. neoformans infection in zebrafish are analysed.   
. 
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2.1 Ethics statement 
Handling of zebrafish lines was carried out in compliance with guidelines and 
legislation set out in UK law in the Animals (Scientific Procedures) Act 1986 and 
local animal welfare regulations. All animal work was approved by the University 
of Sheffield Local Ethical Review Panel.  
2.2 Fish husbandry  
The wild-type and transgenic zebrafish lines used in this work are listed in Table 
3. Zebrafish strains were raised and maintained by following standard protocols 
(Joseph Fetcho, 2003). Adult fish were maintained in a continuous re-circulating 
closed aquarium system at 28° C on a 14‑hour light, and 10-hour dark daily cycle 
in UK Home Office approved aquaria in the Bateson Centre at the University of 
Sheffield. Zebrafish at 5‑days post fertilisation (dpf) were fed Tetra A‑Z powdered 
fish feed, then live artemia twice daily from 13dpf onwards.  
Embryos for experimentation were obtained either by mating individual pairs or 
marbling a tank for group mating. For mating pairs, two adult zebrafish male and 
female were put into breeding traps composed of two plastic containers that fit 
tightly into one another. The inner container held the fish and had a grid base to 
allow embryos to fall into the outer container. For collective mating, a container 
with marbles was placed into a fish tank containing up to 40 adult zebrafish. This 
container consisted of two plastic containers that were tightly fitted together. The 
inner container had a wire-mesh bottom which was filled with marbles. Zebrafish 
mate and spawn at dawn, thus in all cases, mating set-up was performed in the 
evening and embryos were harvested the following morning before noon. The 
embryos were collected by pouring the water from the outer container through a 
small strainer where they were collected in the mesh. They were then washed 
with system water to remove any dirt and transferred into a Petri dish (Scientific 
Laboratory Supplies Ltd. (SLS), Coatbridge, UK). Fertilised healthy embryos 
were sorted using a Pasteur pipette into Petri dishes with approximately 30 mL 
of 1x E3 medium with 0.1% (w/v) methylene blue (Stock- 10x E3: 5 mM 
NaCl+0.17 mM KCl+0.33 mM CaCl2+0.33 mM MgSO4+ dH20 made up to 1L) at 
a density of approximately 60 viable embryos per dish. This solution aids in 
 CHAPTER 2| MATERIALS AND METHODS 73 
 
distinguishing dead (which stain blue) from live embryos and also reduces 
bacterial growth. The embryos were maintained at 28.5º C in a designated 
incubator for further development. At the end of all experiments, and before the 
zebrafish reached 5.2dpf, they were killed by immersion in liquid bleach. All 
protocols were carried out following UK Home Office legislation, which allows the 
use of embryos up to 5.2dpf without the Animals (Scientific Procedures) Act.  
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Table 3: Zebrafish lines used for experimental work 
Zebrafish line Description Reference 
Nacre Wild-type (Lister et al., 1999)) 
Tg(mpeg1:mCherryCAAX)sh378 Macrophage fluorescent marker mCherry under the control 
of the macrophage-specific mpeg1 promoter 
(Bojarczuk et al., 2016) 
Tg(mpeg1:Gal4-
VP16/UAS:Kaede)  
Zebrafish line expressing a photoconvertible protein kaede 
under control of the Gal4 UAS sequence in macrophages. 
Used as a macrophage line 
(Ellett et al., 2011) 
Tg(mpeg1:Gal4-UNM)sh256 Macrophage line expressing Gal4 driven by UNM promoter  
Tg(mpx:eGFP)i114 Neutrophil fluorescent GFP transgenic zebrafish (Renshaw et al., 2006) 
TgBAC(tnfa:GFP)pd1028 TNFα promoter BAC driving GFP line (Marjoram et al., 2015)  
Tg(cfms:GFP)sh377 Macrophages marker GFP driven by the fms promoter  (Dee et al., 2016) 
Tg(il1:GFP)sh445 Il-1 promoter driving GFP  
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2.3 C. neoformans strains and cultivation  
Cryptococcus neoformans strains used in this study are listed in Table 4. The 
strains were stored long-term in Microbank™ vials (Pro-Lab Diagnostics) in a 
minus 80º C freezer (New Brunswick Scientific, Eppendorf, Hamburg, Germany). 
The strains from minus 80º C freezer were cultured on YPD agar (50g/L YPD + 
Agar 2g/L – both from Sigma-Aldrich) at 28º C for 48 hours and thereafter they 
were stored at 4º C until needed or for no longer than 1 month. The cultures were 
maintained by sub-culturing on fresh media periodically and checked for 
contamination before use.  
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Table 4: C. neoformans strains used in this study 
Cryptococcus neoformans 
var. grubii 
Description Reference 
Kn99 C. neoformans serotype A mating type α. Congenic 
strain in the H99 genetic background 
(Nielsen et al., 2003) 
Kn99-GFP Kn99 strain biolistically transformed with a plasmid 
pAG32_GFP 
(Gibson et al., 2017) 
Kn99-mCherry Kn99 strain biolistically transformed with a plasmid 
pRS426H-CnmCherry 
(Gibson et al., 2017) 
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2.4 Infection assay 
2.4.1 Preparation of C. neoformans prior to injection  
A day before infection, a colony of C. neoformans from YPD agar was inoculated 
into 2mL YPD broth (50g/L) in a 5mL T405 sterile plastic tube (Simport® 
Scientific, Beloeil, Canada) and incubated at 28º C overnight (approximately 18 
hours) at 20 rotations per minute (rpm).  
Preparing fungal suspension - The overnight 2mL liquid culture was mixed by 
pipetting up and down. Before the cryptococci had a chance to settle, 5µL of the 
culture was added in 95µL PBS (making 1:20 dilution) and mixed by pipetting up 
and down prior to counting.  
Counting – 10µL of the diluted cryptococci suspension was added to a neubauer 
haemocytometer (Camlab, Cambridge, UK) and the cryptococci was counted 
using a 10x objective on all 4 sets of 16 corner squares.  
Calculations – To calculate the number of cryptococci cells per mL, the average 
count of the all 4 sets of 16 corner squares was multiplied with 104 (volume 
correction to 1mL) and 20 (dilution factor).  
i.e. if average of 301 cryptococci were counted 
Then per mL = 301x104 x20 = 6.02x107 cfu/mL 
To prepare fungal suspension for injection, 1mL of well-mixed culture was 
transferred into a 1.5mL Eppendorf microtube (Sigma-Aldrich) and then pelleted 
at 3300g in GenFuge 24D centrifuge (Progen Scientific, London, UK) for 1 min. 
The supernatant was then decanted and the cryptococci cells were washed 3x in 
1mL 1xPBS (1 tablet/100mL, Oxoid, Basingstoke, UK) and suspended in1mL 
1xPBS after the last wash.  
To calculate a volume that will give the required fungal inoculum per nanoliter, 
the following example calculation was used. This example was to give 1000 
fungal cells/nanoliter based on a suspension containing 6.02x107 cells/mL.  
Volume to give
1000cfu
nL
=
1000 𝑥 10−6
6.02 𝑥 107
   = 60.2µL 
 CHAPTER 2| MATERIALS AND METHODS 78 
 
This volume (62µL for example) was taken from the washed suspension into 
another 1.5mL Eppendorf microtube and centrifuged at 3300g for 1 min and the 
pellet was re-suspended in sterile 10% (vol/vol) Polyvinylpyrrolidinone (PVP)-
0.5% Phenol Red (Sigma-Aldrich) in PBS. PVP increases the viscosity of the 
injection solution and inhibits clumping of cells in the needle (Spaink et al., 2013).  
2.4.2 Intramuscular injection   
To perform injections, 3dpf zebrafish larvae were anesthetised by immersion in 
0.168 mg/mL tricaine (Stock solution: 400 mg Tricaine methanesulfonate or 
MS222, Sigma-Aldrich; + 97.9 mL dH20 + 2.1 mL 1 M Tris–HCl, pH 9.0) in E3 for 
at least 15 min. The injection solution (C. neoformans and/or immunomodulatory 
compounds) were loaded into a Kwik-Fil borosilicate glass capillary (World 
Precision Instruments, Hitchin, UK) pulled into 51-gauge needle using P-1000 
Next Generation Micropipette Puller (Sutter Instrument, CA, USA). Using a 
graticule slide, the micromanipulator was set to dispense a droplet size equivalent 
to 0.5 nl. The larvae were laid on 10g/L agarose (Sigma Aldrich) in petri dish. Two 
0.5 nl droplets were injected into either 15, 16 or 17 myotomes (Figure 9). After 
injections, larvae were transferred into fresh E3 to recover from the anaesthetic 
and maintained at 28º C. Any larvae that were visibly damaged or had solution 
accidentally injected into the bloodstream were excluded from the experiment.  
2.4.3 High content imaging method 
Before imaging, infected larvae were anesthetised by immersion in 0.168 mg/mL 
tricaine in E3 and transferred into plastic 96-wells-F plates (VWR, Pennsylvania, 
USA) with a single larva per well. For time-lapse imaging, larvae were mounted 
in 5g/L low gelling agarose (Sigma Aldrich) in E3 containing 0.168 mg/mL tricaine 
into glass-bottomed 96-well plates (Porvair sciences, Wrexham, UK). The larvae 
were imaged on a Nikon Ti-E with either a CFI Plan Apochromat λ 10X N.A.0.45 
or 20X N.A. 0.75 or 40X N.A. 0.95 objective lens, a custom built 500 μm Piezo 
Z‑stage (Mad City Labs, Madison, WI, USA) and using SPECTRA X light engine 
with 7 bandpass filters (Lumencor, Beaverton, Oregon, USA). Images were 
captured with Neo sCMOS, 16.6 mm x 14.0 mm Sensor Size, 6.5 μm pixel size 
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camera (Andor, Belfast, UK) and NIS-Elements (Nikon, Richmond, UK). Settings 
used and imaging sections used will be described in each section below.  
2.5 Effects of immunomodulation on infection outcomes 
2.5.1 Preparation of immunomodulatory compounds for injection 
Chemical compounds were dissolved in dH20 or as indicated (Table 5). The 
required volume of stock solution was added to cryptococci suspension in 10% 
PVP-0.5% Phenol Red to make a working concentration. For example, to make 
a concentration of 100cells/nl in 5µg/mL IFNγ, 2µL C. neoformans (1000cells/nl) 
+ 2µL IFNγ (50µg/mL) + 16µL PVP were mixed. Testing of immunomodulatory 
compounds was always carried out alongside appropriate vehicle control as 
indicated. The immunomodulatory compounds used in this study are listed in 
Table 5. 
2.5.2 Inoculation and imaging 
Three dpf zebrafish larvae were co-injected with C. neoformans and an 
immunomodulatory compound prepared as described in section 2.5.1. Injections 
were performed as described above (Section 2.4.2). Because of the technical 
difficulty to inject the same number of fungal cells in each larva, the fungal 
inoculum was set at 1 and 25 cryptococci per larva and cryptococci numbers 
outside this limit were discarded.  
To quantitate the initial fungal inoculum, the larvae were imaged immediately 
(zero-hour post infection) in 96-well plate. Imaging was performed as described 
in above except a CFI Plan Achromat UW 10X N.A. 0.45 objective lens was used 
and each larva was imaged on the infected region (between 15-17 myotome) 
taking 21 z‑sections, 5µm apart, captured in GFP channel. Following imaging, 
tricaine E3 was replaced with fresh E3 to recover the fish from the anaesthetic. 
The larvae were maintained at 28º C until 48hpi. At 48hpi, larvae were 
anaesthetised in 0.168 mg/mL tricaine E3 and imaged with the same settings at 
before (0 hpi).  
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2.5.3 Measurement of fungal burden 
The fungal burden at zero and forty-eight hours-post infection was determined in 
NIS-Elements by manually counting individual fungal cells per fish. Larvae with a 
fungal inoculum of <1 or >25 were removed from the analysis. Each biological 
repeat contained 30-50 infected larvae.  
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Table 5: Immunomodulatory compounds used in this study 
Condition Manufacturer Stock [C] Solvent Working [C] 
Interferon-gamma from Kingfisher, Biotech, MN, USA 
Protein Sequence: SVPENLDKSI EELKAYYIKE DSQLHNAHPI 
FLRILKDLKV NLEESEQNLL MSIVMDTYSR IFTRMQNDSV 
DEATKERLAH VQEHLKKLQE SYFPGKSAEL RTYAETLWAI 
KENDPIVQRK ALFELKRVYR EATLLKNLKN KERKRRQAKA 
SRSKSLNRG (159)  
50 µg/mL dH20 5 µg/mL 
Lipopolysaccharide 
(E. coli serotype 
055:K59[B5]H)   
Invivogen, CA, USA 100 µg/mL dH20 10 µg/mL 
Imiquimod (R837) Invivogen, CA, USA 100 µg/mL dH20 10 µg/mL 
Pam2SCK4 Invivogen, CA, USA 100 µg/mL dH20 10 µg/mL 
CpG ODN 2395 Invivogen, CA, USA 25 µg/mL dH20 2.5 µg/mL 
S. aureus CWP Generous gift from Simon Foster, UOS 10mg/mL dH20 5 mg/mL 
Vibrio DNA Generous gift from Victoriano Mulero 
University of Murcia, Spain  
50 µg/ml dH20 5 µg/ml 
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2.5.4 Effects of immunomodulatory compounds of fungal growth  
To examine if the compounds at this concentration (shown in Table 5) are not 
toxic to the fungal cells, C. neoformans was prepared with the immunomodulatory 
compounds as described in section 2.5.1. The solutions were left for two hours 
and 10µl was transferred to YPD agar, incubated at 28.5º C overnight and 
colonies counted and calculated per mL. 
2.6 Assays to analyse macrophage and neutrophil response during 
cryptococcal infection in zebrafish  
2.6.1 Macrophage and neutrophil recruitment and phagocytosis assay 
To assess the effect of C. neoformans or immunomodulatory compounds on 
recruitment of immune cells to the site of infection, C. neoformans and/or 
immunomodulatory compounds were prepared as described above (section 2.4.1 
and 2.5.1). Three dpf Tg(mpeg1:Gal4-VP16/UAS:Kaede) larvae for 
macrophages, and Tg(mpx:GFP)i114 larvae for neutrophils, were inoculated with 
the solutions as described above (Section 2.4.2). At 2, 12 and 24 hpi, larvae were 
anaesthetised and imaged using Nikon Ti-E with a CFI Plan Apochromat λ 20X 
N.A. 0.75 objective lens taking 21 z‑sections, 5µm apart, captured in GFP, Red 
channels. The other settings were as described above (Section 2.4.3). The 
numbers of neutrophils and macrophages at the infection site were counted as 
describe in Figure 6.  
For phagocytosis assay, the number of extracellular cryptococci, proportion of 
intracellular cryptococci and phagocytic index in both neutrophils and 
macrophages were obtained at time-points. The formula in Figure 7 were used to 
obtain these numbers. The numbers were calculated separately for neutrophils 
and macrophages. Where feasible, blind counting to experimental conditions was 
carried out.   
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Figure 6. Schematic diagram of enumeration of recruited macrophages or 
neutrophils.  
Enumeration of recruited innate cells was carried out on a region surrounding the wound 
site. A region (red box) was drawn on a wound (blue circle) site covering 2-3 somites on 
both sides of the wound site. The same criteria were applied to all fish analysed in the 
experiment.  
 
 
Figure 7: Formulas used to calculate number and proportion of extracellular 
cryptococci and phagocytic index. 
a = total number of cryptococci; b = number of intracellular cryptococci; c = number of 
infected macrophages  
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2.6.2 Tumour necrosis factor-α GFP expression assay 
To investigate the effect of immunomodulatory compounds on the expression of 
TNFα GFP, 3dpf TgBAC(tnfa:GFP)pd1028 crossed to 
Tg(mpeg1:mCherryCAAX)sh378 larvae were co-injected intramuscularly with 
C. neoformans and immunomodulatory compounds. At 12, 24 and 36 hpi, larvae 
were mounted in 5g/L low gelling agarose in E3 containing 0.168g/mL tricaine 
and imaging was performed as described above with the following adjustments: 
Images were captured with CFI Plan Apochromat λ 40X N.A. 0.95 objective lens, 
45vz-sections, 2µm apart, using the following settings: GFP, filter 49002, 700 ms 
exposure, gain 1; mCherry, filter 49008, 900 ms exposure, gain 1; and bright field, 
30ms, gain 1. The image analysis was performed using NIS-elements. A line was 
drawn around the infected macrophages and values of GFP mean fluorescent 
intensity were obtained. Background GFP mean fluorescent intensity values were 
also obtained. Actual GFP mean fluorescent intensity of a macrophage was 
obtained by subtracting background GFP mean fluorescent intensity value. GFP 
TNFα expression per fish was obtained by adding up all actual GFP mean 
fluorescent intensity values of each macrophage.  
2.6.3 Interleukin-1 (IL-1) expression assay  
To investigate the effect of immunomodulatory compounds on the expression of 
IL-1 GFP, 3dpf Tg(il1:GFP)sh445 crossed to nacre were co-injected 
intramuscularly with C. neoformans and immunomodulatory compounds. Larvae 
were mounted and time lapse imaging was performed as described above 
(Section 2.4.3) with the following adjustments: Images were captured with CFI 
Plan Apochromat λ 20X N.A. 0.75 objective lens, 21 z‑sections, 5µm apart, with 
Perfect Focus system, every 15 minutes for 12 hours. A line was drawn around 
the injection site, and values of GFP mean fluorescent intensity were obtained.  
2.7 Lysosomal pH 
To investigate if IFNγ enhances acidification of lysosomal pH, cresyl violet was 
employed as a fluorescent lysosomal marker as shown by Ostrowski et al. (2016). 
Cresyl violet is an acidotropic compound in that it can cross the membrane in its 
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unprotonated state. Once protonated, cresyl violet is trapped and eventually 
accumulates in acidic organelles such as lysosomes. Cresyl violet excitation and 
emission wavelengths are 585 and 627 respectively. Cresyl violet has higher 
emission wavelength than most conventional red fluorescent dyes and is more 
photostable than lysotracker red (Ostrowski et al, 2016). A solution comprising 
C. neoformans, 5µg/mL IFNγ and 0.5mM cresyl violet (Sigma Aldrich) was 
injected in 3dpf Tg(fms:Gal4.VP16)i186 as described above (Section 2.4.2). To 
make a concentration of 100cells/nl in 5µg/mL IFNγ and 0.5mM cresyl violet for 
example, 2µL C. neoformans (1000cells/nl) + 2µL IFNγ (50µg/mL) + 2ul cresyl 
violet (5mM) +14µL PVP were mixed. Images were captured with CFI Plan 
Apochromat λ 20X N.A. 0.75 objective lens, 45vz-sections, 2µm apart. Analysis 
was performed using NIS-elements. A line was drawn around the infected 
macrophages and values of Cy7 mean fluorescent intensity were obtained. 
Background Cy7 mean fluorescent intensity values were also obtained from 
macrophages of infected larvae that were not treated with cresyl violet. The actual 
Cy7 mean fluorescent intensity of a macrophage was obtained by subtracting 
background Cy7 mean fluorescent intensity value. Phagosome acidification per 
fish was obtained by adding up all actual Cy7 mean fluorescent intensity values 
of each macrophage.  
2.7.1 Proliferation rate assay in macrophages 
To assess the ability of immunomodulatory compounds to inhibit proliferation of 
C. neoformans within macrophages in zebrafish, 3dpf 
Tg(mpeg1:Gal4-VP16/UAS:Kaede) larvae were co-injected with C. neoformans 
and immunomodulatory compounds as described above (Section 2.4.2). At 
12hpi, at which almost all cryptococci were internalised, zebrafish larvae were 
mounted in 5g/L low gelling agarose in E3 containing 0.168g/mL tricaine. 
Time-lapse imaging was carried out as described above with the following 
adjustments: images were captured with CFI Plan Apochromat λ 20X N.A. 0.75 
objective lens, 21 z-sections, 5µm apart, with Perfect Focus system, every 15 
minutes for 12 hours. 
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For calculation of the proliferation rate (PR) within macrophages, the number of 
internalised cryptococci in each macrophage were recorded every 15 min until 
the end of imaging.  
To obtain PR per hour, the following calculations were performed: PR = (total 
number of cryptococci within a macrophage at the end of time-lapse imaging 
minus the total number of cryptococci within the same macrophage at the 
beginning of the time-lapse imaging) divide by total number of time-lapse hours.   
2.8 Macrophage ablation assay using metronidazole 
Ablation of macrophages was performed as previously described (Curado et al., 
2008). Zero-dpf Tg(mpeg1:Gal4-UNM)sh256 zebrafish transgenic embryos were 
immersed in freshly prepared 5mM Metronidazole (Sigma Aldrich) in E3 with 
0.2% (vol/vol) DMSO (sigma-Aldrich). Control embryos were immersed in E3 with 
0.2% DMSO. Embryos were transferred into freshly prepared 5mM 
Metronidazole in E3 with 0.2% DMSO daily until ready for infection (at 3dpf). 
Larvae were inoculated with C. neoformans and immunomodulatory compounds 
as described above (Section.2.4.2). Following infection, larvae were transferred 
to freshly prepared 2.5mM metronidazole in 0.2% DMSO and E3. The zebrafish 
were incubated at 28º C and wrapped with aluminium foil throughout the 
experiment. Imaging was carried out as described above except that CFI Plan 
Achromat UW 10X N.A. 0.45 objective lens was used and three adjacent fields 
of view that were assigned from bright-field images were taken. Using a custom 
built 500μm Piezo Z-stage, 80 z-sections, 5 μm apart, were captured in GFP and 
Red channels and each position in that order. The fungal burden at the site of 
infection was obtained as described above. To confirm ablation, the total body 
macrophage count was performed by manually counting the macrophages in 
images in NIS-elements. As a control, metronidazole had no significant effect on 
the fungal burden upon ablation of neutrophils (Data provided by Josie Gibson). 
2.9 α-nitrotyrosine staining  
To investigate the effect of IFNγ on the production of nitrotyrosine, 3dpf 
Tg(cfms:GFP)sh377 larvae were injected with wild type C. neoformans as 
described above and incubated at 28.5° C for 6, 12 and 24hrs post infection. 
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Following incubation, the fish were anaesthetised with tricaine and transferred 
into a microfuge tube. The tricaineted E3 was removed and immediately 4% 
Paraformaldehyde (PFA) + 0.4% TritonX-100 (TX) was added and incubated 
overnight at 4° C to fix the fish. The fish were then washed 4x in 0.4% TX:PBS at 
5min each wash. Then 1mL of 10µg/mL proteinase-K:0.4%TX:PBS was added 
and left at room temperature for 30min. Since a protease enzyme can degrade 
the proteins of interest, the proteinase-K was not left longer than 30min. The fish 
were then washed again 4x at 10min each wash on a Rocker in 0.4%TX:PBS. 
Following the final wash, 1mL sheep serum (5% SS:0.4%TX:PBS) was added 
and left for 2h at room temperature on a Rocker. Then 100-200µl α-nitrotyrosine 
antibody (diluted 1:250 in SS:0.4%TX:PBS) was added and incubated at 4° C on 
orbital shaker overnight. The antibody was then washed off 4x at 10min each 
wash on a Rocker in 0.4%TX:PBS. Then 500µl sheep serum (5% 
SS:0.4%TX:PBS) was added and left for 1h at room temperature on a Rocker. 
Then added 200µl Alexa Fluor 657 (red) Goat Anti-Rabbit secondary antibody 
(diluted 1:500 in 5% SS:0.4%TX:PBS) for 2h at room temperature in the dark 
(wrapped with aluminium foil) then washed off 4x at 20 min each wash on a 
Rocker in 0.4%TX:PBS, in the dark. The fish were then washed again in 
4%PFA:0.4TX:PBS for 20 min at room temperature and then rinsed briefly in 
0.4%TX:PBS and store in the same at 4° C in aluminium foil until (maximum of 1 
week) ready to image. 
2.10 Statistics 
Statistical analysis was performed using GraphPad Software (La Jolla, CA, USA). 
To compare if the mean of two groups (that are normally distributed) are 
significantly different from each other, the unpaired t test was used. However, if 
the two groups are not normally distributed, Mann-Whitney test was used instead. 
To compared multiple comparison, one-way or two-way analysis of variance 
(ANOVA) with Bonferroni test was used to compare every mean to every other 
mean whereas Dunnett’s test was used to compare every mean to the control 
mean. However, for non-parametric data, ANOVA with Dunn’s test was 
employed. P-values were adjusted to correct for multiple comparisons. Fisher’s 
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exact test was employed to compare categorical variables such as intracellular 
and extracellular fungi. In all analyses, statistical significance was set at P < 0.05.  
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3.1 Introduction 
3.1.1 Animal models of C. neoformans  
Cryptococcus neoformans remains the leading fungal pathogen of the 
life-threatening illness in individuals with immunocompromised immunity. A 
comprehensive understanding of C. neoformans pathogenesis should help to 
facilitate the development of new therapeutic strategies. Therefore, establishing 
an efficient animal model system to study and investigate new therapies for 
C. neoformans is critical. Mice are the predominant animal models used in 
C. neoformans infection research.  However, mice are difficult to use in 
large-scale studies because of the limited number of progeny produced, 
exorbitant costs and ethical issues. As discussed in Chapter 1, several 
invertebrate organisms have been used to study C. neoformans infection. They 
include Galleria mellonella (wax moth), Acanthamoeba castellanii, Dictyostelium 
discoideum (social amoeba) and Caenorhabditis elegans (nematode) (reviewed 
in Sabiiti et al., 2012). The advantages of using some of these hosts include a 
well-developed innate immunity, widely available molecular tools, affordable care 
systems and the possibility of enabling high-throughput infection and drug 
screening assays (Mylonakis et al., 2007). However, some of these hosts have 
some limitation regarding genetic tools, physiology and anatomical structure, 
highlighting the necessity for other models to study the complex host‑pathogen 
interactions.  
The use of zebrafish (Danio rerio) in biomedical research has been increasing, 
mainly due to its ability to produce a large numbers of offspring, transparency of 
the larva, genetic malleability and cheaper running costs (Novoa and Figueras, 
2012). Since scientists began using zebrafish to study C. neoformans infection, 
to date, there have been three papers published (Tenor et al., 2015, Davis et al., 
2016, Bojarczuk et al., 2016). See Chapter 1 for a summary of findings from these 
studies.  
3.1.2 Routes of infection 
When developing an animal model to study fungal infection, a route of infection 
must be considered to achieve the desired outcome. In mouse models, routes of 
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infection that have been used include pulmonary, intraperitoneal, intravenous, 
intracerebral and footpad inoculations. Each of these routes is used to study 
specific objectives. For example, to examine BBB crossing of C. neoformans in 
mice, fungal cells are inoculated intravenously whereas to study the progression 
of cryptococcal meningitis, an intracerebral inoculation model is used (Liu et al., 
2012).  
Because C. neoformans infections are acquired through inhalation of infectious 
propagules, most studies use an intranasal inhalation model because it simulates 
the natural entry into the human host. The establishment and consequent 
outcomes of cryptococcal infection in animal models do not always mimic all 
forms of human cryptococcosis. For example, pulmonary inoculation with 
C. neoformans in immunocompetent mice results in dissemination of the fungus 
to the brain (Zaragoza et al., 2007). However, in some patients, particularly in the 
non-HIV infected, cryptococcal infection may remain localised in the lungs or 
other body organs (Pappas, 2013). In consideration of these differences lies the 
objective of animal modelling. The objective is to simulate an infectious process 
in humans by varying the animal models or routes of infection. Thus, localised 
inoculations have been established throughout animal modelling research to 
mimic the human pathology of the targeted organs. This usually involves 
inoculating the pathogen into the organs of interest. The advantage of localised 
infection is that it allows the study of cellular responses such as chemotaxis at 
the infection site.  
In zebrafish, various routes of infection have been established, and each route or 
site of microinjection determines whether infection will develop systemically or 
will remain localised. For example, intravenous injection into the caudal vein at 
the posterior blood island or Duct of Cuvier, (which is a large circulation vessel 
adjacent to the yolk sac linking the heart to the trunk vasculature), will establish 
a rapid systemic infection. Microinjection into the hindbrain ventricle, tail muscle, 
otic vesicle or somite (intramuscular) will create a localised infection (Zakrzewska 
et al., 2010, Le Guyader et al., 2008, Herbomel et al., 1999). However, inoculation 
into the notochord will generate an infection that is inaccessible to phagocytes 
(Alibaud et al., 2011, Benard et al., 2012) (Figure 8). The caudal vein at the 
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posterior blood island is mainly performed in 1dpf embryos but in the later stages 
of embryonic development, penetration of this site becomes more difficult. 
Therefore, the Duct of Cuvier is the preferred site of injection in 2-3 days post 
fertilisation (dpf) zebrafish larvae (Benard et al., 2012).  
Previous zebrafish cryptococcal infection models have used systemic infection 
via the Duct of Cuvier microinjection to model mammalian systemic infection and 
subsequent brain invasion (Tenor et al., 2015). This method is equivalent to the 
tail vein inoculation in mice. However, my aim was to develop a localised 
C. neoformans infection model with an objective of stimulating local host immune 
cells to study their phenotypic behaviour toward C. neoformans in vivo. I selected 
an intramuscular route of infection to be able to characterise migration of 
phagocytes and their interaction with C. neoformans. Zebrafish muscles display 
high stimulation of pro‑inflammatory cytokines, including IL-1β and TNFα, which 
is thought to be due to muscle‑resident macrophages (Chatterjee et al., 2016). 
suggesting that the zebrafish muscle can be an excellent model to study the 
cellular immune responses.   
First, I investigated outcomes of C. neoformans infection following intramuscular 
injection in zebrafish larvae.  
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Figure 8: Microinjection sites  
Schematic diagram of 2dpf zebrafish larva showing various routes of infection. Each of 
these routes are used for a specific purpose. 
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3.2 Results 
3.2.1 Infection model of C. neoformans in zebrafish 
Deciding the right age of larvae to perform intramuscular infection was one of the 
challenging aspects of developing this model. I first started infecting 2dpf larvae 
so I could follow them up for up to 72-hours post infection before the 5.2dpf. 
However, because of their size and fragility, most fish died or developed an 
uncontrolled infection. I then switched to 3dpf larvae, found that they were easier 
to handle and were not significantly harmed by microinjection.  
Therefore, to determine the outcomes of C. neoformans infection in the zebrafish 
larvae, three dpf zebrafish larvae were intramuscularly infected (Figure 9a) with 
a fungal inoculum of 1-25 yeast cells and outcomes of infection were determined 
at 48-hours post infection (hpi). The following infection outcomes were observed: 
Cleared infection – defined as complete clearance of fungal infection at the site 
of infection; controlled infection – defined as of up to 10-fold of the initial fungal 
inoculum; and uncontrolled infection – defined as fungal burden over 10‑fold to 
that of the initial fungal inoculum.  
At 48hpi, C. neoformans cells remained at the site of infection. The outcomes 
were as follows: of the 145 zebrafish larvae infected, 28 (19%) cleared the 
infection, 90 (62%) controlled the infection, 23 (16%) failed to control the infection 
and 4 (3%) died (Figure 9b&c). Although mortality was observed, it was not 
significantly different from uninfected fish (P =0.317). There was a direct 
correlation between the number of injected cryptococci and the percentage of 
cleared infection (R2 = 0.611; P = 0.0075) and uncontrolled infection (R2 = 0.698; 
P = 0.0026) but not with controlled infection (R2 = 0.255; P = 0.14; Figure 9e).  
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Figure 9: Infection model of C. neoformans in zebrafish 
(a) Schematic diagram of larva showing the site (Red box, myotome 15-17) of microinjection with 
C. neoformans. (b-d) Three dpf nacre larvae were injected intramuscularly with a range of 1 to 
2.5x10 C. neoformans and infection outcomes determined at 48-hours post infection (hpi). (b) 
Percentage infection outcomes. Data is representative of 3 independent experiments (n=145) (c) 
Percent survival analysed using Log-rank (Manted-Cox) test, hazard ratio = 2.5 (logrank; 95% 
confidence interval 0.4, 2.3; infected vs uninfected larvae, P = 317. (d) Representative time-point 
fluorescent micrographs of C. neoformans initial inoculum at 0hpi and fungal burden or infection 
outcome at 48hpi of (i) cleared infection (ii) controlled infection and (iii) uncontrolled infection (e) 
Correlation, number of injected cryptococci vs cleared infection (%) **P = 0.0075; vs controlled 
infection (%) P=0.14; vs uncontrolled infection (%) **P = 0.0026. Data was analysed using 
correlation and slop was constructed using linear regression.  
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3.3 Discussion 
The intramuscular zebrafish model described here is the first to be used in the 
study of cryptococcal infection. Previous studies of the zebrafish-C. neoformans 
infection model employed intravenous microinjection method (Tenor et al., 2015, 
Davis et al., 2016, Bojarczuk et al., 2016). To date, zebrafish have been used to 
study other fungal infections including Candida albicans, Mucor circinelloides and 
Aspergillus fumigatus and were microinjected into the hindbrain ventricles (Chao 
et al., 2010, Voelz et al., 2015, Knox et al., 2014). 
My findings show that intramuscular inoculation of C. neoformans in zebrafish 
larvae results in infection being completely cleared, controlled or uncontrolled. 
Cleared and uncontrolled, but not controlled infection outcomes were dependent 
on the number of injected cryptococci. There was a higher proportion of zebrafish 
larvae that controlled the infection than those that cleared or failed to control the 
infection. The fact that controlled infection outcomes did not correlate with the 
number of injected cryptococci requires further investigation. One explanation for 
this is that the zebrafish used are not clonal, hence variable in their genetic and/or 
phenotypic makeup and response to infection. Clonal lines are important for 
attaining stable and reproducible data in biological studies. Techniques to 
generate zebrafish clonal lines are emerging. Recently, Hou et al. (2015) 
demonstrated the generation of clonal zebrafish line using cold-shock 
androgenesis without egg irradiation (Hou et al., 2015).  
The susceptibility of the host to C. neoformans infection depends on the route of 
infection. For example, both mice and zebrafish larvae easily succumb to 
cryptococcal infection when inoculated intravenously (Tenor et al., 2015, 
Bojarczuk et al., 2016, Zaragoza et al., 2007). In contrast, mortality in my 
intramuscular zebrafish model is significantly low despite the high fungal burden. 
Interestingly, the mouse model is invariably fatal, even following localised 
infection. CBA/J mice have only a 20 % survival rate after intratracheal inoculation 
even though the mice are considered immunocompetent (Zaragoza et al., 2007). 
Susceptibility to C. neoformans infection might involve both host and pathogen 
factors. Mice that are more susceptible to C. neoformans infection display a 
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Th2-type response (Carroll et al., 2012). On the other hand, C. neoformans does 
not induce robust pro-inflammatory responses both in vitro and in vivo 
experiments. C. neoformans fails to activate monocytes and macrophages to 
produce pro-inflammatory cytokines such as TNFα and IL-1β (Levitz et al., 1994, 
Naslund et al., 1995, Vecchiarelli et al., 1995). It also induces low levels of IFNγ 
in T cells (Vecchiarelli et al., 1994) and limited leukocyte infiltration in organs 
harbouring C. neoformans (Murphy, 1989, Clemons et al., 2000). This has been 
attributable to the presence of circulating cryptococcal polysaccharide capsule 
that stimulates shedding of L-selectin from neutrophil surfaces, thus preventing 
first step of extravasation (Clemons et al., 2000). Thus, C. neoformans is able to 
hide and protect itself from being detected and eliminated by host immunity. This 
reflects the complex interplay between host and pathogen attributes that drive 
infection outcomes.  
Zebrafish have a physiological temperature of 28° C that is lower than murine 
and human hosts’ body temperatures. The ability of C. neoformans to grow at 
37° C is considered a virulence factor because 38 other cryptococcal species fail 
to grow at temperatures above 30° C. C. neoformans can grow and be 
pathogenic in a wide range of temperatures (Casadevall, 1998; Fuchs and 
Mylonakis, 2006). Apart from causing infection inside the human host, 
C. neoformans can also cause infection at low-temperature environments, such 
as the skin, suggesting that temperature is not a hindrance to its pathogenicity. 
Besides, genes that are tolerant to higher temperatures are studied at 
mammalian physiological temperature. However, not all temperature-tolerant 
genes can be studied at mammalian physiological temperature. For instance, an 
eca1 C. neoformans mutant displayed growth defects at 37° C. As such it was 
difficult to associate the mutant with virulence in mammalian models, Galleria or 
amoeba being incubated at 37° C. The mutant showed virulence using Galleria 
at 30° C and C. elegans at 25° C (Fan et al., 2007). Moreover, it was shown that 
C. neoformans genes that mediate the trehalose pathways are required for 
growth at 37° C. The trehalose mutant is avirulent in rabbits and mice. 
Interestingly, the mutant is also attenuated in virulence in C. elegans where the 
 CHAPTER 3| ZEBRAFISH CAN CLEAR, CONTROL OR FAIL TO CONTROL C. NEOFORMANS 
INFECTION AT A LOCALISED SITE 
98 
 
in vivo high-temperature environment is not present, suggesting that the 
trehalose pathways are involved in other host survival activities apart from simply 
mediating protection from high-temperature pressures (Petzold et al., 2006). 
Recently, C. neoformans has been shown to be virulent in zebrafish larvae that 
are maintained at 28° C (Tenor et al., 2015, Bojarczuk et al., 2016). Thus, 
studying C. neoformans at different temperatures can give valuable findings that 
would have otherwise be undiscovered. 
In summary, this is novel promising model capable of enabling a detailed 
dissection of the pathogenesis of C. neoformans and its interactions with the host 
immunity. I have established a zebrafish-C. neoformans intramuscular infection 
model and show outcomes of infection. Transparency of the zebrafish larva 
enables significant benefits in research because it allows in vivo imaging assays 
that are difficult to perform in other vertebrate models. Interactions of 
C. neoformans with fluorescently labelled immune cells can also be examined. 
Thus, in the next two chapters, I will show the effects of modulation of innate 
immunity by Th1-type cytokine IFNγ and TLR agonists on cryptococcal burden 
and cellular responses.  
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4.1 Introduction 
The Th1-type CD4+ T cells mediated cellular immunity is the main host defence 
mechanism against cryptococcal disease as evidenced by high incidences of 
cryptococcosis in individuals with compromised cell-mediated immunity (CMI) 
(Chuck & Sande, 1989; Collins et al, 1951; Dismukes, 1988; Eng et al, 1986; 
Kovacs et al, 1985). Protective anti-cryptococcal host immunity by CD4+ T cells 
involves the generation of Th1-type cytokines such as IL-12, IFNγ and the 
pro-inflammatory cytokine, TNFα (Bauman et al, 2003; Decken et al, 1998; 
Herring et al, 2002; Kawakami et al, 1996a; Kawakami et al, 1996b; Kawakami 
et al, 1996c; Zhou et al, 2007). Neutralisation of IL-12, IFNγ or TNFα results in 
increased susceptibility to cryptococcal infection in murine models (Decken et al, 
1998; Herring et al, 2002; Huffnagle et al, 1996; Kawakami et al, 1996a). 
Administration of recombinant Th1-type cytokines have been shown to enhance 
anti-cryptococcal chemotherapy as shown in experimental and clinical studies 
(Clemons et al, 1994; Clemons et al, 2001; Jarvis et al, 2012; Kawakami et al, 
1997b; Kawakami et al, 1996c). In contrast, generation of Th2-type cytokines 
including IL-4 and IL-13, results in diminished control of infection (Arora et al, 
2011; Blackstock et al, 1999; Hardison et al, 2012b; Müller et al, 2012; Müller et 
al, 2007; Müller et al, 2013; Qiu et al, 2012). 
Experimental studies with the Th1-type cytokine IFNγ have generated promising 
findings that it may be a potential adjunct immunotherapy to anti-fungal 
chemotherapy (Joly et al, 1994; Lutz et al, 2000). For example, in experimental 
pulmonary and peritoneal cryptococcosis, the administration of IFNγ prolongs 
mice survival and significantly reduces fungal burden (Joly et al., 1994, Kawakami 
et al., 1996b). Although treatment with IFNγ alone has little efficacy in an 
experimental systemic cryptococcosis, when administered in combination with 
amphotericin B, IFNγ displays an additive effect over amphotericin B alone in 
clearing brain infections (Clemons et al, 2001; Lutz et al, 2000). Neutralisation of 
IFNγ by anti-IFNγ antibody in an experimental murine cryptococcal infection 
results in increased fungal burden and shortened survival time (Aguirre et al., 
1995, Hoag et al., 1997, Kawakami et al., 1996b). Besides, IFNγ mediates 
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induction of anti-cryptococcal activity by other pro-inflammatory cytokines. For 
example, the protective effects induced by anti-CD40/IL-2, or IL-12 are abrogated 
in IFNγ and IFNγR knockout mice (Kawakami et al, 1996c; Zhou et al, 2006). In 
patients with cryptococcal meningitis, levels of IFNγ in the cerebrospinal fluid 
(CSF) correlated to the rates of infection clearance following anti-fungal treatment 
(Siddiqui et al., 2005, Bicanic et al., 2009). In a randomised controlled trial, the 
adjunct of exogenous IFNγ to standard anti-fungal therapy in patients with 
HIV-associated cryptococcal meningitis increased the rates of cryptococcal 
clearance from the CSF (Jarvis et al, 2012). Another clinical trial demonstrated a 
trend towards more rapid sterilisation of the CSF in IFNγ-treated patients with 
cryptococcal meningitis (Pappas et al, 2004). Taken together these data suggest 
that IFNγ is a potential adjunctive therapy for cryptococcosis in the 
immunocompromised host.   
4.1.1 Mechanisms of IFNγ protection  
Interferon-γ belongs to a group of cytokines known as interferons. There are three 
types of interferons, Type I, Type II and Type III. IFNγ is the only type II interferon 
and differs from type I and III interferons by structure, receptor and chromosome 
locus that encode them (Platanias, 2005). IFNγ was first thought to be secreted 
by CD4+ Th1, CD8+ cytotoxic T cells and NK cells (Bach et al, 1997; Young, 
1996). However, there is evidence that prove that other cells including B cells, 
NKT cell and APC also produce IFNγ (Carnaud et al, 1999; Flaishon et al, 2000; 
Frucht et al, 2001; Gessani & Belardelli, 1998). IFNγ was at first described as an 
antiviral agent. However, IFNγ has since been shown to promote cellular immune 
responses including activation of macrophages, NK cells, enhancement of MHC 
expression and leukocyte migration. IFNγ is an effector cytokine of Th1-type 
immune responses (Billiau & Matthys, 2009). 
The mechanisms by which IFNγ enhances resistance to cryptococcal infection 
have not been completely described. During infection, inhaled C. neoformans 
basidiospores are taken up by the innate immune cells such as alveolar 
macrophages. Studies in an experimental pulmonary cryptococcosis suggest that 
IFNγ produced by the Th1-type CD4+ T cells directly activates effector cells such 
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as alveolar macrophages. This leads to phagocytosis of the cryptococci 
(Kawakami et al, 1995), intracellular killing and skewing to the Th1-type immune 
responses (Hardison et al, 2010). The effect of IFNγ in in vitro experiments have 
produced contrasting findings between human and mouse macrophages. The 
mouse bone marrow-derived macrophages treated with IFNγ display increased 
fungicidal activity and increased uptake of C. neoformans (Flesch et al, 1989; 
Ikeda-Dantsuji et al, 2015). On the other hand, the addition of IFNγ to the human 
alveolar macrophages or the human monocyte-derived macrophages results in 
either reduced (Levitz & Farrell, 1990; Reardon et al, 1996) or no change in 
fungistatic capacity (Voelz et al, 2009). Infection with IFNγ-producing 
C. neoformans strain, H99γ, results in increased leukocyte recruitment to the 
lungs (Wormley et al, 2007), increased classically activated macrophages 
(Hardison et al, 2010) and increased macrophage fungistatic activity when 
cultured in vitro (Hardison et al, 2012b). In contrast, IFNγ knockout mice display 
the alternatively activated macrophage phenotypes with increased levels of 
intracellular cryptococci (Arora et al, 2005). Similarly, administration of anti-IFNγ 
results in reduced accumulation of the inflammatory cells and iNOS expressing 
macrophages in the lungs (Aguirre et al., 1995, Hoag et al., 1997, Kawakami et 
al., 1996b).  
Despite these observations, little work has been done in vivo on the effects of 
IFNγ on the interactions between phagocytes and C. neoformans. This chapter 
reports a systemic investigation of the influence of IFNγ on cellular responses to 
cryptococcal infection. My findings will help to add knowledge to the mechanism 
of protection associated with IFNγ. 
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4.2 Results 
4.2.1 A single dose of interferon-γ markedly reduces fungal burden and 
improves fungal clearance in zebrafish challenged with C. neoformans 
I first measured the capacity IFNγ to protect zebrafish from cryptococcal infection. 
The objective was to describe the infection outcomes with a single dose of IFNγ. 
This was also done to mimic a short course of IFNγ that is as effective as a two-
week course in patients with cryptococcal meningitis (Jarvis 20102). In addition, 
a single dose was chosen because multiple doses would introduce multiple 
wounds that could interfere with immune responses to the cryptococcal infection.  
The concentration of IFNγ (5µg/ml) used has previously been demonstrated to 
reduce fungal burden in an experimental murine model of cryptococcosis (Lutz et 
al, 2000). Three dpf nacre zebrafish larvae were intramuscularly challenged with 
C. neoformans in phenol red (vehicle control) alone or supplemented with 5µg/mL 
IFNγ. I found that at 48hpi, IFNγ-treated larvae had significantly reduced fungal 
burden compared to those larvae treated with phenol red (Figure 10a, P < 
0.0001). Further analysis showed that the percentage of larvae that completely 
cleared the infection was significantly higher in IFNγ-treated larvae compared to 
larvae in control group (Figure 10b, P = 0.003). These results corroborate 
previous studies in mice and humans that demonstrated that administration of 
IFNγ in combination with anti-fungal chemotherapy can stimulate protective 
immunity against C. neoformans leading to a reduction in fungal load (Jarvis et 
al, 2012; Joly et al, 1994; Kawakami et al, 1996b). No significant difference in 
mortality was observed between the groups (Figure 10c, P = 0.65), and was 
extremely low in both groups (3 and 3.6 %, phenol red and IFNγ respectively). To 
detect any IFNγ-evoked toxic effects on C. neoformans, growth was monitored 
over 24 hours in vitro. C. neoformans exhibited no growth defects following 
treatment with IFNγ compared to controls (Figure 10d, P = 0.3168).  
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Figure 10: Interferon-γ markedly reduces fungal burden and improves fungal 
clearance in zebrafish challenged with C. neoformans.  
(a) Fungal burden at 48hpi of nacre larvae challenged with C. neoformans in phenol red alone or 
supplemented with 5ug/mL IFNγ: data are a combination of three independent experiments 
(n=140-156 per group) and expressed as a mean ±standard deviation analysed using Mann 
Whitney test; Phenol red vs IFNγ, ****P < 0.0001. (b) Percentage of larvae that cleared infection 
per group: data presented as %, however, statistical analysis was performed on raw data (total 
number of larvae that cleared infection vs total number of larvae that did not clear infection) using 
Fisher’s exact test; results are expressed as a percent mean ± standard deviation, Phenol red vs 
IFNγ, **P = 0.003. (c) Survival of 3dpf nacre larvae (n=64 per group) challenged with 
C. neoformans with Phenol red alone or supplemented with 5ug/mL IFNγ and analysed using 
Log-rank (Manted-Cox) test, hazard ratio = 2.5 (logrank; 95% confidence interval 0.4, 2.3; Phenol 
red or IFNγ, P = 0.25. (d) IFNγ treatment does not influence C. neoformans survival: data 
presented as a mean ± standard deviation representative of three independent experiments 
analysed using unpaired t-test, Phenol red or IFNγ, P = 0.31 
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4.2.2 Interferon-γ promotes phagocytes infiltration to infection site during 
C. neoformans infection in zebrafish 
I then investigated the possible mechanisms that initiated the improved fungal 
clearance in IFNγ-treated larvae. I first determined the effect of IFNγ to recruit 
phagocytes to the site of infection. The transgenic zebrafish, with marked 
macrophages, Tg(mpeg1:Gal4-VP16/UAS:Kaede), were used to determine influx 
of macrophages. Larvae that were challenged with IFNγ+C. neoformans induced 
an increase in the influx of macrophages at the site of infection at 2hrs (P < 
0.0001) and 24hrs (P = 0.002) post inoculation than phenol red+C. neoformans 
challenged larvae (Figure 11a). However, C. neoformans inhibited the 
recruitment of macrophages. The influx of macrophages at 24hpi was more 
pronounced in larvae treated with Phenol red or IFNγ alone compared with larvae 
co-injected with phenol red+C. neoformans (P < 0.0001) or IFNγ+C. neoformans 
(P < 0.0001) respectively. These differences were not observed early during 
infection at 2hpi (P > 0.999). The transgenic zebrafish with marked neutrophils 
Tg(mpx:GFP)i114 larvae were used to examine infiltration of neutrophils. I found 
that the larvae that were inoculated with IFNγ+C. neoformans had increased 
infiltration of neutrophils at 12 and 24hpi than the larvae treated with phenol 
red+C. neoformans (P = 0.038 and P=0.027 respectively). This difference was 
not observed at 2hpi (P=0.18). Infiltration of neutrophils was significantly 
increased in larvae treated with phenol red alone compared to phenol 
red+C. neoformans challenged larvae at 2 (P = 0.007), but not at 12 (P = 0.418) 
and 24 (P > 0.999) hpi (Figure 11b). However, C. neoformans inhibition of 
neutrophil infiltration was rescued by IFNγ treatment. The number of recruited 
neutrophils between larvae treated with IFNγ alone and larvae challenged with 
IFNγ+C. neoformans was not significantly different at 2hpi (P = 0.313), 12 (P = 
0.171) and 24 (P = 0.999) hpi (Figure 11b).  
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Figure 11: Administration of IFNγ increases influx of phagocytes at the site of 
infection.  
Kinetics of influx of phagocytes quantitated by manual counting at different time-points. 
Tg(mpeg1:Gal4-VP16);Tg(UAS:Kaede) for macrophages and Tg(mpx:GFP)i114 for neutrophils 
larvae were challenged with C. neoformans in phenol red alone or supplemented with 5ug/mL 
IFNγ. Mean number of (a) macrophages, Phenol red+C. neoformans vs IFNγ+C. neoformans, 
2hpi ****P < 0.0001 and 24hpi **P = 0.0022 (b) neutrophils, Phenol red+C. neoformans vs 
IFNγ+C. neoformans, 2hpi P=0.18; 12hpi, *P = 0.038 and 24hpi, *P=0.027. In both graphs (a&b), 
data were obtained from three independent experiments (n=22-24 per group) presented as a 
mean ±standard deviation and analysed using Ordinary one-way ANOVA with Dunnett’s multiple 
comparison test. Representative fluorescent images of (c) macrophages at 2hpi (d) neutrophils 
at 12hpi at infection site of larvae inoculated with phenol red+C. neoformans alone and larvae 
inoculated with IFNγ+C. neoformans, Scale bar is 20μm.  
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4.2.3 Interferon-γ is associated with increased fungal uptake by both 
macrophages and neutrophils during C. neoformans infection in zebrafish 
Second, to investigate whether IFNγ influences the rate of fungal uptake by 
phagocytes, phenol red alone or supplemented with IFNγ were co-injected with 
C. neoformans into 3dpf Tg(mpeg1:Gal4-VP16/UAS:Kaede) and 
Tg(mpx:GFP)i114 zebrafish larvae for macrophage and neutrophils respectively. 
I found that following two hours of infection in Tg(mpeg1:Gal4-VP16/UAS:Kaede) 
larvae, the proportion of internalised C. neoformans cells by macrophages was 
significantly higher in IFNγ-treated larvae compared to phenol red-treated larvae 
(P < 0.0001, Figure 12a). At 12hrs post infection, fungal uptake markedly 
increased in both groups with IFNγ-treated larvae still having significantly higher 
uptake than phenol red-treated larvae (P = 0.0004). On the other hand, fungal 
uptake in IFNγ-treated larvae by neutrophils showed a small but significant 
change compared to phenol red treated larvae at 12 hpi (P = 0.001). No 
significance difference was observed at 2 hpi (P = 0.505, Figure 12b). These 
findings show that by 12 hpi, almost all injected cryptococci are intracellular. To 
confirm this, Tg(mpeg1:Gal4-UNM)sh256 macrophages line were crossed with 
Tg(mpx:eGFP)i114 neutrophils line to obtain double positive Tg(mpeg1:Gal4-
UNM)sh256;Tg(mpx:eGFP)i114 larvae. Uptake rates of the cryptococci by 12 hpi 
in 3dpf Tg(mpeg1:Gal4-UNM);Tg(mpx:eGFP)i114 line were up to 100 % in 
IFNγ-treated larvae and up to 85 % in phenol red treated larvae (P < 0.0001, 
Figure 12e).  
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Figure 12: Administration of IFNγ increases phagocytosis of fungal cells by 
phagocytes.  
Phagocytosis of C. neoformans in 3dpf larvae following challenge with C. neoformans in phenol 
red alone or supplemented with 5ug/mL IFNγ. Percentage phagocytosis of fungal cells per larva 
at 2 hpi and 12 hpi by (a) macrophages, Phenol red vs IFNγ, 2hpi ****P < 0.0001 and 24hpi ***P 
= 0.0004; and (b) neutrophils, Phenol red vs IFNγ, 2hpi P = 0.505, and 12hpi, **P = 0.001. In both 
graphs (a & b), data representative from three independent experiments (n=13-17 per group) and 
presented as %, however, statistical analysis was performed on raw data (total number of 
intracellular cryptococci vs total number of extracellular cryptococci) using Fisher’s exact test 
comparing phenol red- to IFNγ- treated larvae. (c & d) Representative fluorescent images of 
phagocytosis by (c) macrophages (d) neutrophils at infection site, phenol red vs IFNγ at 2hpi, 
Scale bar is 20μm. (e) Percentage phagocytosis at 12 hpi in phagocytes 
(macrophages+neutrophils), Phenol red vs IFNγ, ****P = 0.0001 
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4.2.4 Relative phagocytic capacity is not significantly different between 
groups in both macrophages and neutrophils   
As shown in the previous section (4.2.3), IFNγ increases phagocytosis of fungal 
cells by both macrophages and neutrophils. I then investigated whether 
phagocytes that had taken up fungal cells were primed to take up more cells. 
Phenol red or IFNγ were co-injected with C. neoformans into 3dpf 
Tg(mpeg1:Gal4-VP16/UAS:Kaede) and (Tg(mpx:GFP)i114 zebrafish larvae as 
described above. Phagocytic index in both macrophages and neutrophils was 
determined. The number of fungal count per macrophage (Figure 13a) or 
neutrophil (Figure 13b) at 2hpi (phagocytic index) were not significantly different 
between IFNγ and phenol red treated larvae (Macrophages P = 0.112; 
Neutrophils P = 0.148). 
 
 
Figure 13: Relative phagocytic capacity is not significantly different between 
groups in both macrophages and neutrophils.  
Average fungal count (phagocytic index) per (a) macrophage, Phenol Red vs INFg, P = 0.112 (b) 
neutrophil, Phenol Red vs IFNγ, P = 0.148. Data obtained from two independent experiments 
(n=13-16 per group) and Phagocytic index was analysed using two-tailed, unpaired t-test. 
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4.2.5 Macrophages are essential for Interferon-γ mediated protection 
against C. neoformans  
Previous work in our laboratory demonstrated that deletion of macrophages in an 
experimental systemic infection with C. neoformans in zebrafish, results in 
increased fungal burden and mortality (Bojarczuk et al, 2016). These have also 
demonstrated in mammalian models (Monga, 1981; Osterholzer et al, 2009a). As 
shown above, upon intramuscular injection in zebrafish, C. neoformans are 
phagocytosed mainly by macrophages. To better appreciate the explicit role of 
macrophages in the presence of IFNγ during cryptococcal infection, 
Tg(mpeg1:Gal4-UNM)sh256 zebrafish were chemically ablated of macrophages. 
The larvae were then given an intramuscular inoculation with C. neoformans and 
IFNγ as described above. The fungal burden was quantified at 48 hours post 
inoculation. As expected, the fungal burden was significantly increased in larvae 
which had been ablated of macrophages (IFNγ Mφ¯) compared to control larvae 
(P < 0.0001, Figure 14a). Metronidazole did not inhibit C. neoformans growth in 
vivo as demonstrated by no change in fungal burden upon depletion of 
neutrophils compared to control (Figure 14b – data from Josie Gibson). Larvae 
depleted of macrophages looked healthy. No significant difference in mortality 
between groups was observed (P = 0.368, Figure 14c). To detect if metronidazole 
effectively ablated macrophages, a whole-body count of macrophages was 
performed in Tg(mpeg1:Gal4-UNM)sh256 zebrafish larvae at 5dpf. There was 
significantly reduced number of macrophages in metronidazole-treated larvae 
compared to control (P < 0.0001, Figure 14d&e).  
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Figure 14: Role of macrophages during C. neoformans infection in zebrafish  
(a) Fungal burden at 48hpi of Tg(mpeg1:Gal4-UNM)sh256 larvae either with or depleted of 
macrophages challenged with C. neoformans in phenol red alone or supplemented with 5µg/mL 
IFNγ: data presented as a mean ±standard deviation and analysed using one-way ANOVA with 
Dunn’s multiple comparison test. IFNγ vs Phenol red ****P < 0.0001; IFNγ vs IFNγ Mφ¯, ****P < 
0.0001). n=60-67 per group. (b) Fungal burden at 72hpi of larvae either with (DMSO) or depleted 
(Metronidazole) of neutrophils challenged with C. neoformans. Date was analysed with Mann-
Whitney test, DMSO vs Metronidazole, P = 0.13 (c) Survival of Tg(mpeg1:Gal4-UNM)sh256 
larvae with or depleted of macrophages infected with C. neoformans with Phenol red alone or 
supplemented 5ug/mL IFNγ. Data representative of two independent experiments (n=60-67 per 
group) and analysed using Log-rank (Mantel-Cox) test, Phenol red or IFNγ, P = 0.368. (d) 
Zebrafish 0dpf were immersed in metronidazole and the number of macrophages counted using 
Tg(mpeg1:Gal4-UNM)sh256, DMSO (control) vs Metronidazole at 5dpi, P < 0.0001. Data 
obtained from two independent experiments (n= 24 per group) presented as a mean ±standard 
deviation and analysed using Ordinary one-way ANOVA with Dunnett’s multiple comparison test 
(e) Representative fluorescent images z-stacks of the number of macrophages in DMSO vs 
metronidazole treated larvae at 5dpf, scale bar is 50µm.
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4.2.6 Interferon-γ promotes macrophage fungistatic activity in zebrafish 
Cryptococcus neoformans is known to survive and replicate within macrophages 
(Levitz et al, 1999). I developed an in vivo proliferation assay to determine 
whether IFNγ influences cryptococcal proliferation inside macrophages. Phenol 
red or IFNγ was co-inoculated with C. neoformans and the fungal proliferation 
was monitored within macrophages over 12 hours. Treatment with IFNγ 
significantly reduced fungal replication within macrophages than phenol red 
treatment alone (P = 0.001, Figure 15). 
 
 
 
Figure 15: Interferon-γ promotes macrophage fungistatic activity in zebrafish.  
The number of new fungal cells per hr within macrophages; 3dpf transgenic zebrafish, 
Tg(mpeg1:Gal4-VP16/UAS:Kaede) were challenged with C. neoformans in Phenol red alone or 
supplemented with 5µg/mL IFNγ fungal cells were monitored for proliferation within macrophages 
over 12 hours. Data obtained from three independent experiments (n=23-26 per group) presented 
as a mean ±standard deviation and analysed using unpaired t-test, Phenol red vs IFNγ, ***P = 
0.001  
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4.2.7 Pro-inflammatory cytokine involvement  
Inflammatory cytokines are a group of cytokines that enhance inflammation. 
Inflammatory cytokines including IL-1β, IL-6, IL-8 and TNFα have been shown to 
be secreted in response to C. neoformans (Retini et al, 1996).  
4.2.7.1 Interferon-γ does not alter expression of TNFα GFP in cryptococci 
infected macrophages  
Previous studies by Kawakami et al. (1999) showed that TNFα-producing 
macrophages induced by IFNγ display anti-cryptococcal activity in vitro 
(Kawakami et al, 1999b). In a murine model of cryptococcosis, resistant mice 
strains exhibit elevated levels of TNFα than susceptible mice strains (Guillot et 
al, 2008b). Levels of TNFα in the CSF of patients with HIV-associated 
cryptococcal meningoencephalitis are higher in survivors following anti-fungal 
therapy (Lortholary et al, 2001). In addition, Siddiqui et al. (2005) showed a 
correlation between TNFα levels and clearance of infection in HIV infected 
patients with cryptococcal meningitis (Siddiqui et al, 2005a). Patients with 
increased production of TNFα had no mortality reported following IFNγ treatment 
(Jarvis et al, 2013). Therefore, I examined whether IFNγ-induced fungistatic 
activity of macrophages involves the production of TNFα. To specifically track 
TNFα-expressing macrophages, the TNF promoter BAC driving GFP transgenic 
zebrafish line TgBAC(tnfa:GFP)pd1028 (Marjoram et al., 2015) was crossed to 
the macrophage reporter line Tg(mpeg1:mCherryCAAX)sh378 (Bojarczuk et al, 
2016) to produce a double transgenic line TgBAC(tnfa:GFP); 
Tg(mpeg1:mCherryCAAX). Three dpf TgBAC(tnfa:GFP); 
Tg(mpeg1:mCherryCAAX) were co-inoculated intramuscularly with 
C. neoformans in phenol red alone or supplemented with IFNγ. Expression of 
TNFα GFP in infected macrophages was measured at different time-points 
during infection. I found that C. neoformans induced the expression of TNFα but 
addition of IFNγ did not significantly alter the expression compared to phenol red 
at 12 (P = 0.422), 24 (P = 0.918) or 36 (P = 0.211) hpi as measured by relative 
fluorescent intensity (Figure 16).  
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Figure 16: Expression of TNFα GFP in macrophages infected with cryptococci in 
zebrafish treated with IFNγ 
(a) Cumulative relative fluorescent intensity of macrophages per fish. 3dpf double transgenic 
zebrafish larvae Tg(tnfa:GFP/mpeg1:mCherryCAAX) were challenged with C. neoformans in 
Phenol red alone or supplemented with 5µg/mL IFNγ and imaged macrophages for TNFα 
expression. The relative fluorescent intensity of TNFα GFP; data is representative of three 
independent experiments (n=10-11 fish per group) and expressed as a mean ± standard deviation 
and analysed by unpaired t-test. Phenol red vs IFNγ at 12hpi, P = 0.422; 24hpi, P = 0.918 and 
36hpi P = 0.211. (b) Representative fluorescent images z-stacks of the TNFα GFP expression in 
Phenol red vs IFNγ at 12hpi treated larvae, scale bar is 2µm. 
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4.2.7.2 Interferon-γ treated larvae have higher expression of 
pro-inflammatory cytokine IL-1 GFP at the site of infection 
The Cryptococcus cells and purified capsular polysaccharide has been shown to 
induce the production of pro-inflammatory cytokines such as IL-1β by human 
neutrophils although the levels are significantly lower than LPS stimulation (Retini 
et al, 1996). In vivo, brains of mice with meningeal cryptococcosis have increased 
expression of IL-1β (Uicker et al, 2005). Marroni et al. (2007) report described an 
apparently immunocompetent patient with pulmonary cryptococcosis. This 
patient had functional defects of IL-1β, TNFα and nitric acid production by 
phagocytes (Marroni et al, 2007) suggesting that IL-1β may be potentially 
important in host immune response against C. neoformans. Therefore, I 
investigated whether IL-1β played a role in IFNγ-mediated fungistatic activity. 
Three dpf Tg(il1:GFP)sh445 zebrafish larvae were inoculated intramuscularly 
with C. neoformans in phenol red alone or with IFNγ and imaged at different 
time-points for expression of IL-1β GFP. I found that there was significantly higher 
expression of IL-1β GFP in IFNγ-treated larvae at 12hpi (P = 0.02) but not at 2 (P 
= 0.91) and 6 (P = 0.995) hpi (Figure 17).  
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Figure 17: Interferon-γ treated larvae have higher expression of pro-inflammatory 
cytokine IL-1 GFP at the site of infection 
(a) Relative fluorescent of IL-1 GFP at the site of infection. 3dpf transgenic zebrafish line 
Tg(il1:GFP)sh445 were challenged with C. neoformans in Phenol red alone or supplemented with 
5ug/mL IFNγ and imaged to determine IL-1 GFP expression. Data is representative of three 
independent experiments (8-10 fish per group.) presented as a mean ± standard deviation and 
analysed by Two-way ANOVA with Bonferroni’s multiple comparison test. Phenol red vs IFNγ at 
2hpi, P = 0.91; 6hpi, P = 0.995 and 12hpi, *P = 0.02. (b) Example of fluorescence z-stacks of the 
infection site of 12hpi in the presence or absence of IFNγ, Scale bar is 20µM 
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4.2.8 Nitrosylation is not detectable in zebrafish macrophages but in 
neutrophils following C. neoformans challenge 
Once taken up by phagocytes, intracellular pathogens such as C. neoformans 
are exposed to several antimicrobial mediators, including reactive nitrogen 
species (Shoham & Levitz, 2005). C. neoformans is susceptible to nitric oxide 
produced by M1 macrophages (Aguirre & Gibson, 2000; Alspaugh & Granger, 
1991; Hardison & Brown, 2012a; Müller et al, 2007; Osterholzer et al, 2009b). 
iNOS knockout mice have a high fungal burden in the brain and fail to clear the 
infection from the lungs than wild-type mice (Aguirre & Gibson, 2000). 
Macrophages isolated from iNOS deficient mice fail to control intracellular 
proliferation of C. neoformans (Leopold Wager et al, 2015) suggesting that iNOS 
is essential for immune resistance to cryptococcal infection. Thus, I hypothesised 
that IFNγ induces fungistatic activity of macrophages via nitric oxide production. 
However, the direct measurement of the reactive nitrogen species production has 
proven difficult due to their high reactivity nature (Elks et al, 2013). To get around 
this, an anti-nitrotyrosine antibody test has been previously employed in zebrafish 
and in other fish models of infection (Elks et al, 2013; Forlenza et al, 2008; van 
der Vaart et al, 2012). Nitrotyrosine is a downstream product of nitric oxide and 
is formed when nitric oxide reacts with superoxide to produce peroxynitrite 
(Ischiropoulos et al, 1992). Peroxynitrite reacts with tyrosine residues of proteins 
in an irreversible process to form nitrotyrosine (Beckman et al, 1990). The major 
advantage of tyrosine nitrosylation is that it forms a stable protein, which enables 
the detection of the historical nitric oxide production (Elks et al, 2013). To 
accurately locate anti-nitrotyrosine staining in macrophages, three dpf 
macrophage reporter line Tg(cfms:GFP)sh377 were infected with C. neoformans 
in phenol red alone or supplemented with IFNγ and imaged at different 
time-points. Surprisingly, anti-nitrotyrosine staining was not detected in 
macrophages in either group at 2, 6, 12 and 24 hpi (Figure 18a). However, 
staining was found in other cells, likely neutrophils in both groups (Figure 18a). 
The nitrosylation levels in neutrophils were not significantly different in the larvae 
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treated with IFNγ compared to the phenol red treated larvae (P = 0.128, Figure 
18b).  
 
Figure 18: Nitrosylation is not detectable in zebrafish macrophages following C. 
neoformans challenge 
Three-dpf transgenic zebrafish line Tg(cfms:GFP)sh377 were challenged with C. neoformans in 
Phenol red alone or supplemented with 5ug/mL IFNγ and imaged to determine anti-nitrotyrosine 
staining. (a). Example of fluorescence z-stacks of the infection site of larvae stained with Alexa-
657 labelled anti-nitrotyrosine antibody (red), imaged at 6hpi in presence and absence of IFNγ. 
Anti-nitrotyrosine is not co-localised with macrophages (labelled with Tg(cfms:GFP)sh377 - 
green), however, some cells non-green labelled cells, possibly neutrophils, had anti-
nitrotyrosine staining (white arrowhead). (b) Relative fluorescence intensity levels of anti-
nitrotyrosine antibody z-stacks in Phenol red vs IFNγ (P = 0.128) treated larvae. Data is a 
representative of three independent experiments (n=25-30 fish per group) presented as mean ± 
standard deviation and analysed by unpaired t-test.  
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4.2.9 Low lysosomal pH in macrophages of larvae treated with IFNγ during 
C. neoformans infection  
The uptake of pathogenic organisms begins with the attachment of the pathogen 
to the cell followed by formation of an endocytic vesicle known as phagosome. 
The phagosome then matures into the phagolysosome which eventually digests 
the pathogen (reviewed in Tjelle et al., 2000). The maturation of the phagosome 
results from the fusion of the phagosome to the lysosome to form 
phagolysosome. Once the internalised material reaches the lysosome, it is 
bombarded with microbicides including reactive oxygen and nitrogen species, 
acidic pH and cathepsin hydrolases (Bogdan, 2015; Cross & Segal, 2004; 
Delamarre et al, 2003; Torres et al, 2006; Trombetta et al, 2003). Similarly, 
following uptake by macrophage and other phagocytes, C. neoformans enters 
the lysosomes (Artavanis-Tsakonas et al., 2011, Artavanis-Tsakonas et al., 2006, 
Levitz et al., 1999, Weber and Levitz, 2001, Wozniak and Levitz, 2008). 
Lysosomes are membrane-bound organelles with a low pH of 4.75 compared to 
neutral pH of the surrounding cytosol. Lysosomal pH is maintained by alveolar 
ATPase (Christensen et al, 2002; Kinchen & Ravichandran, 2008). Despite the 
low lysosomal pH, macrophages fail to control the intracellular growth of 
C. neoformans (Levitz et al., 1999). Therefore, I examined whether administration 
of IFNγ altered pH levels in infected macrophages. To specifically locate 
lysosomal pH in macrophages, three dpf macrophage reporter line 
Tg(cfms:GFP)sh377 were infected with C. neoformans in phenol red alone or 
supplemented with IFNγ and imaged at different time-points. Low lysosomal pH 
was observed in infected macrophages of larvae treated with IFNγ compared to 
controls (P = 0.0036, Figure 19).  
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Figure 19: Low lysosomal pH in macrophages of larvae treated with IFNγ during 
C. neoformans infection 
(a) Relative fluorescence intensity levels of lysosomal acidity z-stacks in Phenol red vs IFNγ, **P 
= 0.0036 treated larvae. Data shown is a representative of three independent experiments and 
presented as mean ± standard deviation from and analysed by unpaired t-test. n=9-10 larvae per 
group (b) example of fluorescence z-stacks of macrophages at infection site of larvae injected 
with cresyl violet (red), imaged at 24hpi in presence and absence of IFNγ. pH co-localised with 
C. neoformans (wild-type) in macrophages (labelled with Tg(cfms:GFP)sh377 - green), Phenol 
red vs IFNγ treatment. Scale bar is 2µm.  
 CHAPTER 4| SINGLE DOSE INTERFERON-GAMMA IS SUFFICIENT TO INCREASES 
MACROPHAGE RECRUITMENT, PHAGOCYTOSIS AND KILLING FOR THE CLEARANCE OF 
C. NEOFORMANS INFECTION 
121 
 
4.3 Discussion 
Evidence from clinical and experimental studies consistently suggest that a 
Th1-type immune response is predominantly required for protection against 
cryptococcosis (Blasi et al, 1994; Buchanan & Doyle, 2000; Hill & Harmsen, 1991; 
Huffnagle et al, 1991; Shoham & Levitz, 2005) and is mediated by Th1-type 
cytokines such as IFNγ and IL-12 (Bauman et al, 2003; Herring et al, 2002; 
Kawakami et al, 1996a). IFNγ is specifically essential for anti-cryptococcal host 
defences induced by most pro-inflammatory cytokines (Zhou et al, 2006; 
Kawakami et al, 1996c). IFNγ is a prototype Th1-type cytokine that induces Th1 
differentiation and directs the host immune response towards a protective Th1 
phenotype (Schroder et al, 2004).  
Using the zebrafish Cryptococcus infection model, I have shown that 
administration of a single dose of IFNγ alone augments host immunity against 
C. neoformans, resulting in reduced fungal burden and increased fungal 
clearance. These findings corroborate and extend previous observations in 
experimental murine models and clinical cryptococcosis (Jarvis et al, 2012; Lutz 
et al, 2000; Pappas et al, 2004). Although in my study IFNγ was given 
concurrently with C. neoformans, only a single dose was enough to yield lower 
fungal counts. Similarly, in a phase-2 clinical trial by Jarvis et al. (2012), a short 
course of adjunctive IFNγ with anti-fungals were as effective as a full two-week 
course of IFNγ (Jarvis et al, 2012) suggesting that IFNγ treatment can have 
long-lasting effects.  
There are several possible mechanisms accounting for enhanced C. neoformans 
clearance. I found that IFNγ induces an influx of macrophages and neutrophils to 
the infected site early (2hpi) and later (12hpi) during infection respectively. 
Previous murine data evaluating local cell-mediated immunity at day 3, 7 and 14 
days post inoculation showed increased leukocyte recruitment to the lungs in 
response to IFNγ-producing C. neoformans H99γ strain at day 7. However, no 
significant increase in macrophage influx was observed (Wormley et al, 2007). 
These discrepancies may result from differences in time-points in which 
 CHAPTER 4| SINGLE DOSE INTERFERON-GAMMA IS SUFFICIENT TO INCREASES 
MACROPHAGE RECRUITMENT, PHAGOCYTOSIS AND KILLING FOR THE CLEARANCE OF 
C. NEOFORMANS INFECTION 
122 
 
recruitment was investigated. This is more likely because macrophage numbers 
at the site of infection were diminished by 24hpi in my experiments. Another 
possible explanation for this inconsistency may be related to zebrafish larvae 
immune defences that rely entirely on innate immunity. Thus, it is possible that 
innate immune cells such as macrophages will respond more readily to the 
exogenous IFNγ than cells in adult immunocompetent mice would. Interestingly, 
significantly increased infiltration of leukocytes, including macrophages but not 
neutrophils, has also been observed at week 3 post inoculation in IFNγ knockout 
(KO) mice with experimental pulmonary C. neoformans infection (Arora et al, 
2005). The IFNγ knockout mice display Th2-type responses, alternatively 
activated macrophages and loss of fungistatic effect resulting in high fungal 
burden (Arora et al, 2005). In addition, IFNγ-R KO mice display elevated 
neutrophil infiltration at week 5 post inoculation and a higher fungal burden than 
wild-type mice (Chen et al, 2005). These findings suggest that early recruitment 
of immune cells is required for protection against cryptococcal infection. Another 
intriguing observation arising from phagocyte recruitment assays was that 
administration of IFNγ alone showed a markedly increased recruitment of both 
neutrophils and macrophages than when administered with C. neoformans. 
Monari et al. (2002) showed that the encapsulated C. neoformans or the addition 
of GXM suppresses the expression of C5aR (Monari et al, 2002) which is required 
for migration of neutrophils towards C. neoformans (Sun et al, 2015). The 
possibility that C. neoformans may be inhibiting recruitment of macrophages also 
requires further exploration in the future.  
An induction of phagocytosis accompanied the influx of both neutrophils and 
macrophages. Almost all fungal cells were intracellular by 12 hpi in IFNγ-treated 
larvae. IFNγ has recently been shown to promote phagocytosis of C. neoformans 
by macrophages in vitro (Ikeda-Dantsuji et al, 2015). Phagocytosis plays a vital 
role in the outcomes of infection by C. neoformans. Histopathological 
examinations of the lungs of mice infected with low-mortality C. neoformans strain 
showed significantly higher numbers of internalised yeasts than high-mortality 
strains (Okubo et al, 2013). It is interesting to note that C. neoformans is more 
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readily phagocytosed by leukocytes in vivo compared to in vitro assays which 
require opsonisation. It has been suggested that since humans begin to develop 
antibodies to C. neoformans as early as 2 years of age (Goldman et al, 2001); 
perhaps these antibodies may act as opsonins for phagocytosis of C. neoformans 
in the human lung. However, the mechanism of phagocytosis or how IFNγ 
enhances uptake of the cryptococci by phagocytic effector cells in the zebrafish 
model remains to be elucidated. I also observed that the numbers of intracellular 
cryptococci per neutrophil or macrophage were not different between groups. 
This suggests that phagocytes that had already taken up fungal cells were not 
primed to take up more fungal cells.  
Macrophages have been shown to play a significant role in C. neoformans 
infection. Indeed, I found that more macrophages are recruited and take up more 
cryptococci than neutrophils following infection, which is consistent with recent 
findings (Davis et al., 2016, Tenor et al., 2015). The administration of IFNγ in 
larvae that were depleted of macrophages prior to intramuscular injection of 
C. neoformans could not arrest fungal proliferation suggesting that IFNγ mediates 
protection predominantly through macrophages. Similar findings have been 
demonstrated in murine and zebrafish models of cryptococcosis (Bojarczuk et al, 
2016; Osterholzer et al, 2009a) highlighting the critical role of macrophages 
across vertebrates. Besides, for the first time, I have shown that the proliferation 
of intracellular cryptococci is markedly lower in macrophages of IFNγ-treated 
larvae (in vivo). It has been observed that mice immunised with IFNγ-producing 
cryptococci display classically activated macrophages (Hardison et al, 2010), and 
macrophages isolated during secondary infection suppress cryptococcal growth 
in vitro (Hardison et al, 2012b). However, in vitro experiments with J774 mouse 
cell lines or human macrophages treated with IFNγ demonstrate either no or 
lower fungistatic activity compared to untreated controls (Levitz & Farrell, 1990; 
Reardon et al, 1996; Voelz et al, 2009). It has been hypothesised that 
macrophages in vitro may already be activated by the addition of cryptococci 
and/or experimental conditions such as tissue culture environments (Voelz et al, 
2009), hence the lower fingistatic activity.  
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Data from Josie Gibson confirms previous findings that neutrophils are not 
essential in host immunity against C. neoformans infection. Cryptococcosis is 
found primarily in patients with impaired adaptive immunity and not in neutropenic 
patients. Murine studies have shown improved survival following concurrent 
transient depletion of neutrophils and pulmonary infection with Cryptococcus 
(Mednick et al, 2003). This finding appears to be attributable to the absence of 
neutrophil-mediated inflammation (Wozniak et al, 2012). Interestingly, neutrophils 
have been shown to kill Cryptococcus in vitro (Chaturvedi et al, 1996; Mambula 
et al, 2000; Qu & Wang, 1991). Neutrophils can eliminate Cryptococcus directly 
from the brain vasculature in mice, an activity that is associated with efficient 
recruitment of neutrophils (Sun et al, 2016; Sun et al, 2015; Zhang et al, 2016). 
Thus, further investigation of the role of neutrophils and how they can be exploited 
for developing new therapies for cryptococcal infections would be valuable.  
Interestingly, I did not observe a significant increase in the expression of the 
pro-inflammatory cytokine TNFα in macrophages of IFNγ-treated larvae at any 
time-point examined. TNFα has previously been shown to be associated with 
protective immune responses against C. neoformans in experimental murine 
models (Uicker et al., 2005, Kawakami et al., 1996a, Herring et al., 2002) and 
human disease. TNFα levels in the CSF of patients with cryptococcal meningitis 
are significantly higher in survivors compared with non-survivors (Siddiqui et al, 
2005a). Transient TNFα depletion in mice results in high fungal burden and 
inhibition of fungal clearance (Herring et al, 2005; Huffnagle et al, 1996; Xu et al, 
2016). In fact, anti-TNFα therapies are associated with an increased 
predisposition to invasive fungal infections, including cryptococcosis (Ellerin et al, 
2003; Tsiodras et al, 2008). Mice infected with IFNγ-producing C. neoformans 
H99γ strain had significantly higher levels of pro-inflammatory cytokines, 
including TNFα, than wild-type strain-infected mice (Wormley et al, 2007). 
Similarly, survivors of cryptococcal meningitis at two weeks following IFNγ 
therapy had higher proportions of IFNγ– and TNFα-producing CD4+ T cells and 
a trend towards more rapid clearance of infection from the CSF (Jarvis et al, 
2013). However, it should be noted that in the previous studies in mice by Wormly 
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et al, (2007), TNFα production was increased at day 7 post inoculation (Wormley 
et al, 2007). Thus, while my results may not completely correlate with those 
observed in mice and humans, they suggest a more significant role of other 
cytokines such as IL-1β (see below), in the elicitation of protective responses 
against C. neoformans infections.  
Testing of another pro-inflammatory cytokine, IL-1β showed that its expression is 
increased in IFNγ-treated zebrafish larvae at 12 hpi. The Tg(il1:GFP)sh445 
expression in this line is not cell lineage specific. IL-1β has been demonstrated 
to be expressed in many cells (reviewed Sims & Smith, 2010). As with TNFα, 
IL-1β elevation has been shown to be increased in C. neoformans H99γ strain 
infection in mice (Wormley et al, 2007). The role of IL-1β in C. neoformans 
infection has been highlighted in a clinical case report of a 21-year-old Italian 
female smoker with impaired IL-1β, TNFα and nitric oxide production who 
developed pulmonary cryptococcal disease (Marroni et al, 2007). No further 
studies have been reported regarding IL-1β in human cryptococcal disease, thus 
more studies would be needed to determine whether IL-1β is involved in host 
defence against C. neoformans infection. 
Macrophages can be induced towards phenotypically and functionally distinct 
effector cells, mostly influenced by the cytokine environment (reviewed in 
Martinez et al, 2009; Mosser & Edwards, 2008). The macrophage polarisation 
status is a well characterised phenomenon in mouse and human macrophages. 
The most used markers of M1 macrophages are inducible nitric oxide synthase 
(iNOS) or iNOS generated nitric oxide (NO). NO production by M1 macrophages 
in mice is required for control of the intracellular replication of C. neoformans 
(Leopold Wager et al, 2015). IFNγ cytokine environments induce M1 
macrophages. Although M1 subsets have been identified in zebrafish with TNFα 
as a marker (Nguyen-Chi et al, 2015), I could not find the nitric oxide-derived 
inflammatory oxidant, nitrotyrosine, in macrophages of infected zebrafish treated 
with IFNγ at any of the time-points examined. However, I detected nitrotyrosine 
staining exclusively in the neutrophils, both infected and uninfected. Elks et al. 
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(2013) showed that nitrosylation in zebrafish was predominantly observed in 
neutrophils of larvae injected with Mycobacterium marinum or vehicle control 
(phenol red) (Elks et al, 2013). The nitrosylation observed in zebrafish neutrophils 
in the absence of infection is thought to be due to myeloperoxidase activity, a 
zebrafish-specific neutrophil enzyme (Eiserich et al, 1998; Forlenza et al, 2008; 
Lieschke et al, 2001). Recently, anti-nitrotyrosine staining was detected in 
macrophages of larvae infected with Mycobacterium laprae (Madigan et al, 
2017). Elks et al. (2013) have also reported staining of other cells thought to be 
macrophages in uninfected larvae. However, these findings could not be 
replicated in my hands using the same method. Further experimentation of the 
role of iNOS/NO in cryptococcal immunity is required.  
Finally, I report that phagolysosomal acidification is enhanced in the presence of 
IFNγ. The effect of pH, independent of host, on the C. neoformans growth has 
been studied since the 1950s. An acidic environment enhances C. neoformans 
growth whereas an alkaline milieu inhibits growth of the fungus (Howard, 1961; 
Mosberg & McAlpine, 1951). More recent studies support those findings. Levitz 
et al, (1997) demonstrated that pH5 is optimal for C. neoformans growth, but the 
fungus is significantly inhibited at pH values that are slightly above neutrality 
(Levitz et al, 1997). Since during the pathogenesis process of C. neoformans, the 
fungus goes through different pH phases from neutral to acidic conditions in the 
mature phagolysosome. It is not known whether lower pH (i.e. < 5) inhibits 
C. neoformans growth. In contrast to previous findings (Levitz et al., 1999), recent 
results by Smith et al. (2015) showed that live but not heat or UV killed cryptococci 
are capable of manipulating host pH in macrophage phagolysosome (Smith et al, 
2015). However, how C. neoformans can alter phagosome maturation is currently 
unclear. The phagolysosome containing cryptococci has been demonstrated to 
permeabilise immediately following phagocytosis (Chayakulkeeree et al., 2011, 
Tucker and Casadevall, 2002, Johnston and May, 2010) allowing dilution of 
phagosomal content and increase in the luminal pH from the phagolysosome. 
Interestingly, failure of acidification of the phagosome has been observed in 
microglia cells, in which only one-third of phagolysosomes reached full 
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acidification (Orsi et al, 2009). Recently it has been shown that treatment of 
macrophages with IFNγ protects the phagolysosomal membrane from damage 
and enhances the fungicidal activity of macrophages (Davis et al, 2015). Taken 
together, low pH of the phagolysosome compartments may not be the only 
important anti-cryptococcal mechanism by macrophages. However, maintenance 
of the phagolysosome membrane integrity may prevent dilution of the lysosomal 
content, thus, enabling other antimicrobial effects, including reactive nitrogen 
species, to kill intracellular fungi. In addition, these observations suggest that 
mediations that protect the integrity of the phagosome membrane to maintain low 
pH, could have potential treatment applications.  
Collectively, my data show that intramuscular infection with C. neoformans and a 
single dose of IFNγ activated rapid influx of macrophages, increased uptake of 
the cryptococci and caused highly acidic phagolysosomes. This resulted in 
reduced replication of yeast within macrophages, low fungal burden and 
increased fungal clearance. These findings provide a critical framework from 
which to develop our understanding in formulating strategies for inducing local 
protective immune responses against invasive fungal infections. The 
administration of a host cytokine to a local infection site in a ‘see-through’ animal 
model is a novel way to investigate immune responses to C. neoformans infection 
in vivo. Using this approach, we can examine the pathogen-phagocyte 
interactions directly during infection. Although larger clinical studies are needed 
to explore the benefits of IFNγ treatment in cryptcoccosis, its underlying 
mechanism needs to be understood. My study and other studies committed to 
unravelling the mechanism of IFNγ will be helpful in developing potential 
immune-based treatments for human mycoses. In addition, although caution 
should be taken in deducing the results of animal studies as translatable to 
humans; my findings are consistent with clinical outcomes. My findings 
collaborate with previous findings that administration of IFNγ in patients with 
cryptococcal meningitis augments anti-cryptococcal chemotherapy resulting in 
increased rates of cryptococcal clearance from the CSF (Jarvis et al, 2012). In 
contrast, treatment of human macrophages in vitro fail to show increased 
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fungistatic activity (Levitz & Farrell, 1990; Reardon et al, 1996; Voelz et al, 2009) 
highlighting the usefulness of using a range of models to study human disease.  
The necessity for new treatments remains a prominent matter considering an 
increasing patient population with impaired immunity. These include individuals 
with HIV/AIDS, those receiving immunosuppressant therapy and organ transplant 
recipients. Thus, the viability of immunotherapy in immunocompromised 
individuals may not be a cause of concern. However, considering the diversity of 
the patient population at risk of cryptococcosis, identifying individuals who can 
benefit from immunotherapy cannot be overemphasized. In addition, reflecting on 
an ongoing outbreak of C. gattii in the immunocompetent hosts (Byrnes and 
Heitman, 2009b), indicates that there is a need to develop therapeutic strategies 
to protect both healthy and immunocompromised individuals from fungal 
infections. Since cryptococcal infection in immunocompetent persons is more 
often confined to the lungs, any strategies like those presented here, in which 
therapies are administered in such a way as to enhance local anti-cryptococcal 
host immune responses, can provide protection against future infections or 
existing latent infections. Added together, the findings presented here, promote 
the concept that strategies that exploit Th1-type cytokines against life-threatening 
fungal infections including cryptococcosis can result in the clearance of 
infections.  
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5.1 Introduction to immunomodulation 
Immunomodulation involves exploitation by either suppression or enhancement 
of the natural immune defences depending upon the circumstances required to 
treat specific disease. The ability to modulate the immune response has proved 
to be a valuable therapeutic strategy in a wide range of ailments including 
prevention and treatment of infections, dampening of autoimmune and 
inflammatory responses, and induction of antitumor immune responses in 
patients with cancer (Ulevitch, 2004, Hamill et al., 2008). The objective of 
immunomodulation for the treatment of infections is to initiate or potentiate 
protective antimicrobial immunity without causing detrimental effects such as 
inflammatory tissue damage. One advantage of immunomodulation is the 
targeting of the host rather than the pathogen thereby avoiding selective pressure 
that may lead to the development of microbial resistance. Immunomodulatory 
molecules for the stimulation of protective antimicrobial immunity include agonists 
of pattern recognition receptors (PRRs), immunomodulatory host defence 
peptides (also referred to as antimicrobial peptides), and natural bacterial 
signalling molecules.  
The toll-like receptor (TLR) family is one of the major classes of PRRs. The TLR 
family in humans includes ten transmembrane proteins. Each member is 
specialised for the recognition of specific classes of ligands (agonists) which are 
typically signature components of microbes. Such microbial components include 
lipopolysaccharides (LPS), flagellin, DNA, lipoteichoic acid, lipoproteins, dsRNA, 
SS-RNA etc. (for further details see Chapter 1). The interaction of microbial 
signature components with TLRs results in the induction of signal transductions 
pathways, such as MAPK and NF-κB through TIR domain-containing adaptor 
proteins (including MYD88, TIRAP, TRIF) leading to activation of innate immunity. 
This in turn, activates the production of, for example, pro-inflammatory cytokines 
and induces antimicrobial effector functions such as phagocytosis, oxidative burst 
and production of antimicrobial peptides (Reviewed in Hancock et al., 2012). This 
stimulation of innate immunity that is referred to as stimulated innate resistance 
appears to provide a broad-spectrum protection. The stimulation of innate 
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immune resistance by TLR agonists has been demonstrated in mice models of 
infection. For example, LPS (a TLR4 agonist) protects mice from Bordetella 
pertussis infection when administered concurrently (Evans et al., 2010). The 
administration of flagellin (a TLR5 agonist) gives protection against 
Streptococcus pneumonia and Pseudomonas aeruginosa infections in mice 
when given concurrently (Munoz et al., 2010, Yu et al., 2010). Besides, flagellin 
also reduces colonisation of vancomycin resistant Pseudomonas aeruginosa in 
the guts of mice undergoing a broad-spectrum antibiotic therapy (Kinnebrew et 
al., 2010). The TLR agonists have also been shown to treat fungal infection in a 
mouse model. The exogenous administration of LPS or imiquimod (a TLR7 
agonist) helped to clear Fonsecaea pedrosoi infection in mice. F. pedrosoi is a 
fungus that causes a chronic skin infection known as chromoblastomycosis 
(Sousa et al., 2011). 
5.2 Rationale of immune modulation 
The innate receptors’ agonists for inducing resistance to infection have been used 
in research for some time now (Hancock et al., 2012). The rationale is to initiate 
or enhance an innate response that significantly exceeds in quantity and quality 
the innate response induced by the pathogen itself while minimising 
inflammation-associated tissue damage. The rationale to explore 
immunomodulation of innate immunity as a strategy to infer protection against 
C. neoformans are two-fold:  
Firstly, C. neoformans do not appear to induce a robust pro-inflammatory 
response both in vitro and in vivo. Without the use of opsonins in in vitro assays, 
phagocytosis of C. neoformans by macrophages is minimal (Levitz, 2002). In in 
vitro assays, C. neoformans fails to stimulate monocytes and macrophages to 
produce pro-inflammatory cytokines such as TNFα (Levitz et al., 1994; Naslund 
et al., 1995, Vecchiarelli et al., 1995), IL-1β (Vecchiarelli et al., 1995), IL-6 (Delfino 
et al., 1997) or IL-12 (Retini et al., 1999) and induces low levels of IFNγ in T cells 
(Vecchiarelli et al., 1994). Instead, as shown in experimental mouse models, 
C. neoformans activates the Th2-type immune responses resulting in the 
generation of M2 macrophages (Osterholzer et al., 2009, Arora et al., 2005). 
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Recently Davis et al. (2013) showed that following intratracheal infection, 
C. neoformans proliferates rapidly to high titre in the first week and mice display 
Th2-type response characterised by M2 macrophages (Davis et al., 2013). 
C. neoformans laccase, urease and the polysaccharide capsule have been 
implicated in cryptococcal-mediated immune modulation of macrophages 
towards M2 (Osterholzer et al., 2009, Qiu et al., 2012, Almeida et al., 2001).  
Secondly, TLR signalling is critically required for the generation of protective 
innate immune defences against C. neoformans infection. Toll-like receptor 
(TLR)9-/- mice have impaired pulmonary clearance of C. neoformans and are 
associated with diminished CD4+, CD8+ T cell, CD19+ B cells, macrophage 
recruitment, increased induction of arg1 and FIZZI (found in an inflammatory 
zone) but reduced nitric oxide synthase (Nakamura et al., 2008, Zhang et al., 
2010). TLR2 and TLR4 recognise C. neoformans GXM (Shoham et al., 2001, 
Yauch et al., 2004, Yauch et al., 2005) but GXM fail to induce MAPK pathways 
and TNFα secretion (Shoham et al., 2001). TLR2-/- mice are more susceptible to 
cryptococcal infection than wild-type (Yauch et al., 2004, Biondo et al., 2005, 
Nakamura et al., 2008). TLR4 and C-type lectin receptors including mannose 
receptor and DC-SIGN recognise C. neoformans but play a minor role, if any, in 
resistance to cryptococcosis (Yauch et al., 2004, Nakamura et al., 2006, Mansour 
et al., 2006, Dan et al., 2008b). Dectin-1, Dectin-2, Dectin-3 or Mincle do not 
appear to have any role in anti-cryptococcal immunity (Campuzano et al., 2017, 
Nakamura et al., 2007, Walsh et al., 2017, Nakamura et al., 2015, Heung, 2017). 
The contribution of TLR or IL-1R signalling in host defence against cryptococcal 
disease is highlighted in MyD88 deficient mice model. Mice deficient in MyD88, 
an adaptor molecule required for signalling by all TLR except TLR3 and IL-1R 
(reviewed in Warner and Nunez, 2013), succumb to C. neoformans early during 
infection. TLR2 and myD88 deficient mice display decreased expression of 
pro-inflammatory cytokines, IL-12p40, TNFα, IFNγ in various organs  and 
reduced production of IFNγ in peritoneal macrophages (Biondo et al., 2005, 
Yauch et al., 2004). 
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Despite these observations, little work has been done on the exploitation of 
TLR-driven responses as potential therapy for cryptococcal infections. TLRs are 
already being investigated as drug targets for many infectious diseases in 
ongoing experimental studies and clinical trials. Considering the weak 
immunogenic nature of C. neoformans and the vital role of TLRs in cryptococcal 
disease, I hypothesised that; activation of TLR signalling may enhance 
appropriate protective immune responses and suppression of cryptococcal 
infections (Figure 20).  
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Figure 20: Hypothesis 
Activation of TLR signalling activates new and appropriate protective innate defences against 
C. neoformans infection. 
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5.3 TLR agonists tested 
5.3.1 Lipopolysaccharides (LPS) 
Lipopolysaccharide is a bacterial endotoxin and a major structural component of 
the outer membrane of Gram-negative bacteria. LPS is a large molecule 
comprised of three units, a lipid A, an inner and outer core oligosaccharide and a 
highly variable O-antigen consisting of repeating oligosaccharide units (Reviewed 
in Erridge et al., 2002). LPS has been shown to be recognised by both human 
and murine TLR4 (Hoshino et al., 1999, Schwartz, 2001) leading to induction of 
overwhelming immune response that can cause life-threatening septic shock in 
humans.   
5.3.2 Imiquimod 
Imiquimod, which is also known as R837, is a small molecule imidazoquinoline 
amine compound belonging to a group of immune response modifiers that 
possess antitumor and antiviral effects (Beutner et al., 1998, Craft et al., 2005). 
Imiquimod is used for the treatment of genital warts, caused by human 
papillomavirus infection, and malignant tumours of the skin (Smits et al., 2008). 
Imiquimod is an agonist that preferentially binds to TLR7 (Lee et al., 2003) leading 
to activation of MyD88 and induction of NF-κB (Hemmi et al., 2002). Recently 
imiquimod has been shown to have beneficial effects in the treatment of a chronic 
subcutaneous mycosis, chromoblastomycosis (de Sousa et al., 2014).  
5.3.3 Vibrio anguillarum DNA  
Vibrio anguillarum DNA (VaDNA) is phenol-extracted genomic DNA from 
Vibrio anguillarum ATCC19264 cells (Sepulcre et al., 2009). This was a generous 
gift from Victoriano Mulero at Department of Cell Biology and Histology, Faculty 
of Biology, University of Murcia, Spain. Most dsDNAs are recognised by 
mammalian TLR9. VaDNA has been shown to stimulate expression of TLR21 in 
zebrafish (Gao et al., 2013). 
5.3.4 Pam2CSK4  
Pam2CSK4 is a synthetic diacylated lipopeptide that induces immune signalling 
through TLR2 (Buwitt-Beckmann et al., 2005).  
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5.3.5 CpG ODN 2359  
CpG ODN 2359 is a synthetic class C CpG oligonucleotide that comprises 
unmethylated CpG dinucleotides. CpG ODN is recognised by human, mouse and 
zebrafish TLR9, and chicken and zebrafish TLR21 leading to immunostimulatory 
effects (Vollmer et al., 2004, Brownlie et al., 2009, Keestra et al., 2010, Hemmi 
et al., 2000, Bauer et al., 2001, Chuang et al., 2002).  
5.3.6 Staphylococcus aureus cell wall preparations 
Staphylococcus aureus is as a gram-positive bacterium characterised by a thick 
peptidoglycan layer in the cell envelope that retains gentian violet following 
staining with Gram stain. S. aureus cell wall is composed of an inner (plasma) 
membrane and the outer peptidoglycan with different glycopolymers, teichoic 
acids and lipoprotein, that are attached to either the peptidoglycan or lipid part of 
the plasma membrane (reviewed in Weidenmaier and Peschel, 2008) (Figure 
21). The cell wall glycopolymers stretch through the peptidoglycan layers to the 
bacterial cell surface. Here they mediate interactions with the host by binding with 
host receptors and triggering an innate immune response such as inflammation, 
complement activation or opsonisation.  
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Figure 21: Schematic structure of S. aureus cell wall 
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Peptidoglycan – Peptidoglycan (PGN) is made up of linear glycan strands of 
alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) 
residues cross-linked by short peptides, β-1→4 bonds (Schleifer and Kandler, 
1972).  Peptidoglycan is located on the outside of the plasma membrane (Guan 
and Mariuzza, 2007). The core functions of peptidoglycan are to preserve the 
integrity of the cell, maintain cell shape, and anchor other cell envelops including 
teichoic acid and proteins (Dramsi et al., 2008, Neuhaus and Baddiley, 2003). 
Peptidoglycan has been shown to be detected by the pattern recognition 
receptors (PRRs) present on monocytes, macrophages and dendritic cells. The 
PRRs that recognise peptidoglycan include TLR2 (though not conclusively) 
(Travassos et al., 2004, Dziarski and Gupta, 2005), NOD1 (Chamaillard et al. 
2003) and membrane-bound adaptor molecule CD14 (Dziarski et al., 1998).  
Teichoic acids – Teichoic acids (TAs) are cell-wall glycopolymers that are 
constitutively produced. TAs are either attached to peptidoglycan (wall-teichoic 
acids, WTAs) or lipids of the plasma membrane (lipoteichoic acid, LTA). WTA is 
composed of 40 ribitol phosphate units that are substituted with D-alanine ester 
and N-acetylglucosaminyl residues. The chain is covalently linked to 
peptidoglycan via a phosphodiester linkage to the C6 hydroxyl of the N-acetyl 
muramic acid sugars (Neuhaus and Baddiley, 2003). However, LTA is composed 
of approximately 25 poly (1-3)-glycerol phosphate linked to a diacylglycerolipid 
anchor which attaches to the surface of cytoplasmic membrane (Fournier and 
Philpott, 2005). The actual function of TAs is not well understood, but WTA is not 
required for viability of the bacteria under laboratory conditions but plays a vital 
role during infection in vivo (Weidenmaier et al., 2004, D'Elia et al., 2006, D'Elia 
et al., 2009). On the other hand, LTA is required in growth condition below 37° C 
and deletion of both WTA and LTA is lethal (Oku et al., 2009, Schirner et al., 
2009), suggesting that TAs are essential for viability of the bacteria. WTA and 
LTA are exposed on the bacterial surface and interacts with several host 
receptors. Soluble C-type lectin receptor, Mannose-binding lectin (MBL) has 
been shown to recognise both WTA and LTA. WTA binds to MBL and function as 
an opsonin but only in the serum of infants who have not developed anti-WTA 
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IgG antibodies (Park et al., 2010). MBL-deficiency individuals are more 
susceptible to bacterial infection including S. aureus especially during infancy 
(Kurokawa et al., 2016). The WTA deficient S. aureus mutants exhibit defects in 
adherence to epithelial and endothelial cells, nasal colonisation and 
dissemination of the bacteria from the blood stream to sub-endothelial tissues in 
endovascular infections in animal models (Weidenmaier et al., 2004, 
Weidenmaier et al., 2005, Weidenmaier et al., 2008). Recently the first receptor 
of WTA on nasal epithelial cells has been reported. F scavenger receptor, 
SREC-1 was shown to bind to WTA and facilitated adhesion to nasal epithelial 
cells in vitro (Baur et al., 2014). LTA also binds MBL and L-ficolin leading to 
activation of lectin-initiated complement pathway and subsequently bacterial 
opsonisation (Polotsky et al., 1996, Lynch et al., 2004, Nahid and Sugii, 2006). 
LTA has also been shown to elicit innate immune system through TLR2 (Morath 
et al., 2001, Hermann et al., 2002, Draing et al., 2008). However, this has been 
controversial because the commonly used LTA preparations are contaminated 
with bacterial lipopeptides, which are major inducers of TLR2 mediated 
pro-inflammatory responses (Hashimoto et al., 2006, Zahringer et al., 2008, 
Hashimoto et al., 2007). 
Lipoproteins – Lipoproteins (LPP) are a distinctive class of surface proteins 
comprised of N-terminal lipid modification of proteins with 
N-acyl-S-diacyl-glyceryl-cysteine (Hantke and Braun, 1973). Lipoproteins in the 
Gram-positive bacteria are anchored by a lipid moiety at the N terminus in the 
outer leaflet of the plasma membrane and extends into the cell wall. During 
S. aureus interactions with the host, LPP are required for virulence and TLR2 
signalling (reviewed in Nguyen and Gotz, 2016). S. aureus mutants lacking 
matured LPP (∆lgt) have decreased induction of pro-inflammatory cytokines via 
the TLR2-MyD88 signalling pathway in murine peritoneal macrophages. Also, 
∆lgt display severely impaired pathogenicity in the C57BL/6 mouse sepsis model 
(Stoll et al., 2005, Schmaler et al., 2009). 
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5.4 Results 
5.4.1 S. aureus CWP and VaDNA reduce fungal burden in zebrafish 
The following TLR agonists were used to activate innate immunity in cryptococcal 
infection: lipopolysaccharide, imiquimod, Vibrio anguillarum genomic DNA 
(VaDNA) and Staphylococcus aureus SH1000 strain cell wall preparations 
(CWP), denoted as S. aureus CWP. These agonists were selected based on the 
following previously published and unpublished work. LPS and imiquimod 
induced robust inflammatory responses to the fungus Fonsecaea pedrosoi 
resulting in clearance of infection in mice (Sousa et al., 2011). Vibrio anguillarum 
DNA had been shown to induce inflammatory genes in zebrafish (Sepulcre et al., 
2009) whereas S. aureus CWP elicit severe inflammation in zebrafish infected 
with non-lethal inoculum of S. aureus (Boldock, 2016). To test the capacity of TLR 
agonists to control C. neoformans infection, 3dpf nacre zebrafish larvae were 
injected intramuscularly with C. neoformans in phenol red alone (vehicle control) 
or supplemented with individual TLR agonists. Fungal burden was determined at 
48-hours post challenge. The mean cryptococcal burden in larvae treated with 
LPS or imiquimod were not significantly different from phenol red treated larvae 
(LPS P = 0.31; Imiquimod P=0.89; Figure 22a). However, cryptococcal burden 
was significantly lower in larvae that were injected with S. aureus CWP or VaDNA 
compared to phenol red treated larvae (S. aureus CWP, P = 0.03; VaDNA, P < 
0.0001; Figure 22a). It is worth mentioning that IFNγ was slightly more effective 
at reducing fungal burden than S. aureus CWP (P = 0.04). 
TLR2 recognises Staphylococcus aureus CWP while TLR9 or TLR21 recognises 
VaDNA. Thus, I supposed that administration of synthetic TLR2 or TLR9/21 
agonists, Pam2CSK4 and CpG oligodeoxynucleotides (CpG ODN) respectively, 
would yield similar results of S. aureus CWP and VaDNA. CpG ODN is a ligand 
to zebrafish TLR9 and TLR21 (Yeh et al., 2013) and both Vibrio anguillarum and 
CpG ODN have been shown to induce the expression of TLR21 in zebrafish (Gao 
et al., 2013). Surprisingly, there was no significant reduction of the fungal burden 
in larvae injected with Pam2CSK4 or CpG ODN than larvae which were treated 
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with vehicle control (Figure 22b&c; Pam2CSK4 P = 0.29; CpG ODN P = 0.29).  
As a control, the agonists were tested for their effect on the fungal growth in vitro 
at the concentration injected. None of the agonists showed any effect on the 
growth of Cryptococcus (Figure 22d).  
 
 CHAPTER 5| INTRAMUSCULAR ADMINISTRATION OF S. AUREUS CELL WALL 
PREPARATIONS PROTECTS ZEBRAFISH AGAINST C. NEOFORMANS INFECTION 
142 
 
 
Figure 22: S. aureus CWP and VaDNA reduce fungal burden in zebrafish. 
Fungal burden at 48hpi of 3dpf nacre larvae challenged with (a) C. neoformans in phenol red 
alone or supplemented either with 10 µg/mL lipopolysaccharide, or 10 µg/mL imiquimod, or 5 
mg/mL S. aureus CWP or 5µg/mL VaDNA. Data from three independent experiments (n=130-140 
per group) presented as a mean ±standard deviation analysed by one-way ANOVA with Dunn’s 
Multiple comparison test for each treatment group versus phenol red. Phenol red vs IFNγ, ****P 
< 0.0001, S. aureus CWP, *P = 0.03, VaDNA, ****P < 0.0001 (b) C. neoformans in phenol red 
alone or with 10 µg/mL PAM2CSK4. Data from three independent experiments (n=78-83 per 
group) presented as a mean ± standard deviation analysed by Mann-Whitney test; Phenol red vs 
PamCSK4, P = 0.29.  (c) C. neoformans in phenol red alone or with 50 µg/mL ODN2395, data 
from three independent experiments (n=105-106 per group) presented as a mean ± standard 
deviation analysed by Mann-Whitney test, Phenol red vs CpG ODN 2395, P = 0.29. (d) Colony 
forming units of C. neoformans at 24h following in vitro exposure to TLR agonists at concentration 
used above. Data from three repeats presented as a mean ± standard deviation analysed by 
Ordinary one-way ANOVA with Dunnett's multiple comparisons test of Phenol red vs LPS (P = 
0.33); imiquimod (P = 0.99); Peptidoglycan (P = 0.97); Pam2CSK4 (P = 0.71); CpG ODN 2395 
(P = 0.89); VaDNA (P = 0.99).   
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5.4.2 S. aureus Lipoproteins are not required for CWP-mediated 
protection against C. neoformans infection in zebrafish 
As described above, the S. aureus cell consists of the inner plasma membrane, 
outer peptidoglycan, lipoproteins, and glycopolymers that are wall teichoic acid 
and lipoteichoic acid (Figure 21). Therefore, I tried to determine which of these 
cell wall components are required for S. aureus CWP mediated protection against 
C. neoformans. I first tested whether lipoproteins were required for protection. 
Three dpf nacre zebrafish larvae were challenged intramuscularly with 
C. neoformans in phenol red alone or supplemented with CWP made from 
lipoprotein-null S. aureus ∆lgt mutant or CWP from S. aureus. Fungal burden was 
determined at 48 hpi as described before. The fungal burden in the larvae that 
were treated with ∆lgt CWP or S. aureus was significantly lower compared to the 
larvae injected with phenol red alone (Figure 23; ∆lgt CWP, P < 0.0001; S. aureus 
CWP, P < 0.0001). The fungal burden between ∆lgt CWP and S. aureus 
CWP-treated larvae were not significantly different (P = 0.35; Figure 23). These 
results suggest that lipoproteins are not essential for S. aureus CWP-mediated 
protection against C. neoformans.  
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Figure 23: S. aureus lipoproteins are not required for CWP mediated protection 
against C. neoformans infection in zebrafish.  
Fungal burden at 48hpi of 3dpf nacre larvae challenged with C. neoformans in phenol red alone 
or supplemented either with 5mg/mL S. aureus CWP or with 5 mg/mL ∆lgt CWP. Results are a 
combination of three independent experiments (n=54-58 per group) and data presented as a 
mean ± standard deviation and tested for statistical significance using one-way ANOVA with 
Dunn’s multiple comparison test for each treatment group versus phenol red. S. aureus CWP vs 
Phenol red, ****P < 0.0001; S. aureus CWP vs ∆lgt CWP, P = 0.35.  
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5.4.3 S. aureus wall-teichoic acid is required for CWP-mediated 
protection against C. neoformans infection 
I then evaluated whether S. aureus cell wall glycopolymer, wall-teichoic acid 
(WTA) may be essential in S. aureus CWP driven protection against 
C. neoformans infection in zebrafish. I used the CWP made from S. aureus that 
have been treated with hydrofluoric acid (denoted as S. aureus CWP-HF) to 
remove wall teichoic acid and the CWP made from WTA-null S. aureus strain, 
∆tarO. The tarO is the first gene in the WTA biosynthetic pathway (Weidenmaier 
et al., 2004). Interestingly, there was no significant difference in the mean fungal 
burden in larvae injected with the S. aureus CWP-HF or the ∆tarO CWP 
compared to larvae treated with phenol red (Figure 24; S. aureus CWP-HF, P = 
0.67; ∆tarO CWP, P = 0.12). These results strongly suggest that WTA is essential 
for protection. However, efforts to test wall teichoic acid alone for protection 
proved impossible because we were unable to obtain pure wall teichoic acid.  
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Figure 24: S. aureus wall-teichoic acid is required for CWP-mediated protection 
against C. neoformans infection.  
Fungal burden at 48hpi of 3dpf nacre larvae challenged with C. neoformans in phenol red alone 
or supplemented either 5mg/mL ∆tarO CWP or 5mg/mL S. aureus CWP-HF. Results are a 
combination of three independent experiments (n=99-124 per group) and data presented as a 
mean ± standard deviation. Tested for statistical significance using one-way ANOVA with Dunn’s 
multiple comparison test for each treatment group versus phenol red. Phenol red vs ∆tarO CWP, 
P = 0.12; Phenol red vs S. aureus CWP-HF, P = 0.67.  
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5.4.4 S. aureus CWP must be particulate to induce protection against 
C. neoformans  
Unlike soluble PRR agonists such as Pam2CSK4 and lipoteichoic acid, S. aureus 
CWP is an insoluble particulate antigen. Particulate antigens bind and are likely 
internalised by macrophages through phagocytosis. To determine whether the 
particulate form of S. aureus CWP was needed to induce protection, S. aureus 
CWP were treated with mutanolysin to solubilise the preparation. Mutanolysin 
cleaves β-N-acetylmuramyl-(1→4)-N-acetylglucosamine linkage of PGN without 
degrading WTA (Shimada et al., 2010). All types of mutanolysin-digested CWP 
including ∆lgt CWP or S. aureus CWP that showed efficacy in particulate form 
failed to induce innate immunity for protection against C. neoformans (Figure 25). 
These results profoundly suggest that a particulate form of S. aureus CWP is 
needed to induce protection. 
 
Figure 25: Mutanolysin-digested S. aureus CWP fails to induce protection against 
C. neoformans in zebrafish.  
Fungal burden at 48hpi of 3dpf nacre larvae challenged with C. neoformans in phenol red alone 
or supplemented with either solubilised 5 mg/mL S. aureus CWP or 5 mg/ml ∆tarO CWP or 5 
mg/mL ∆lgt CWP. Results are a representative of three independent experiments (n=36-47 per 
group) and data presented as a mean ± standard deviation and tested for statistical significance 
using one-way ANOVA with Dunn’s multiple comparison test for each treatment group versus 
phenol red. Phenol red vs IFNγ, **P = 0.0019; S. aureus CWP, P = 0.25; vs ∆tarO CWP, P = 0.49; 
vs ∆lgt CWP, P = 0.6.    
 CHAPTER 5| INTRAMUSCULAR ADMINISTRATION OF S. AUREUS CELL WALL 
PREPARATIONS PROTECTS ZEBRAFISH AGAINST C. NEOFORMANS INFECTION 
148 
 
5.4.5 Immune correlates associated with S. aureus CWP protective effect  
So far, I have shown that S. aureus CWP induces zebrafish innate defence 
against C. neoformans. I have also demonstrated that the glycopolymer wall 
teichoic acid, but not lipoproteins are required for this induction. In the sections 
below, I will try to decipher how S. aureus CWP promotes protective 
anti-cryptococcal defences. My work in Chapter 4 had shown that IFNγ-mediated 
protection was associated with increased recruitment of macrophages, 
phagocytosis and expression of IL-1 GFP. Therefore, I investigated whether 
S. aureus CWP effected innate resistance through the same.  
5.4.5.1 S. aureus CWP is associated with increased macrophage 
recruitment  
As I have shown in the previous chapter, a potential mechanism by which 
S. aureus CWP reduced fungal burden in zebrafish larvae is through the 
alteration of macrophage recruitment. To address this, I quantified the number of 
macrophages at the site of infection in phenol red-, ∆tarO CWP- and S. aureus 
CWP-treated larvae infected with C. neoformans. The ∆tarO CWP was used as 
a negative control to test for S. aureus CWP because the ∆tarO CWP did not 
induce protection. Macrophage recruitment in the ∆lgt CWP-treated larvae were 
also tested. There was a significant increase in the infiltration of macrophages at 
2hpi but not at 24 hpi in the larvae injected with S. aureus CWP compared to 
∆tarO CWP-treated larvae (2hpi P = 0.001; 24hpi P = 0.051; Figure 26a). 
Interestingly, larvae that received ∆tarO CWP showed intermediate recruitment 
of macrophages but significantly higher than phenol red treated larvae at 2 (P = 
0.002) and 24 (P = 0.02) hpi (Figure 26a). Moreover, the number of macrophages 
remained unchanged between 2 and 24hpi in both the ∆tarO CWP and S. aureus 
CWP-treated larvae (∆tarO CWP P = 0.54; S. aureus CWP P = 0.58; Figure 26a).  
The ∆lgt CWP also induced significantly higher macrophage influx than phenol 
red treatment at 2 and 24hpi (Figure 26b; 2hpi P < 0.0001; 24hpi P = 0.01) but 
the number of recruited macrophages was lower at 24hpi than at 2hpi in ∆lgt 
CWP-treated larvae (P < 0.0001; Figure 26b). 
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Figure 26: S. aureus CWP is associated with increased macrophage recruitment.  
Number of macrophages at the site of infection at 2 and 24 hpi of 3dpf 
Tg(mpeg1:Gal4-VP16/UAS:Kaede) larvae challenged with C. neoformans in phenol red alone or 
supplemented with either (a) 5 mg/mL S. aureus CWP or 5 mg/ml ∆tarO CWP. Results are a 
representative of three independent experiments (n=9 per group) and data presented as a mean 
± standard deviation and tested for statistical significance using two-way ANOVA and Dunnett’s 
multiple comparison test for each treatment group versus ∆tarO CWP. At 2 hpi, ∆tarO CWP vs S. 
aureus CWP, ***P = 0.001; vs Phenol red, **P = 0.002. At 24hpi, ∆tarO CWP vs S. aureus CWP 
P = 0.051; vs Phenol red, *P = 0.02. Comparison between time-points, in ∆tarO CWP-treated 
larvae, 2hpi vs 24h P = 0.54; S. aureus CWP, 2hi vs 24hpi, P = 0.58). Data analysed using un-
paired t-test (b) ∆lgt CWP data is a combination of three independent experiments (n=23-29 per 
group/exp.) and data presented as a mean ± standard deviation and tested for statistical 
significance using two-way ANOVA with Dunnett’s multiple comparison tests, ∆lgt CWP vs Phenol 
red, ****P < 0.0001 at 2hpi, and *P = 0.01 at 24hpi. Comparison between time-points, in ∆lgt CWP 
-treated larvae, 2hpi vs 24 ****P < 0.0001, data analysed using unpaired t-test.  
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5.4.5.2 S. aureus CWP does not enhance phagocytosis of C. neoformans 
by macrophages 
The ability of microglial cells to take up C. neoformans is increased in vitro 
following stimulation by TLR agonists, (Redlich et al., 2013). I hypothesised that 
induction of innate immunity with S. aureus CWP will enhance phagocytosis of 
C. neoformans by macrophages in vivo. Unlike IFNγ (see Chapter 4), 
macrophages in larvae treated with the S. aureus CWP did not have increased 
phagocytosis than ∆tarO CWP-treated larvae at 2hpi (P = 0.75; Figure 27). 
 
Figure 27: S. aureus CWP does not enhance phagocytosis of C. neoformans by 
macrophages.  
Proportion of internalised fungal cells per larva at 2 hpi macrophages. Data is combination of two 
independent experiments (n=16-17 per group) and presented as %, however, statistical analysis 
was performed on raw data (total number of intracellular cryptococci vs total number of 
extracellular cryptococci) using Fisher’s exact test ∆tarO CWP vs S. aureus CWP, P = 0.75; vs 
Phenol red, P = 0.34. 
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5.4.5.3 S. aureus CWP does not increase TNFα GFP expression in 
infected macrophages 
I further evaluated whether S. aureus CWP modulated the behaviour of 
macrophages. I analysed the expression of the pro-inflammatory cytokine TNFα 
GFP, in zebrafish macrophages. To specifically follow TNFα expressing 
macrophages, a TNFα promoter BAC driving GFP transgenic zebrafish line 
TgBAC(tnfa:GFP)pd1028 was crossed to a macrophage reporter line 
Tg(mpeg1:mCherryCAAX)sh378, to produce double transgenic line 
TgBAC(tnfa:GFP);Tg(mpeg1:mCherryCAAX). Three dpf double transgenic 
larvae TgBAC(tnfa:GFP);Tg(mpeg1:mCherryCAAX), were injected with 
C. neoformans with phenol red or with ∆tarO CWP or S. aureus CWP. The 
expression of TNFα GFP was examined in macrophages with internalised 
cryptococci at 12, 24 and 36hpi. The cumulative relative fluorescent intensity of 
TNFα GFP was significantly higher in both S. aureus CWP (P = 0.004) and ∆tarO 
CWP (P = 0.003) at 12hpi compared to phenol red treated larvae. However, there 
was no significant difference in the cumulative relative fluorescent intensity of 
TNFα GFP in larvae that were treated with S. aureus CWP compared to ∆tarO 
CWP-treated larvae at 12 (P = 0.9), 24 (P = 0.951) and 36 (P = 0.602) hpi (Figure 
28). 
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Figure 28: S. aureus CWP does not increase TNFα GFP expression in infected 
macrophages.  
(a) Relative fluorescent intensity of TNFα GFP in 3dpf double transgenic larvae 
TgBAC(tnfa:GFP);Tg(mpeg1:mCherryCAAX) challenged with C. neoformans in phenol red alone 
or supplemented either with 5 mg/mL S. aureus CWP or with 5 mg/ml ∆tarO CWP. Results are a 
representation of three independent experiments (n=7-10 per group) and data presented as a 
mean ± standard deviation and tested for statistical significance using Ordinary one-way ANOVA 
with Dunnett’s multiple comparison test for each treatment group versus ∆tarO CWP. At 24 hpi, 
Phenol red vs ∆tarO CWP, **P = 0.004; vs S. aureus CWP, **P = 0.003. (b) Representative 
fluorescent images z-stacks of the TNFα GFP expression in Phenol red, ∆tarO CWP and S. 
aureus CWP at 24hpi treated larvae, scale bar is 2µm 
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5.5 Discussion  
Here I describe a new approach of stimulated innate immune resistance to 
C. neoformans that effectively reduced fungal burden by use of PRR agonists in 
a zebrafish infection model. Firstly, I show that TLR agonists including VaDNA 
and S. aureus CWP but not LPS and imiquimod reduced cryptococcal burden 
in vivo. Although LPS and imiquimod have been shown to exert innate immune 
resistance to Fonsecaea pedrosoi infection in mice (Sousa et al., 2011), they 
failed to display the same effect on C. neoformans infection in the zebrafish 
model. Besides, VaDNA and S. aureus CWP are TLR9 and TLR2 agonists 
respectively and induced protection. However, agonists CpG ODN and 
Pam2CSK4 of the same TLRs, failed to induce resistance. CpG ODN is 
recognised by zebrafish TLR9 and TLR21 (Yeh et al., 2013, Meijer et al., 2004) 
and mammalian TLR9 (Vollmer et al., 2004). Interestingly, immunisation with 
CpG ODN three days before cryptococcal infection has been shown to reduce 
cryptococcal burden in mice with pulmonary cryptococcosis via induction of IFNγ 
production by T cells (Edwards et al., 2005) perhaps that is why it takes longer to 
induce anti-cryptococcal innate resistance. This may explain why CpG ODN 
failed to induce protection in zebrafish larvae because they lack functional T cells 
(Edwards et al., 2005). In addition, the sequence of the CpG ODN motif used in 
the previous study is different from my study. It has been shown that different 
sequences of the CpG ODN motifs produce varied responses. For example, CpG 
ODN with GACGTT or AACGTT has a better activity to TLR9 while motifs that 
are recognised by both TLR9 and TLR21 trigger more potent cytokine production 
than those that bind to TLR9 or TLR21 alone (Yeh et al., 2013).  
The mechanism of action of VaDNA reduction of cryptococcal burden requires 
further investigation because the corresponding TLR9 agonist, CpG ODN could 
not produce similar findings. Administration of VaDNA has been shown to 
increase expression of inflammatory genes in spotted green pufferfish but fail to 
induce NF-κB in MyD88 zebrafish morphants (Sepulcre et al., 2009). Vibrio 
anguillarum causes vibriosis in aquatic animals. Interestingly, Debaryomyces 
hansenii and Yarrowia lypolitica yeasts protect zebrafish from Vibrio anguillarum 
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infection by reducing bacterial burden and pro-inflammatory responses (Caruffo 
et al., 2016). Perhaps a synergistic or antagonistic effect exists between the yeast 
C. neoformans and VaDNA which leads to a required host response capable of 
suppressing cryptococcal growth.  
Secondly, I identified that wall-teichoic acid but not lipoproteins are required for 
S. aureus CWP-mediated innate immune resistance to C. neoformans. WTA is 
widely known as a binding site of Gram-positive bacteria for uptake by host 
immune cells. WTA-deficient S. aureus does not adhere to polymorphonuclear 
leukocytes, dendritic cells and is not phagocytosed as efficiently as the wild-type 
strain (Kurokawa et al., 2013, Hong et al., 2017). WTA has been implicated in 
S. aureus attachment to nasal epithelial cells during nasal colonisation 
(Weidenmaier et al., 2008, Weidenmaier et al., 2004). WTA is also required for 
maturation and activation of DCs (Hong et al., 2017). Thus, WTA appears to 
facilitate bacterial adherence and internalisation by phagocytes leading to 
activation of host immune cells. Although I was unable to test wall teichoic acid 
alone, the presence of intact WTA in solubilised S. aureus CWP failed to induce 
innate immune resistance to C. neoformans. This suggests that free WTA alone 
may not induce protection and perhaps WTA attached to intact peptidoglycan is 
required to elicit protection against C. neoformans infection.  
Interestingly, S. aureus has been shown to kill C. neoformans in vitro and the 
addition of soluble capsular polysaccharide prevents the killing (Saito and Ikeda, 
2005). Killing occurs when the glycolytic enzyme of S. aureus recognises 
mannose residues in the backbone of GXM (Ikeda et al., 2007). However, the 
possibility of S. aureus CWP killing C. neoformans was ruled out because the 
fungi did not show any growth defects following co-incubation with S. aureus 
CWP. This suggests that stimulated innate resistance by S. aureus CWP is the 
only possibility that lead to reduced fungal burden in zebrafish. Recently at the 
10th international conference of Cryptococcus and cryptococcosis, a poster by 
Tseng et al. (2017) presented the case of a 25-year-old patient who had both 
S. aureus and C. neoformans infection. The patient only developed signs of 
cryptococcal meningitis and showed positive CSF culture for C. neoformans 
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following commencement of antibiotics (Tseng, 2017). Perhaps these findings not 
only reveal that S. aureus may kill C. neoformans in vivo but also highlight the 
induction of anti-cryptococcal immunity by S. aureus.  
Further work is required to identify receptors of WTA and PGN in zebrafish. Wall 
teichoic acid binds to MBL (Park et al., 2010). Other S. aureus cell wall 
components that bind to MBL include PGN (Ma et al., 2004) and LTA (Polotsky 
et al., 1996, Ip et al., 2008). MBL is a soluble CLR and is a member of the collectin 
family which is found in human serum and other animals (Holmskov et al., 2003). 
Human MBL binds to mannose and GlcNAc residues present on the 
glycopolymers of bacteria (Weis and Drickamer, 1996) and functions as an 
opsonin, activating the lectin complement pathway (Fujita, 2002). The activation 
of the lectin pathway induces opsonophagocytosis of S. aureus by PMNs in the 
serum of infants lacking Anti-WTA (Park et al., 2010). However, adult serum 
containing Anti-WTA immunoglobulin elicits opsonophagocytosis of S. aureus 
following binding of the antibody-WTA complex with C1q, leading to activation of 
the classical pathway (Park et al., 2010). Thus, I hoped to see increased 
phagocytosis in S. aureus CWP-treated larvae. However, uptake rates were not 
significantly higher at 2hpi and there is need to investigate the rates at later time 
points. The activation of the lectin pathway results in opsonisation of the pathogen 
by complement fragments including C4b and C2a. This leads to the formation of 
anaphylatoxins C3a and C5b that stimulate inflammation and act as 
chemoattractants of macrophages and neutrophils (Ricklin et al., 2010). Since I 
have shown that S. aureus CWP-treated larvae have higher influx of 
macrophages, thus it would be interesting to investigate whether this recruitment 
is mediated by MBL-WTA complex.  
I further demonstrated that the particulate nature of CWP from S. aureus is 
essential for the activation of innate immune resistance. The particulate S. aureus 
PGN is required for activation of NLRP3 inflammasomes and secretion of IL-1β 
in mouse macrophages. This effect requires that the S. aureus PGN particles 
must be internalised via phagocytosis (Shimada et al., 2010). Nod-like receptor 
(NLR) family, including NOD1 and NOD2 recognise peptidoglycan in the 
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cytoplasm. NOD1 recognises peptidoglycan fragments of Gram-negative and 
some Gram-positive rods while NOD2 senses peptidoglycan fragments from all 
bacteria (Girardin et al., 2003, Chamaillard et al., 2003, Inohara et al., 2003). 
Although the functions of the NLR family members are not well characterised in 
zebrafish, the canonical members of their mammalian counterparts, NOD1, 
NOD2, and NOD3 are present (Stein et al., 2007). Morpholino-mediated 
depletion of Nod1 or Nod2 results in higher bacterial counts and reduced survival 
of embryos infected with Salmonella enterica (Oehlers et al., 2011) suggesting 
that NLRs play a vital role in innate antibacterial immunity in zebrafish. Whether 
zebrafish NLRs recognise bacterial peptidoglycan fragments remains to be 
elucidated. It is worth to note that ligand recognition by some but not all innate 
receptors in zebrafish correspond to their mammalian counterparts. For example, 
zebrafish TLR2 recognises lipopeptides and Pam3CSK4 (Yang et al., 2015, 
Meijer et al., 2004) which are both recognised by murine and human TLR2 (Kang 
et al., 2009, Jin et al., 2007, Zahringer et al., 2008, Omueti et al., 2005). However, 
zebrafish TLR4 is not responsive to LPS stimulation (Li et al., 2017), highlighting 
the similarities and differences between zebrafish and mammalian models.  
On testing the expression of inflammatory cytokine TNFα, I found higher 
expression in both S. aureus CWP and ∆tarO CWP treatment compared to 
controls. However, the TNFα expression in S. aureus CWP treatment was not 
significantly higher than ∆tarO CWP treatment. WTA is not very inflammatory. 
Previous studies have shown that PGN but not WTA is required for S. aureus cell 
wall-mediated induction of TNFα (Leemans et al., 2003, Majcherczyk et al., 
2003). This may explain why the two CWP induced similar levels of TNFα 
expression. WTA interfere with certain cellular immune responses. For example, 
S. aureus inhibits the secretion of superoxide in macrophages, to escape killing 
following phagocytosis (Watanabe et al., 2007). However, a WTA-deficient 
S. aureus strain induces increased superoxide concentration and is readily killed 
compared to wild-type S. aureus (Shiratsuchi et al., 2010). Thus, WTA acts to 
protect both the bacteria from killing and the host from inflammatory damage. It 
has also been shown that WTA interferes with the recognition of peptidoglycan 
 CHAPTER 5| INTRAMUSCULAR ADMINISTRATION OF S. AUREUS CELL WALL 
PREPARATIONS PROTECTS ZEBRAFISH AGAINST C. NEOFORMANS INFECTION 
157 
 
by PGRP-SA in Drosophila resulting in reduced production of AMP-like 
drosomycin (Tabuchi et al., 2010) suggesting that WTA act as a regulator of 
inflammation and less as a pro-inflammatory activator.   
In this age of emerging pathogens, the development of antibiotic resistance and 
an increasing immunosuppressed population, infections are becoming hard to 
treat. The management of cryptococcal disease remains a challenge, particularly 
in the immunocompromised. Despite anti-fungal treatment in HIV-associated 
cryptococcal disease mortality remains excessively high (reviewed in Williamson 
et al., 2017), demonstrating a pressing need to develop new therapeutic 
strategies to successfully treat this disease. Well-characterised interactions are 
required to identify treatments that target PRRs, particularly the TLRs. The TLRs 
fulfil most of the requirements as potential treatment targets. These include 
diminished disease resistance in knockout animal models, overexpression in 
disease and genetic alteration in TLRs or signalling molecules are associated 
with a risk of disease in humans. Despite few examples of effective interventions 
that target TLRs currently in use in the clinic, one profound example, imiquimod, 
stands out. Imiquimod is a TLR7 and TLR8 agonist that was approved over a 
decade ago for treatment of genital warts and keratosis (Lebwohl et al., 2004, 
Stockfleth et al., 2004). Recently imiquimod showed efficacy in four cases of 
chromoblastomycosis, a chronic skin infection caused by the fungus Fonsecaea 
pedrosoi (de Sousa et al., 2014). This is also a prime example of local induction 
of host immunity and resonates with my findings.  S. aureus CWP is potent at 
enhancing local innate immunity to suppress C. neoformans infection in a somite 
zebrafish model.  
Several studies have examined the administration of bacterial or fungal lysates 
or whole-heat killed microbes to induce protective defences against infection (Liu 
et al., 2011, Clemons et al., 2014, Braido et al., 2007). However, the undefined 
nature of these preparations becomes problematic when designing therapies for 
human use. In light of this, I identified that wall-teichoic acids but not lipoproteins 
are required for S. aureus CWP augmentation of anti-cryptococcal innate immune 
defences. Although there is need for further characterisation, it highlights the 
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potential of using well-defined PAMPs as the basis for developing 
immunomodulatory anti-infective treatments.  
There are still questions as to whether severely immunocompromised patients, 
such as those at risk of C. neoformans infection can mount a robust immune 
response following treatment with PRR agonists. A good example is the use of 
imiquimod in HIV-positive patients for the treatment of neoplastic human 
papillomavirus-associated conditions produce positive outcomes (Conley et al., 
2002, De Panfilis et al., 2002, Silverberg et al., 2002, Richel et al., 2013, Fox et 
al., 2010). This indicates that immunomodulatory treatment is relevant in the 
severely immunocompromised patients. However, prolonged treatment is 
required and recurrences usually occur (Richel et al., 2013, Fox et al., 2010).  
Considering the diversity of patients at risk of cryptococcosis, the target 
population for such treatment strategies will have to be identified. Besides, the 
use of zebrafish, which mainly rely on innate immunity, can provide insights into 
immune responses to immunomodulation therapy in the immunocompromised 
host. Overall, my findings have clearly identified a new compound to stimulate 
local innate immunity that may be exploited therapeutically to treat C. neoformans 
infections.
  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6          
DISCUSSION AND FUTURE WORK 
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6.1 Anticryptococcal Immunomodulation 
The ability to modify specifically the immune system has long shown success in 
the treatment of many diseases. Immunomodulation involves the direct elicitation 
of host innate defences and enabling natural host directed killing mechanisms to 
control pathogens. Most current immunomodulatory treatments typically work by 
correcting an acquired or congenital immune system defect or by enhancing the 
immune responses to a pathogen that poorly provokes an immune response. 
Immunomodulation approaches share a number of advantages. They include, 
being intrinsically incapable of endangering the development of resistance of the 
targeted pathogen, broad-spectrum activity and minimal side effects. Current 
clinical use and ongoing clinical trials are based on a mass of evidence from 
animal models. The evidence demonstrates that immunomodulation by the 
administration of cytokines or other immune modulatory agents such as PRR 
agonists can act as potent treatments to stimulate the clearance of an existing 
infection.  
Despite the treatment with anti-fungal regimens, patients with 
HIV/AIDS-associated cryptococcal meningitis show reduced response. Mortality 
levels are prohibitively high among these patients and survivors often require 
lifelong anti-fungal therapy for prevention of relapses. The pre-requisite of a 
successful treatment is the clearance of fungal cells from the infected site. 
Macrophages are highly specialised for host defence against C. neoformans. 
However, their effector functions are defective in the presence of very low CD4+ 
T cells. The current treatments mainly target the pathogen and are unable to 
resolve macrophage inactivity. Thus, there is a demand to identify novel 
therapeutic strategies that specifically target macrophage activation mechanisms 
to clear C. neoformans infection in the absence of CD4+ T cells.  
The zebrafish model is ideal for screening compounds as it takes a short period 
to obtain results. Zebrafish can be placed in a niche between in vitro cell-based 
assays and in vivo mammalian models. Testing several compounds in murine 
models can be cumbersome because infection establishment and resolution take 
time. It is comparatively straightforward to perform infection burden and 
host-pathogen interaction assays on a zebrafish larva, enabling the identification 
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and interrogation of potential immune modulatory compounds that elicit the 
desired activity.  
6.2 The zebrafish model of C. neoformans infection 
I have developed a zebrafish model of C. neoformans infection and designed an 
infection outcome assay. The aim was to identify potential immunomodulatory 
compounds that could drive suppression or clearance of infection and examine 
their mechanisms of action. In this model, C. neoformans infection can be 
cleared, controlled or fail to be controlled leading to exponentially high fungal 
counts. By taking advantage of the zebrafish transparency, fungal cells can be 
enumerated in live fish larva during infection. Because of the localised nature of 
the infection, most detailed in vivo analysis of the interaction of C. neoformans 
and immune cells was carried out. Thus, the immune response to C. neoformans 
can indeed be interrogated and manipulated therapeutically using this zebrafish 
model.  
6.3 Immune correlates of IFNγ-mediated protective immunity against 
cryptococcal infection 
6.3.1 What do we know so far? – In vitro, murine and human studies 
The use of IFNγ in preventing or treating infectious disease is not a new 
phenomenon. In clinical practice for example, IFNγ is given as a prophylaxis to 
prevent infection in patients with chronic granulomatous disease (Marciano et al., 
2004). The investigations of IFNγ as a potential agent to elicit anti-cryptococcal 
activity in effector cells in vitro or in vivo date back nearly 30 years. The 
therapeutic potential of IFNγ has been studied predominantly in macrophages 
in vitro, mice experimental cryptococcosis and human cryptococcal disease. 
There appears to be a difference in IFNγ signalling in mice and human 
macrophages in in vitro assays. IFNγ has been clearly demonstrated to increase 
the fungicidal effect of mouse macrophages (Flesch et al., 1989). However, in 
human macrophages, IFNγ treatment results in no change in intracellular 
proliferation rates (Voelz et al., 2009). In fact, another study showed increased 
intracellular replication in human macrophages upon addition of IFNγ in vitro 
(Reardon et al., 1996). In mice, treatment with IFNγ using a C. neoformans strain 
engineered to produce IFNγ, leads to reduced fungal burden. This infection is 
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accompanied by increased leukocyte recruitment, the classically activated 
macrophages that is shown by iNOS expression mediated via STAT1, and the 
production of Th1-type cytokines such as IFNγ, TNFα, IL-1α, IL-2, IL-12 p40, p70, 
IL-17, G-CSF, MIP-1α and RANTES (Wormley et al., 2007, Hardison et al., 2010, 
Hardison et al., 2012b, Leopold Wager et al., 2014). The Th2-type response 
appears to be detrimental in mice. It is characterised by the production of IL-10, 
IL-4 and IL-13, and abrogated fungicidal activity by innate effector cells (Arora et 
al., 2011, Hardison et al., 2012b, Wozniak et al., 2012). The administration of 
IFNγ in patients with HIV-associated cryptococcal meningitis significantly 
increased the rate of clearance of cryptococcal infection from the CSF (Jarvis et 
al., 2012). Survivors have a higher proportion of IFNγ-, TNFα-producing CD4+ T 
cells (Jarvis et al., 2013) and higher levels of pro‑inflammatory cytokines in their 
CSF, including IL-6, IL-8, TNFα and IFNγ (Siddiqui et al., 2005). Non-survivors 
have higher levels of MCP‑1 and MIP-α than survivors (Jarvis et al., 2013). In 
contrast to findings in mice, non-survivors of human cryptococcal disease do not 
display increased Th2-type cytokine production. In fact, survivors have higher 
levels of IL-10 (Jarvis et al., 2013; Figure 29).  
6.3.2 What has this research revealed? – Zebrafish  
In zebrafish, my findings from Chapter 4 reveal that treatment of IFNγ results in 
increased clearance of C. neoformans infection. The immune correlates for 
IFNγ-mediated protective immunity include increased recruitment of phagocytes 
to the site of infection and increased fungal uptake by macrophages. Besides, 
most fungal cells are taken up by macrophages, and macrophage-deficient larvae 
fail to clear or suppress cryptococcal infection despite treatment with IFNγ. In 
addition, there is low lysosomal pH and elevated expression of IL-1 in infected 
macrophages of IFNγ-treated larvae (Figure 29). Furthermore, my results reveal 
that neutrophils do not play an essential role in C. neoformans infection. Although 
neutrophils take up the fungus, their depletion does not alter the C. neoformans 
burden.  
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6.3.3 Where do we go from here? 
6.3.3.1 Recruitment of macrophages 
Following infection of mice by C. neoformans, there is a mass recruitment of 
leukocytes to the lungs (Wormley et al., 2007). The alveolar macrophages are 
one of the first immune host cells to interact with C. neoformans as evidenced by 
the frequent presence of the fungi in lung macrophages (Feldmesser et al., 2000). 
External signals, particularly cytokines such as IFNγ, induce the recruitment of 
phagocytes (Gordon, 2003). However, the mechanism of how IFNγ mediates 
macrophage recruitment is poorly understood. CCL2 (MCP-1) is a chemokine 
that mediates monocyte chemotaxis and binds to its receptor CCR2 (Deshmane 
et al., 2009). Previous studies have shown that CCR2 deficient mice have 
impaired accumulation of macrophages and diminished clearance of 
C. neoformans (Traynor et al., 2002, Traynor et al., 2000). Macrophages primed 
with IFNγ display increased expression of CCR2 and exhibit enhanced migration 
in response to CCL2 (Hu et al., 2005). Recently, a functional zebrafish CCR2 
orthologue has been identified. Zebrafish larvae that are deficient in CCR2 have 
reduced macrophage migration in response to human CCL2 (Cambier et al., 
2014). Thus, it would be interesting to investigate whether IFNγ enhances 
expression of zebrafish CCR2.  
In addition, further work is required to determine more immune correlates of IFNγ 
effects. For example, molecular factors involved in chemotaxis of phagocytes, 
uptake, killing of fungal cells, and signalling pathways in zebrafish have not been 
identified. An interesting way to investigate this would be to use RNAseq to define 
transcriptome features associated with IFNγ treatment. To do this, cells can be 
obtained from zebrafish larvae from infected sites as described previously 
(Nguyen-Chi et al., 2015). Macrophages can be isolated using flow cytometry for 
RNAseq. Expression profiles from RNAseq data of cleared infections can then be 
compared with unresolved infections. Blocking with antibodies, using 
morpholinos or generation of transgenic lines can be used to confirm which hits 
obtained from the RNAseq may be essential for clearance. Imaging can also 
provide valuable information regarding phenotypic behaviours of macrophages 
and their interactions with C. neoformans in the transgenic zebrafish lines.  
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6.3.3.2 Phagocytosis   
Phagocytosis is mediated via the attachment of antibodies or complement factors 
to pathogens. IFNγ has been shown to activate FcγRI, a receptor for IgG-type 
antibodies (Pan et al., 1998, Mendoza-Coronel and Ortega, 2017), increase 
expression of early components of complement cascade, including C1q, C3 and 
C4a and induce antibody/complement mediated opsonophagocytosis 
(Chakrabarty et al., 2010, Barnum et al., 1992, Mitchell et al., 1996). Both FcγR 
(Yoder et al., 2007) and some complement components have been identified in 
zebrafish and display similar functions demonstrated in humans (reviewed in 
Zhang and Cui, 2014). Considering that zebrafish larvae used in my study may 
not have developed antibodies, perhaps IFNγ mediates phagocytosis via 
activation of the complement cascade. Further experimentation is required to 
determine whether complement components are essential in fungal uptake by 
zebrafish immune effector cells.  
6.3.3.3 IL-1 
One other finding of the immune mechanism of IFNγ was that of IL-1β induction. 
Unlike TNFα production in human monocytes, IL-1β is not inhibited by purified 
capsular polysaccharide nor by inhibition of TNFα (Vecchiarelli et al., 1995). IL-1β 
is associated with protective immune responses in the C. neoformans infected 
brains of mice (Uicker et al., 2005). In fact, transcriptome analysis of monocytes 
following exposure to C. neoformans revealed increased expression of IL-1β 
(Chen et al., 2015). However, there are conflicting reports of the effect of IFNγ on 
IL-1β production. Several studies have shown that IFNγ can inhibit the production 
of IL-1β in LPS stimulated macrophages (Ghezzi and Dinarello, 1988, Ruschen 
et al., 1989, Schindler et al., 1989, De Boer et al., 2001) via the STAT1 dependent 
pathway (Ghezzi and Dinarello, 1988). In contrast, other studies have reported 
increased production of IL-1β by IFNγ following stimulation by certain TLR 
agonists such as S. aureus (Boraschi et al., 1984, Arenzana-Seisdedos et al., 
1985, Gerrard et al., 1987, Burchett et al., 1988, Schindler et al., 1990) which in 
my study may be facilitated by C. neoformans. Although the induction of IL-1β 
has only been shown in a single graph and time point, it would be particularly 
useful to investigate further to ascertain if IL-1β is particularly required in host 
immunity against C. neoformans. An interesting strategy to test this would be to 
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adapt the infection assay but use IL-1-/- zebrafish larvae with or without IFNγ to 
determine whether IL-1 is essential for protection or whether IFNγ protective 
activity is mediated via IL-1. Interestingly, IFNγ inhibits IL-1β in mice cells but 
promotes IL-1β production in human cells (Masters et al., 2010). This suggests 
why IFNγ treatment sometimes may not be beneficial in a human disease, though 
success is demonstrated in mouse models of the disease. Thus, diseases 
outcomes may differ among vertebrates. 
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Figure 29: Summary of immune correlates of IFNγ-mediated protective immunity against cryptococcal infection 
↑- increased; ↓- reduced; = - no change; Leuk. – Leukocytes; mac. – Macrophages; proli. – Proliferation. 
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6.4 Immunomodulation via activation of TLR signalling to treat 
C. neoformans infections   
To date, there is only one published study that has shown the exploitation of the 
TLR signalling for treatment of C. neoformans. In this study, immunisation with 
CpG ODN three-days prior to cryptococcal inoculation resulted in reduced fungal 
burden in mice with pulmonary cryptococcosis (Edwards et al., 2005). Recently, 
it was shown that treatment of microglia cells with PAM3CSK4 and CpG ODN 
resulted in activation. The activated microglial cells showed increased 
phagocytosis activity, enhanced intracellular killing of C. neoformans and 
increased secretion of TNFα, CXCL1, IL-6, IL-10 and MIP-2 (Redlich et al., 2013). 
These studies highlight the potential use of agonists for the treatment of 
cryptococcal infections.  
6.4.1 What has this research shown? 
6.4.1.1 S. aureus CWP is a potent inducer of innate defences against 
C. neoformans 
Perhaps the most exciting outcome of this work is the identification of a 
compound that can induce innate immune resistance to C. neoformans in vivo. I 
demonstrate that S. aureus CWP is a potent inducer of innate immune resistance 
to C. neoformans. S. aureus cell wall components are recognised by TLR2. 
However, a synthetic TLR2 agonist, Pam2CSK4, failed to elicit innate immune 
resistance to C. neoformans. An involvement of more than one TLR in S. aureus 
CWP efficacy could be a possible reason for the discrepancy. I have also shown 
that wall teichoic acids, but not lipoproteins, are required for S. aureus 
CWP-mediated protection against cryptococcal infection in zebrafish.  
6.4.1.2 What are the potential receptors and signalling pathways 
involved? 
At this stage, the actual receptors of wall teichoic acid and/or peptidoglycan in 
zebrafish have not been identified. Therefore, further work is required to 
determine the receptor(s) and the signalling pathway(s) that are involved. The 
potential targets might be TLR2 and NOD1/2, as peptidoglycan (PGN) has been 
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shown to bind to these receptors (Dziarski and Gupta, 2005, Chamaillard et al., 
2003, Dziarski et al., 1998). However, the role of TLR2 as the major PGN receptor 
has been challenged (Travassos et al., 2004). The NOD1/2, which are located in 
the cytosol are recruited to the plasma membrane. After recognition of 
peptidoglycan during bacterial invasion, NOD1 or NOD2 binds to Rip2. The 
ubiquitination of K63 of Rip2 leads to initiation of NF-κB and MAPK signalling and 
subsequent chemokine and cytokine production (Reviewed in Fujimoto et al., 
2012) (Figure 30). 
On the other hand, the potential targets of wall teichoic acid receptors would be 
MBL (Baur et al., 2014) (See chapter 5 for further details) and a recently reported 
class F scavenger receptor termed Scavenger receptor expressed by endothelial 
cell-I (SREC-I). SREC-I is present on nasal human epithelial cells and binds to 
WTA. Addition of SREC-I antibody results in reduced nasal colonisation in a 
murine model (Baur et al., 2014). Alias SCARF1, SREC-1 is known to bind to 
LDL, LPS, apoptotic bodies, Hsp70, Hsp90, calreticulin, gp96, and zymogen 
granule protein 2 (Reviewed in Murshid et al., 2016). SREC-1/SCARF1 has been 
shown to trigger an inflammatory immune response in collaboration with plasma 
membrane TLRs including TLR2, TLR3 and TLR4. For instance, 
SREC-I/SCARF1 in association with TLR2 recognise β-glucans from 
C. neoformans and induces the production of IL-1β, CXCL2 and CXCL1 (Means 
et al., 2009). The downstream signalling of SREC-1/SCARF1 have been shown 
with the ligand Poly I:C in collaboration with TLR3. The complex leads to 
activation of NF-κB, MAPK and IRF3 signalling and production of the 
pro-inflammatory cytokines such as IL-8 and IL-6 (Murshid et al., 2015a). 
Interestingly, IL-1α, IL-1β, and TNFα were demonstrated to hinder 
SREC-I/SCARF1 promoter activity, possibly denoting a negative feedback loop 
to limit inflammatory signalling in circumstances where levels of pro-inflammatory 
cytokines are high (Adachi and Tsujimoto, 2002). A zebrafish homology of the 
human scarf-1 has been shown to be expressed in endothelial cells (Sumanas et 
al., 2005).   
Thus, further experimentation would be to test whether similar receptors are 
involved in zebrafish. An interesting way to identify receptors and signalling 
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pathways involved would be to use the same approach described above (Section 
6.3.3.1) in which macrophages in treated and untreated larvae can be isolated 
and their transcription profile can be characterised using RNAseq. To identify 
receptors of S. aureus CWP, expression levels of potential receptors could be 
compared to untreated larvae. Zebrafish knockouts of the potential receptors 
identified by RNAseq can be generated using CRISPR 
 
 
Figure 30: Schematic diagram of NOD1 and NOD2 signalling pathways 
NOD1 and NOD2 recognise peptidoglycan fragments iE-DAP (γ-D-Glu-mDAP) and MDP 
(Muramyl dipeptide) respectively. NOD induced pro-inflammatory signalling involving NF-κB and 
MAPK transcription factors through recruitment of common adaptor RIP2 by homophilic 
CARD-CARD interactions. This follows phosphorylation of IκBα and freeing of NF-κB subunits, 
p50 and p65 and at the same time, TAK1 recruits TAB1 and TAB2 leading to activation of MAPK 
(ERK, p38 and JNK) pathways. Induction of both pathways culminates in the production of 
pro-inflammatory cytokine. 
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6.4.1.3 Cellular response of other phagocytes  
Further work is required to test whether S. aureus CWP affects other effector cells 
such as neutrophils in exerting its influence. Neutrophils are required for immune 
defences against S. aureus infections. Individuals with neutrophil deficiencies are 
highly at high risk of severe S. aureus infections (Lekstrom-Himes and Gallin, 
2000). Therefore, performing experiments to assess neutrophil infiltration and 
phagocytosis in the presence of S. aureus CWP treatments might be informative 
along with whether the effect on fungal burden is maintained following depletion 
of macrophages. Investigating phenotypic changes of immune cells such as 
shape, movement and speed could also give valuable information.  
6.4.1.3 VaDNA efficacy, what’s next? 
Although I also demonstrated that VaDNA elicited innate immune resistance to 
C. neoformans, its corresponding TLR9/21 agonist CpG ODN 2395 did not. The 
administration of VaDNA and CpG ODN 1668 in zebrafish cause increased 
TLR21 expression (Gao et al., 2013). VaDNA also causes increased expressions 
of Il-1b, Il-6 and tnf𝛼 in zebrafish (Sepulcre et al., 2009). Vibrio anguillarum (Va) 
is one of the main fish pathogens that causes septicaemia. This may explain the 
strong effect of VaDNA on the outcome of cryptococcal infection due to its ability 
to activate zebrafish TLR21. It would be worth mentioning that the preparation of 
VaDNA is not clean and may be contaminated with LPS or any other protein 
which may have caused this effect. To investigate whether a protein may be 
involved, VaDNA can be treated with DNAse and then tested for efficacy. On the 
other hand, to test whether the DNA of Vibrio anguillarum is solely responsible 
for this effect, the VaDNA prep could be boiled to denature any proteins present 
and then tested for efficacy. In addition, it has been shown that activation of the 
TLR21 depends on the sequences of the CpG ODN motifs. Perhaps testing for 
CpG ODN 1668 as opposed to CpG ODN 2395 would trigger the same immune 
signalling as VaDNA and provide protection. However, whether these findings 
are translatable to mammalian models considering they lack TLR21 requires 
further exploration.  
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6.5 Benefits versus potential side effects, how to strike the balance? 
The strategies of immune modulation employed in this project have the 
advantage of being intrinsically unable to engender resistance of C. neoformans. 
A potential caution against their use in the clinic is the necessity to establish a 
proper balance where an immunomodulatory compound induces an effective 
host immune response and controls infection but also limits host damage through 
inflammation. Since most immunomodulatory agents are typically non-specific in 
their induction of immune responses, it would be ideal to measure the 
consequences of such stimulation using zebrafish inflammation model. 
Inflammation resolution assays are well established in zebrafish. This can include 
determining the inflammation resolution by the numbers of neutrophils or 
macrophages at the site of infection following treatment with immunomodulatory 
agents. Clearance of immune cells particularly neutrophils from the site of 
infection is essential for successful inflammation resolution (Savill et al, 1989). 
Thus, it would be particularly useful to carry out resolution assays in addition to 
immune enhancement experiments.  
6.6 Overall strategy  
Concomitant administration of C. neoformans with immune modulatory 
compounds markedly enhanced anti-cryptococcal immunity. However, 
immunomodulatory compounds can be administered as prophylaxis in high-risk 
groups to boost immunity against subsequent infections. For example, 
cryptococcal meningitis usually occurs in individuals that are severely 
immunocompromised i.e. those that have less than 100 CD4+ T cells/mm3. Such 
patients can benefit from prophylactic treatments. To explore the prophylactic 
potential of these compounds to cryptococcal infection using this model, 
immunomodulatory agents could be injected at least 24 hours before inoculation 
of C. neoformans.  
6.7 Thesis Summary 
To summarise, in this project I have described the intramuscular 
zebrafish-C. neoformans infection and immunomodulatory model. This has been 
possible by exploiting the special advantages of transparency and ability to create 
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localised infection. I aimed to test IFNγ and several TLR agonists’ ability to 
stimulate host innate immunity and their subsequent mechanism to control 
C. neoformans infection in zebrafish. Using this model, I have successfully 
identified the induction of innate immunity that can suppress C. neoformans 
infection by IFNγ and two other TLR agonists namely VaDNA and S. aureus 
CWP. Using transgenic zebrafish lines, I established that macrophages are 
required for IFNγ-mediated control of C. neoformans. The most interesting of 
these was the discovery of S. aureus CWP to induce the host innate immunity to 
arrest C. neoformans infection and that WTA but not lipoproteins are essential for 
this mechanism.  
More work will be required to determine the mechanism of immunomodulation 
and its mediation of infection clearance. This will involve identifying receptors, 
signalling pathways in zebrafish and characterisation of effector cells involved. 
This work demonstrates that the zebrafish larva is an exciting new animal model 
to study immunomodulatory therapy for C. neoformans infection. 
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